documents incorporated reference document part proxy statement annual meeting shareholders held may filed part iii securities exchange commission within days close fiscal year covered reporttable contents table contents part item business item risk factors cautionary factors may affect future results item b unresolved staff comments item properties item legal proceedings item mine safety disclosures executive officers registrant part ii item market registrants common equity related stockholder matters issuer purchases equity securities item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data afinancial statements notes consolidated financial statements report independent registered public accounting firm bsupplementary data item changes disagreements accountants accounting financial disclosure item controls procedures managements report item b information part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules item summary signatures table contents part item business merck co inc merck company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health products companys operations principally managed products basis include four operating segments pharmaceutical animal health healthcare services alliances segments pharmaceutical segment reportable segment pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities company also animal health segment discovers develops manufactures markets animal health products including vaccines company sells veterinarians distributors animal producers companys healthcare services segment provides services solutions focus engagement health analytics clinical services improve value care delivered patients company incorporated new jersey financial information information companys segments see item managements discussion analysis financial condition results operations item financial statements supplementary data product service marks appearing type form different surrounding text trademarks service marks owned licensed promoted distributed merck subsidiaries affiliates except noted trademarks services marks respective owners product sales total company sales including sales companys top pharmaceutical products well total sales animal health products follows millions total sales pharmaceutical januviajanumet keytruda gardasilgardasil zetiavytorin proquadmmr iivarivax zepatier isentressisentress hd remicade pneumovax simponi animal health revenues revenues primarily comprised miscellaneous corporate revenues including revenue hedging activities thirdparty manufacturing sales table contents pharmaceutical companys pharmaceutical products include therapeutic preventive agents generally sold prescription treatment human disorders certain products within companys franchises follows primary care womens health cardiovascular zetia ezetimibe marketed ezetrol countries outside united states vytorin ezetimibesimvastatin marketed inegy outside united states atozet ezetimibe atorvastatin marketed certain countries outside united states cholesterol modifying medicines adempas riociguat cardiovascular drug treatment pulmonary arterial hypertension diabetes januvia sitagliptin janumet sitagliptinmetformin hcl treatment type diabetes general medicine womens health nuvaring etonogestrelethinyl estradiol vaginal ring vaginal contraceptive product implanon etonogestrel implant singlerod subdermal contraceptive implantnexplanon etonogestrel implant single radiopaque rodshaped subdermal contraceptive implant follistim aq follitropin beta injection marketed puregon countries outside united states fertility treatment hospital specialty hepatitis zepatier elbasvir grazoprevir treatment adult patients chronic hepatitis c virus hcv genotype gt gt infection ribavirin certain patient populations hiv isentressisentress hd raltegravir hiv integrase inhibitor use combination antiretroviral agents treatment hiv infection hospital acute care bridion sugammadex injection medication reversal two types neuromuscular blocking agents used surgery noxafil posaconazole prevention invasive fungal infections invanz ertapenem sodium treatment certain infections cancidas caspofungin acetate antifungal product cubicin daptomycin injection iv antibiotic complicated skin skin structure infections bacteremia caused designated susceptible organisms primaxin imipenem cilastatin sodium antibacterial product immunology remicade infliximab treatment inflammatory diseases simponi golimumab oncemonthly subcutaneous treatment certain inflammatory diseases company markets europe russia turkey oncology keytruda pembrolizumab companys antipd programmed death receptor therapy monotherapy treatment certain patients nonsmallcell lunch cancer nsclc melanoma classical hodgkin lymphoma chl urothelial carcinoma head neck squamous cell carcinoma hnscc gastric gastroesophageal junction adenocarcinoma microsatellite instabilityhigh msih mismatch repair deficient cancer combination pemetrexed carboplatin certain patients nsclc emend aprepitant prevention chemotherapyinduced postoperative nausea vomiting temodar temozolomide marketed temodal outside united states treatment certain types brain tumors diversified brands respiratory singulair montelukast medicine indicated chronic treatment asthma relief symptoms allergic rhinitis nasonex mometasone furoate monohydrate inhaled nasal corticosteroid treatment nasal allergy symptoms dulera inhalation aerosol mometasone furoateformoterol fumarate dihydrate combination medicine treatment asthma cozaar losartan potassium hyzaar losartan potassium hydrochlorothiazide treatments hypertension arcoxia etoricoxib treatment arthritis pain company markets outside united states fosamax alendronate sodium marketed fosamac japan treatment prevention osteoporosis table contents vaccines gardasil human papillomavirus quadrivalent types vaccine recombinantgardasil human papillomavirus valent vaccine recombinant vaccines help prevent certain diseases caused certain types human papillomavirus hpv proquad measles mumps rubella varicella virus vaccine live pediatric combination vaccine help protect measles mumps rubella varicella mmr ii measles mumps rubella virus vaccine live vaccine help prevent measles mumps rubella varivax varicella virus vaccine live vaccine help prevent chickenpox varicella pneumovax pneumococcal vaccine polyvalent vaccine help prevent pneumococcal disease rotateq rotavirus vaccine live oral pentavalent vaccine help protect rotavirus gastroenteritis infants children zostavax zoster vaccine live vaccine help prevent shingles herpes zoster animal health animal health segment discovers develops manufactures markets animal health products including vaccines principal products segment include livestock products nuflor florfenicol antibiotic range use cattle swine bovilisvista vaccine lines infectious diseases cattle banamine flunixin meglumine bovine swine antiinflammatory estrumate cloprostenol sodium treatment fertility disorders cattle matrix altrenogest fertility management swine resflor florfenicol flunixin meglumine combination broadspectrum antibiotic nonsteroidal antiinflammatory drug bovine respiratory disease zuprevo tildipirosin bovine respiratory disease zilmax zilpaterol hydrochloride revalor trenbolone acetate estradiol improve production efficiencies beef cattle safeguard fenbendazole dewormer cattle mpac mycoplasma hyopneumoniae bacterin swine pneumonia vaccine porcilis lawsonia intracellularis baterin circumvent porcine circovirus vaccine type killed baculovirus vector vaccine lines infectious diseases swine poultry products nobilisinnovax live mareks disease vector vaccine lines poultry paracox coccivac coccidiosis vaccines exzolt systemic treatment poultry red mite infestations companion animal products bravecto fluralaner line oral topical products kills fleas ticks dogs cats weeks nobivac vaccine lines flexible dog cat vaccination otomax gentamicin sulfate usp betamethasone valerate usp clotrimazole usp ointmentmometamax gentamicin sulfate usp mometasone furoate monohydrate clotrimazole usp otic suspensionposatex orbifloxacin mometasone furoate monohydrate posaconazole suspension ear ointments acute chronic otitis caninsulinvetsulin porcine insulin zinc suspension diabetes mellitus treatment dogs cats panacur fenbendazolesafeguard fenbendazole broadspectrum anthelmintic dewormer use many animals regumate altrenogest fertility management horses prestige vaccine line horses activyl indoxacrbscalibor deltamethrinexspot protecting bites fleas ticks mosquitoes sandflies aquaculture products slice emamectin benzoate parasiticide sea lice salmon aquavac avirulent live culturenorvax vaccines bacterial viral disease fish compact pd vaccine salmon aquaflor florfenicol antibiotic farmraised fish discussion sales companys products see item managements discussion analysis financial condition results operations table contents product approvals set forth summary significant product approvals received company product date approval japanese ministry health labour welfare approved keytruda treatment patients december radically unresectable urothelial carcinoma progressed cancer chemotherapy us food drug administration fda approved keytruda previously treated patients september recurrent locally advanced metastatic gastric gastroesophageal junction cancer whose tumors express pdl european commission ec approved keytruda treatment certain patients locally september advanced metastatic urothelial carcinoma type bladder cancer fda approved keytruda treatment adult pediatric patients previously treated may unresectable metastatic microsatellite instabilityhigh msih mismatch repair deficient solid tumors fda approved keytruda treatment certain patients locally advanced metastatic urothelial keytruda may carcinoma type bladder cancer fda approved keytruda combination pemetrexed carboplatin firstline treatment may patients metastatic nonsquamous nsclc ec approved keytruda treatment adult patients relapsed refractory classical hodgkin may lymphoma chl failed autologous stem cell transplant asct brentuximab vedotin bv transplanteligible failed bv fda approved keytruda treatment adult pediatric patients refractory chl march relapsed three prior lines therapy ec approved keytruda firstline treatment metastatic nsclc adults whose tumors high january pdl expression egfr alk positive tumor mutations fda approved oral poly adpribose polymerase parp inhibitor lynparza olaparib follows new use lynparza maintenance treatment recurrent epithelial ovarian fallopian tube primary peritoneal adult cancer response platinumbased chemotherapy regardless brca status lynparza august new use lynparza tablets tablets twice daily opposed capsules capsules twice daily lynparza tablets also indicated use patients deleterious suspected deleterious germline brcamutated advanced ovarian cancer treated three prior lines chemotherapy fda approved isentress use combination antiretroviral agents treatment hiv isentress november neonates newborn patients birth four weeks age weighing least kg table contents ec approved isentress mg filmcoated tablets combination antiretroviral medicinal july products oncedaily treatment hiv infection patients treatmentnave virologically suppressed initial regimen isentress mg twice daily isentress hd fda approved isentress hd oncedaily dose isentress combination antiretroviral agents may treatment hiv infection patients treatmentnave whose virus suppressed initial regimen isentress mg given twice daily fda approved prevymis letermovir prophylaxis prevention cytomegalovirus cmv infection prevymis november disease adult cmvseropositive recipients r allogeneic hematopoietic stem cell transplant hsct steglatro fda approved steglatro ertugliflozin tablets oral sodiumglucose cotransporter sglt inhibitor steglujan december fixeddose combination steglujan ertugliflozin sitagliptin tablets fixeddose combination segluromet segluromet ertugliflozin metformin hydrochloride treatment type diabetes july merck astrazeneca entered global strategic oncology collaboration codevelop cocommercialize astrazenecas lynparza multiple cancer types merck pfizer inc announced entered worldwide collaboration except japan codevelopment copromotion ertugliflozin competition health care environment competition markets company conducts business pharmaceutical industry general highly competitive highly regulated companys competitors include worldwide researchbased pharmaceutical companies smaller research companies limited therapeutic focus generic drug manufacturers animal health care companies companys operations may adversely affected generic biosimilar competition companys products mature well technological advances competitors industry consolidation patents granted competitors competitive combination products new products competitors generic availability competitors branded products new information clinical trials marketed products postmarketing surveillance addition patent rights increasingly challenged competitors outcome highly uncertain adverse result patent dispute preclude commercialization products negatively affect sales existing products could result payment royalties recognition impairment charge respect intangible assets associated certain products competitive pressures intensified pressures industry grown pharmaceutical competition involves rigorous search technological innovations ability market innovations effectively long standing emphasis research development company well positioned compete search technological innovations additional resources required meet market challenges include quality control flexibility meet customer specifications efficient distribution system strong technical information service company active acquiring marketing products external alliances licensing arrangements collaborations refining sales marketing efforts address changing industry conditions however introduction new products processes competitors may result price reductions product displacements even products protected patents example number compounds available treat particular disease typically increases time result slowed sales growth reduced sales companys products therapeutic category highly competitive animal health business affected several factors including regulatory legislative issues scientific technological advances product innovation quality price companys products effective promotional efforts frequent introduction generic products competitors table contents health care environment government regulation global efforts toward health care cost containment continue exert pressure product pricing market access united states federal state governments many years also pursued methods reduce cost drugs vaccines pay example federal laws require company pay specified rebates medicines reimbursed medicaid provide discounts outpatient medicines purchased certain public health service entities hospitals serving disproportionate share low income uninsured patients backdrop united states enacted major health care reform legislation patient protection affordable care act aca various insurance market reforms since advanced state federal insurance exchanges launched respect effect law pharmaceutical industry law increased mandated medicaid rebate expanded rebate medicaid managed care utilization increased types entities eligible federal b drug discount program law also requires pharmaceutical manufacturers pay point service discount medicare part beneficiaries medicare part coverage gap ie socalled donut hole approximately million million million recorded merck reduction revenue respectively related donut hole provision beginning point service discount increase point service discount coverage gap result balanced budget act addition point service discount extended biosimilar products also pharmaceutical manufacturers required pay annual nontax deductible health care reform fee total annual industry fee billion increase billion annual fee decline billion currently planned remain amount thereafter fee assessed company proportion share prior year branded pharmaceutical sales certain government programs medicare medicaid company recorded million million million costs within marketing administrative expenses respectively annual health care reform fee february centers medicare medicaid services cms issued medicaid rebate final rule implements provisions aca effective april rule provides comprehensive guidance calculation average manufacturer price best price two metrics utilized determine rebates drug manufacturers required pay state medicaid programs impact changes resulting issuance rule material merck time however company still awaiting guidance cms two aspects rule deferred later implementation include definition constitutes product line extension delay participation us territories medicaid drug rebate program april company evaluate financial impact two elements become effective significant uncertainty future aca particular health care laws general united states company participating debate monitoring proposed changes could affect business company unable predict likelihood changes aca depending nature repeal replacement aca actions could material adverse effect companys results operations financial condition business also vermont legislature passed pharmaceutical cost transparency law law requires manufacturers identified vermont green mountain care board report certain product price information vermont attorney general attorney general required submit report legislature nevada california passed similar price transparency bills requiring manufacturers disclose certain pricing information provide advance notification price increases number states introduced legislation kind company expects states continue focus pharmaceutical price transparency extent proposals pass law unknown time company also faces increasing pricing pressure globally managed care organizations government agencies programs could negatively affect companys sales profit margins united states include practices managed care organizations federal state exchanges institutional governmental purchasers ii us federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act aca changes health care system enacted part health care reform united states well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries table contents could result pricing pressures example health care reform contributing increase number patients medicaid program sales pharmaceutical products subject substantial rebates addition effort contain us federal deficit pharmaceutical industry could considered potential source savings via legislative proposals debated enacted types revenue generating cost saving proposals include additional direct price controls medicare prescription drug program part addition congress may consider proposals allow certain conditions importation medicines countries remains uncertain proposals may included part future federal budget deficit reduction proposals would directly indirectly affect company us private sector consolidation integration among health care providers major factor competitive marketplace pharmaceutical products health plans pharmacy benefit managers consolidating fewer larger entities thus enhancing purchasing strength importance private thirdparty insurers well governments increasingly employ formularies control costs negotiating discounted prices exchange formulary inclusion failure obtain timely adequate pricing formulary placement mercks products obtaining pricing placement unfavorable pricing could adversely impact revenue addition formulary tier copay differentials private health insurance companies selfinsured employers raising copayments required beneficiaries particularly branded pharmaceuticals biotechnology products private health insurance companies also increasingly imposing utilization management tools clinical protocols requiring prior authorization branded product generic product available requiring patient first fail one generic products permitting access branded medicine utilization management tools also used treatment areas payer taken position multiple branded products therapeutically comparable us payer market concentrates drugs become available generic form pharmaceutical companies may face greater pricing pressure private thirdparty payers order provide information companys pricing practices company recently posted website pricing action transparency report united states years report provides companys average annual list price net price increases across companys us portfolio dating back report shows companys average annual net price increases taking sales deductions rebates discounts returns account across us human health portfolio low midsingle digits average net price across companys portfolio declined reflecting specific inyear dynamics including impact loss patent protection three major merck medicines additionally weighted average annual discount rate steadily increasing time reflecting competitive market branded medicines impact aca companys gross us sales reduced result rebates discounts returns efforts toward health care cost containment also remain intense european countries company faces competitive pricing pressure resulting generic biosimilar drugs addition majority countries europe attempt contain drug costs engaging reference pricing authorities examine predetermined markets published prices drugs brand authorities use price data markets set new local prices brandname drugs including companys guidelines examining reference pricing usually set local markets changed pursuant local regulations addition japan pharmaceutical industry subject governmentmandated biennial price reductions pharmaceutical products certain vaccines occur furthermore government order repricings classes drugs determines appropriate applicable rules certain markets outside united states also implemented cost management strategies health technology assessments hta require additional data reviews administrative processes increase complexity timing costs obtaining product reimbursement exert downward pressure available reimbursement united states htas also used government private payers companys focus emerging markets continued governments many emerging markets also focused constraining health care costs enacted price controls related measures compulsory licenses aim put pressure price pharmaceuticals constrain market access company anticipates pricing pressures market access challenges continue varying degrees emerging markets table contents beyond pricing market access challenges conditions emerging market countries affect companys efforts continue grow markets including potential political instability significant currency fluctuation controls financial crises limited changing availability funding health care developments may adversely impact business environment company company may engage thirdparty agents assist operating emerging market countries may affect ability realize continued growth may also increase companys risk exposure addressing cost containment pressures company engages public policy advocacy policymakers continues work demonstrate medicines provide value patients pay health care company advocates government policymakers encourage longterm approach sustainable health care financing ensures access innovative medicines disproportionately target pharmaceuticals source budget savings markets historically low rates health care spending company encourages governments increase investments adopt market reforms order improve citizens access appropriate health care including medicines operating conditions become challenging global pressures competition industry regulation cost containment efforts although one predict effect factors companys business company continually takes measures evaluate adapt improve organization business practices better meet customer needs believes well positioned respond evolving health care environment market forces pharmaceutical industry also subject regulation regional country state local agencies around world focused standards processes determining drug safety effectiveness well conditions sale reimbursement particular importance fda united states administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals cases fda requirements practices increased amount time resources necessary develop new products bring market united states time fda committed expediting development review products bearing breakthrough therapy designation accelerated regulatory review process medicines designation european union eu adopted directives legislation concerning classification labeling advertising wholesale distribution integrity supply chain enhanced pharmacovigilance monitoring approval marketing medicinal products human use provide mandatory standards throughout eu may supplemented implemented additional regulations eu member states companys policies procedures already consistent substance directives consequently believed material effect companys business company believes continue able conduct operations including launching new drugs regulatory environment see research development discussion regulatory approval process access medicines global health care company mercks primary role discover develop innovative medicines vaccines company also recognizes important role play helping improve access products around world companys efforts regard wideranging include set principles company strives embed operations business strategies guide companys worldwide approach expanding access health care addition company many farreaching philanthropic programs merck patient assistance program provides medicines adult vaccines free people united states prescription drug health insurance coverage without companys assistance afford merck medicine vaccines merck launched merck mothers longterm effort global health partners end preventable deaths complications pregnancy childbirth merck also provided funds merck foundation independent organization partnered variety organizations dedicated improving global health table contents privacy data protection company subject significant number privacy data protection laws regulations globally many place restrictions companys ability transfer access use personal data across business legislative regulatory landscape privacy data protection continues evolve increased attention privacy data protection issues developed emerging markets potential affect directly companys business including new eu general data protection regulation become effective impose penalties global revenue additional laws regulations enacted united states europe asia latin america increased enforcement litigation activity united states developed markets increased regulatory cooperation among privacy authorities globally company adopted comprehensive global privacy program manage evolving risks certified compliant approved asia pacific economic cooperation crossborder privacy rules system euus privacy shield program binding corporate rules eu distribution company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccines sold primarily physicians wholesalers physician distributors government entities companys professional representatives communicate effectiveness safety value companys pharmaceutical vaccine products health care professionals private practice group practices hospitals managed care organizations company sells animal health products veterinarians distributors animal producers raw materials raw materials supplies generally available multiple sources purchased worldwide normally available quantities adequate meet needs companys business patents trademarks licenses patent protection considered aggregate material importance companys marketing products united states major foreign markets patents may cover products per se pharmaceutical formulations processes intermediates useful manufacture products uses products protection individual products extends varying periods accordance legal life patents various countries protection afforded may also vary country country depends upon type patent scope coverage food drug administration modernization act includes pediatric exclusivity provision may provide additional six months market exclusivity united states indications new currently marketed drugs certain agreed upon pediatric studies completed applicant current us patent law provides additional patent term periods patented product regulatory review fda eu also provides additional six months pediatric market exclusivity attached products supplementary protection certificate spc japan provides additional term pediatric studies attached market exclusivity unrelated patent rights table contents patent portfolios developed products introduced company normally provide market exclusivity company following key patent protection united states eu japan including potential patent term extensions pte spcs indicated following marketed products product year expiration us year expiration eu year expiration japan cancidas expired expired zostavax expired use na zetia expired vytorin expired asmanex formulation formulation formulation nuvaring delivery system delivery system na emend injection follistim aq formulation formulation formulation noxafil na rotateq expired expired recombivax method making expired expired dulera combination na na januvia janumet na janumet xr na na isentress simponi na na adempas patents spcs bridion pending pte nexplanon device device marketed bravecto pending pte patents spcs gardasil gardasil patents spcs na keytruda patents spcs lynparza pending pte patents spcs zerbaxa pending pte patents spcs na sivextro patents spcs na belsomra na prevymis pending pte na steglatro pending pte na na steglujan pending pte na na segluromet pending pte na na zepatier patents spcs pending pte na currently marketing approval note compound patent unless otherwise noted certain products listed may subject patent litigation see item financial statements supplementary data note contingencies environmental liabilities eu date represents expiration date following five countries france germany italy spain united kingdom major eu markets spc granted major eu markets patent expiry date spc expiry date listed eligible months pediatric exclusivity pte system japan allows patent extended provided later approval directed different indication previous approval may result multiple pte approvals given patent expiration date company marketing rights us japan commercialized worldwide collaboration bayer ag developed commercialized global strategic oncology collaboration astrazeneca pte application filed april expected expiry spc applications filed july expected expiry eligible pediatric exclusivity developed promoted worldwide except japan collaboration pfizer expiration product patent normally results loss market exclusivity covered pharmaceutical product commercial benefits may continue derived latergranted patents processes intermediates related economical method manufacture active ingredient product ii patents relating use product iii patents relating novel compositions formulations iv table contents united states certain countries market exclusivity may available relevant law effect product patent expiration pharmaceutical products also depends upon many factors nature market position product growth market complexities economics process manufacture active ingredient product requirements new drug provisions federal food drug cosmetic act similar laws regulations countries additions market exclusivity sought united states countries relevant laws including laws increasing patent life benefits increases patent life partially offset increase number incentives use generic products additionally improvements intellectual property laws sought united states countries reform patent relevant laws implementation international treaties company following key us patent protection drug candidates review united states fda additional patent term may provided pipeline candidates based patent term restoration pediatric exclusivity currently anticipated review us year expiration us v pediatric hexavalent combination vaccine method making mk doravirine mka doravirinelamivudinetenofovir disoproxil fumarate company also following key us patent protection drug candidates phase development currently anticipated phase drug candidate year expiration us v ebola vaccine mk selumetinib mka relebactam imipenemcilastatin mk vericiguat developed commercialized global strategic oncology collaboration astrazeneca developed worldwide clinical development collaboration bayer ag unless otherwise noted patents charts compound patents patent subject future patent term restoration five years six month pediatric market exclusivity either may available addition depending circumstances surrounding final regulatory approval compound may listed patents patent applications pending could relevance product finally approved relevance application would depend upon claims ultimately may granted nature final regulatory approval product also regulatory exclusivity tied protection clinical data complementary patent protection cases may provide effective longer lasting marketing exclusivity compounds patent estate united states data protection generally runs five years first marketing approval new chemical entity extended seven years orphan drug indication years first marketing approval biological product information respect companys patents see item risk factors item financial statements supplementary data note contingencies environmental liabilities worldwide companys important products sold trademarks considered aggregate material importance trademark protection continues countries long used countries long registered registration fixed terms renewed indefinitely royalty income patent knowhow licenses rights amounted million merck also incurred royalty expenses amounting million patent knowhow licenses holds research development companys business characterized introduction new products new uses existing products strong research development program december approximately people employed companys research activities research development expenses billion table contents billion billion included restructuring costs acquisition divestiturerelated costs years company prioritizes research development efforts focuses candidates believes represent breakthrough science make difference patients payers company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development companys research development model designed increase productivity improve probability success prioritizing companys research development resources candidates company believes capable providing unambiguous promotable advantages patients payers delivering maximum value approved medicines vaccines new indications new formulations merck pursuing emerging product opportunities independent therapeutic area modality small molecule biologics vaccines building biologics capabilities company committed ensuring externally sourced programs remain important component pipeline strategy focus supplementing internal research licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well access new technologies company also reviews pipeline examine candidates may provide value outlicensing company continues evaluate certain latestage clinical development platform technology assets determine outlicensing sale potential companys clinical pipeline includes candidates multiple disease areas including cancer cardiovascular diseases diabetes infectious diseases neurosciences obesity pain respiratory diseases vaccines development human health products industry practice government regulations united states foreign countries provide determination effectiveness safety new chemical compounds preclinical tests controlled clinical evaluation new drug vaccine may marketed united states recorded data preclinical clinical experience included new drug application nda drug biologics license application bla vaccine biologic submitted fda required approval companys scientists discover new small molecule compound biologic believe promise treat medical condition company commences preclinical testing compound preclinical testing includes laboratory testing animal safety studies gather data chemistry pharmacology immunogenicity toxicology pending acceptable preclinical data company initiate clinical testing accordance established regulatory requirements clinical testing begins phase studies designed assess safety tolerability pharmacokinetics preliminary pharmacodynamic activity compound humans favorable additional larger phase studies initiated determine efficacy compound affected population define appropriate dosing compound well identify adverse effects could limit compounds usefulness situations clinical program incorporates adaptive design methodology use accumulating data decide modify aspects ongoing clinical study continues without undermining validity integrity trial one type adaptive clinical trial adaptive phase ab trial design twostage trial design consisting phase proofofconcept stage phase b doseoptimization finding stage data phase trials satisfactory company commences largescale phase trials confirm compounds efficacy safety another type adaptive clinical trial adaptive phase trial design study includes interim analysis adaptation changes trial features common phase study eg multiple dose groups design similar phase trial adaptive phase trial design reduces timelines eliminating activities would required start separate study upon completion phase trials satisfactory company submits regulatory filings appropriate regulatory agencies around world product candidate approved marketing assurance compound result particular program obtain regulatory approvals necessary marketed vaccine development follows general pathway drugs preclinical testing focuses vaccines safety ability elicit protective immune response immunogenicity premarketing vaccine clinical trials typically done three phases initial phase clinical studies conducted normal subjects evaluate safety tolerability immunogenicity vaccine candidate phase studies doseranging studies finally phase trials provide necessary data effectiveness safety successful company submits regulatory filings appropriate regulatory agencies table contents united states fda review process begins complete nda bla submitted received accepted review agency within days receipt fda determines application sufficiently complete permit substantive review fda also assesses time whether application granted priority review standard review pursuant prescription drug user fee act v pdufa fda review period target ndas original blas either six months priority review ten months standard review time application deemed sufficiently complete review timelines determined fda generally act upon application within timelines unless major amendment submitted either companys initiative fdas request pending application occurs fda may extend review period allow review new information three months extensions review period communicated company fda act application either issuing approval letter issuing complete response letter crl stating application approved present form describing deficiencies fda identified company wish pursue application receiving crl resubmit application information addresses questions issues identified fda order support approval resubmissions subject review period targets vary depending underlying submission type content resubmission fda four program designations fast track breakthrough therapy accelerated approval priority review facilitate expedite development review new drugs address unmet medical needs treatment serious lifethreatening conditions fast track designation provides pharmaceutical manufacturers opportunities frequent interactions fda reviewers products development ability manufacturer rolling submission ndabla rolling submission allows completed portions application submitted reviewed fda ongoing basis breakthrough therapy designation provides manufacturers features fast track designation well intensive guidance implementing efficient development program product commitment fda involve senior managers experienced staff review accelerated approval designation allows fda approve product based effect surrogate intermediate endpoint reasonably likely predict products clinical benefit generally requires manufacturer conduct required postapproval confirmatory trials verify clinical benefit priority review designation means fdas goal take action ndabla within six months compared ten months standard review addition generating antibiotic incentives act fda may grant qualified infectious disease product qidp status antibacterial antifungal drugs intended treat serious life threatening infections including caused antibiotic antifungal resistant pathogens novel emerging infectious pathogens qualifying pathogens qidp designation offers certain incentives development qualifying drugs including priority review nda filed eligibility fast track designation fiveyear extension applicable exclusivity provisions food drug cosmetic act primary method company uses obtain marketing authorization pharmaceutical products eu centralized procedure procedure compulsory certain pharmaceutical products particular using biotechnological processes also available certain new chemical compounds products company seeking market innovative pharmaceutical product centralized procedure must file complete set safety data efficacy data part marketing authorization application maa european medicines agency ema ema evaluates maa provides recommendation ec ec approves denies maa also possible new chemical products obtain marketing authorization eu mutual recognition procedure application made single member state member state approves pharmaceutical product national procedure applicant may submit approval mutual recognition procedure member states outside united states eu company submits marketing applications national regulatory authorities examples pharmaceuticals medical devices agency japan health canada agncia nacional de vigilncia sanatria brazil korea food drug administration south korea therapeutic goods administration australia china food drug administration country separate independent review process timeline many markets approval times longer regulatory authority requires approval major market united states eu issuance certificate pharmaceutical product market initiating local review process table contents research development update company currently several candidates regulatory review united states internationally keytruda approved antipd therapy clinical development expanded indications different cancer types december fda accepted review supplemental bla keytruda treatment adult pediatric patients refractory primary mediastinal bcell lymphoma pmbcl relapsed two prior lines therapy fda granted priority review status pdufa target action date april additionally keytruda received breakthrough therapy designation fda combination axitnib firstline treatment patients advanced metastatic renal cell carcinoma treatment highrisk earlystage triplenegative breast cancer combination neoadjuvant chemotherapy treatment merkel cell carcinoma also january merck eisai co ltd eisai announced receipt breakthrough therapy designation fda eisais multiple receptor tyrosine kinase inhibitor lenvima lenvatinib combination keytruda potential treatment patients advanced andor metastatic renal cell carcinoma lenvima keytruda combination therapy jointly developed eisai merck marks th breakthrough therapy designation granted keytruda fdas breakthrough therapy designation intended expedite development review candidate planned use alone combination treat serious lifethreatening disease condition preliminary clinical evidence indicates drug may demonstrate substantial improvement existing therapies one clinically significant endpoints january merck announced pivotal phase keynote trial investigating keytruda combination pemetrexed alimta cisplatin carboplatin firstline treatment patients metastatic nonsquamous nsclc met dual primary endpoints overall survival os progressionfree survival pfs based interim analysis conducted independent data monitoring committee treatment keytruda combination pemetrexed plus platinum chemotherapy resulted significantly longer os pfs pemetrexed plus platinum chemotherapy alone results keynote presented upcoming medical meeting submitted regulatory authorities fda placed full clinical hold keynote keynote partial clinical hold cohort keynote three combination studies keytruda lenalidomide pomalidomide versus lenalidomide pomalidomide alone blood cancer multiple myeloma decision followed review data data monitoring committee deaths observed keytruda arms keynote keynote fda determined data available time indicated risks keytruda plus pomalidomide lenalidomide outweighed potential benefit patients multiple myeloma patients enrolled keynote keynote keytrudalenalidomidedexamethasone cohort keynote discontinued investigational treatment keytruda clinical hold apply studies keytruda keytruda clinical development program consists clinical trials including trials combine keytruda cancer treatments studies encompass cancer types including bladder colorectal esophageal gastric head neck hepatocellular hodgkin lymphoma nonhodgkin lymphoma melanoma nasopharyngeal nsclc ovarian pmbcl prostate renal smallcell lung triplenegative breast many currently phase clinical development trials planned cancers mk ertugliflozin investigational oral sglt inhibitor development help improve glycemic control adults type diabetes two fixeddose combination products mka ertugliflozin januvia mkb ertugliflozin metformin review eu january committee medicinal products human use chmp ema adopted positive opinion recommending approval medicines chmp positive opinion considered ec ertugliflozin two fixeddose combination products approved fda december mkj investigational fixeddose combination sitagliptin ipragliflozin review japan pharmaceuticals medical devices agency mk developed commercialization japan table contents collaboration astellas pharma inc astellas ipragliflozin sglt inhibitor codeveloped astellas kotobuki pharmaceutical co ltd kotobuki approved use japan copromoted merck kotobuki mk doravirine investigational nonnucleoside reverse transcriptase inhibitor treatment hiv infection january merck announced fda accepted review two ndas doravirine ndas include data doravirine oncedaily tablet use combination antiretroviral agents use doravirine lamivudine tenofovir disoproxil fumarate oncedaily fixeddose combination single tablet complete regimen mka pdufa action date applications october v investigational pediatric hexavalent combination vaccine dtapipvhibhepb review fda developed approved commercialized joint venture merck sanofi vaccine designed help protect six important diseases diphtheria tetanus pertussis whooping cough polio poliovirus types invasive disease caused haemophilus influenzae type b hib hepatitis b november fda issued crl respect bla v companies working provide additional data requested fda v marketed vaxelis eu addition candidates regulatory review company several drug candidates phase clinical development addition keytruda programs discussed mka combination relebactam investigational betalactamase inhibitor imipenemcilastatin approved carbapenem antibiotic fda designated combination qidp designated fast track status treatment hospitalacquired bacterial pneumonia ventilatorassociated bacterial pneumonia complicated intraabdominal infections complicated urinary tract infections mk lynparza olaparib oral parp inhibitor currently approved certain types ovarian breast cancer july merck astrazeneca entered global strategic oncology collaboration codevelop cocommercialize astrazenecas lynparza multiple cancer types mk selumetinib oral potent selective inhibitor mek part mitogenactivated protein kinase mapk pathway currently developed multiple cancer types additionally february fda granted orphan drug designation selumetinib treatment neurofibromatosis type development selumetinib part global strategic oncology collaboration merck astrazeneca reference v investigational rvsvzebov ebola vaccine candidate studied large scale phase clinical trials november merck newlink genetics announced exclusive licensing collaboration agreement investigational ebola vaccine december merck announced application emergency use assessment listing eual v accepted review world health organization according eual process designed expedite availability vaccines needed public health emergencies another outbreak ebola decision grant v eual status based data regarding quality safety efficacyeffectiveness well riskbenefit analysis emergency use eual designation allows emergency use vaccine remains investigational yet licensed commercial distribution july merck announced fda granted v breakthrough therapy designation ema granted vaccine candidate prime priority medicines status december end study results ring vaccination trial reported lancet supporting july interim assessment v offers substantial protection ebola virus disease reported cases among vaccinated individuals days vaccination randomized nonrandomized clusters results ongoing studies included first regulatory filing anticipated first half mk vericiguat investigational treatment heart failure studied patients suffering chronic heart failure development vericiguat part worldwide strategic collaboration merck bayer v inactivated varicella zoster virus vzv vaccine development prevention herpes zoster company completed phase trial autologous hematopoietic cell transplant patients another phase trial patients solid tumor malignancies undergoing chemotherapy hematological malignancies study autologous hematopoietic cell transplant patients met primary endpoints merck presented results study american society blood marrow transplantation meetings february study table contents patients solid tumor malignancies undergoing chemotherapy met primary endpoints primary efficacy endpoint met patients hematologic malignancies merck present results study upcoming scientific meeting due competitive environment development v currently hold mk selective nonnarcotic orallyadministered pxreceptor agonist developed treatment refractory chronic cough merck plans initiate phase clinical trial first half mk originally developed afferent pharmaceuticals acquired company company also discontinued certain drug candidates february merck announced stopping protocol also known apecs study phase study evaluating verubecestat mk investigational small molecule inhibitor betasite amyloid precursor protein cleaving enzyme bace people prodromal alzheimers disease decision stop study follows recommendation external data monitoring committee edmc assessed overall benefitrisk recent interim safety analysis edmc concluded unlikely positive benefitrisk could established trial continued merck announced submit applications regulatory approval mk anacetrapib companys investigational cholesteryl ester transfer protein cetp inhibitor decision followed thorough review clinical profile anacetrapib including discussions external experts also merck made strategic decision discontinue development investigational combination regimens mkb grazoprevirruzasviruprifosbuvir mkc ruzasviruprifosbuvir treatment hcv infection decision made based review available phase efficacy data consideration evolving marketplace growing number treatment options available patients chronic hcv infection including zepatier currently marketed company treatment adult patients chronic hcv infection table contents chart reflects companys research pipeline february candidates shown phase include specific products date candidate entered phase development candidates shown phase include advanced compound specific mechanism listed compounds mechanism currently intended commercialization given therapeutic area small molecules biologics given mknumber designations vaccine candidates given vnumber designations except otherwise noted candidates phase additional indications therapeutic area respect keytruda additional claims line extensions formulations inline products shown phase phase phase entry date review cancer bacterial infection new molecular entitiesvaccines mk keytruda mka relebactamimipenemcilastatin diabetes mellitus advanced solid tumors october mkj sitagliptinipragliflozin japan ovarian cancer mk ertugliflozin eu prostate mk keytruda mka ertugliflozinsitagliptin eu chronic cough breast october mkb ertugliflozinmetformin eu mk colorectal november hiv diabetes mellitus esophageal december mk doravirine us mk gastric may eu mka doravirinelamivudinetenofovir disoproxil fumarate us hiv infection head neck november eu pediatric hexavalent combination vaccine mk hepatocellular may v us pneumoconjugate vaccine nasopharyngeal april v renal october schizophrenia smallcell lung may certain supplemental filings mk mk lynparza mk keytruda pancreatic december relapsed refractory primary mediastinal bcell lymphoma prostate april pmbcl us mk selumetinib mk lynparza thyroid june broader approval ovarian cancer eu ebola vaccine v march footnotes heart failure mk vericiguat september developed collaboration herpes zoster development currently hold v inactivated vzv vaccine v investigational pediatric hexavalent combination vaccine december dtapipvhibhepb developed approved hiv commercialized partnership merck sanofi november mk doravirine december eu fda issued crl respect v companies mka doravirinelamivudinetenofovir disoproxil fumarate june working provide additional data requested fda eu employees december company approximately employees worldwide approximately employed united states including puerto rico approximately worldwide employees company represented various collective bargaining groups restructuring activities company incurs substantial costs restructuring program activities related mercks productivity cost reduction initiatives well connection integration certain acquired businesses company commenced actions global restructuring programs designed streamline cost structure actions programs include elimination positions sales administrative headquarters organizations well sale closure certain manufacturing research development sites consolidation office facilities company also continues reduce global real estate footprint improve efficiency manufacturing supply network since inception programs december merck eliminated approximately positions comprised employee separations well elimination contractors vacant positions company substantially completed actions programs environmental matters company believes compliance issues associated applicable environmental laws regulations would material adverse effect company company also remediating table contents environmental contamination resulting past industrial activity certain sites expenditures remediation environmental liabilities million estimated million aggregate years amounts consider potential recoveries parties company taken active role identifying accruing costs managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures material adverse effect companys financial position results operations liquidity capital resources year merck believes climate change could present risks business potential impacts climate change business include increased operating costs due additional regulatory requirements physical risks companys facilities water limitations disruptions supply chain potential risks integrated companys business planning including investment reducing energy water use greenhouse gas emissions company believe risks material business time geographic area information companys operations outside united states conducted primarily subsidiaries sales worldwide subsidiaries outside united states percentage total company sales sales sales sales companys worldwide business subject risks currency fluctuations governmental actions governmental proceedings abroad company regard risks deterrent expansion operations abroad however company closely reviews methods operations adopts strategies responsive changing economic political conditions merck operations countries located latin america middle east africa eastern europe asia pacific business developing areas sometimes less stable offers important opportunities growth time financial information geographic areas companys business provided item financial statements supplementary data available information companys internet website address wwwmerckcom company make available free charge investors portion website annual report quarterly reports form q current reports form k amendments reports filed furnished pursuant section securities exchange act amended soon reasonably practicable reports electronically filed furnished us securities exchange commission sec addition company provide without charge copy annual report including financial statements schedules upon written request shareholder merck shareholder services merck co inc galloping hill road k kenilworth nj usa companys corporate governance guidelines charters board directors four standing committees available companys website wwwmerckcomaboutleadership information available print stockholder requests company item risk factors investors carefully consider information set forth including following risk factors deciding invest companys securities risks ones company faces additional risks currently known company company presently deems immaterial may also impair business operations companys business financial condition results operations prospects could materially adversely affected risks also contains forwardlooking statements involve risks uncertainties companys results could materially differ anticipated table contents forwardlooking statements result certain factors including risks faces described elsewhere see cautionary factors may affect future results company dependent patent rights patent rights invalidated circumvented business would adversely affected patent protection considered aggregate material importance companys marketing human health products united states major foreign markets patents covering products introduced normally provide market exclusivity important successful marketing sale products company seeks patents covering products markets intends sell products meaningful patent protection available even company succeeds obtaining patents covering products third parties government authorities may challenge seek invalidate circumvent patents patent applications important companys business defend successfully patent rights provide market exclusivity products company often involved patent disputes relating challenges patents claims third parties infringement company company defends patents within outside united states including filing claims infringement parties see item financial statements supplementary data note contingencies environmental liabilities particular manufacturers generic pharmaceutical products time time file abbreviated ndas fda seeking market generic forms companys products prior expiration relevant patents owned licensed company company normally responds defending patent including filing lawsuits alleging patent infringement patent litigation challenges companys patents costly unpredictable may deprive company market exclusivity patented product cases thirdparty patents may prevent company marketing selling product particular geographic area additionally certain foreign governments indicated compulsory licenses patents may granted case national emergencies circumstances could diminish eliminate sales profits regions negatively affect companys results operations court decisions relating companies patents potential legislation relating patents well regulatory initiatives may result general weakening intellectual property protection one important products lose patent protection profitable markets sales products likely decline significantly result generic versions products becoming available addition products measured fair value capitalized connection acquisitions experience difficulties market negatively impact product cash flows company may recognize material noncash impairment charges respect value products companys results operations may adversely affected lost sales unless company successfully launched commercially successful replacement products chart listing patent protection certain companys marketed products us patent protection candidates review phase candidates set forth item business patents trademarks licenses companys products lose market exclusivity company generally experiences significant rapid loss sales products company depends upon patents provide exclusive marketing rights products period time loss patent protection one companys products typically leads significant rapid loss sales product lower priced generic versions drug become available case products contribute significantly companys sales loss market exclusivity material adverse effect companys business cash flow results operations financial position prospects example pursuant agreement generic manufacturer manufacturer launched united states generic version zetia december addition company lost us patent protection vytorin april result company experienced significant rapid loss sales zetia vytorin united states company expects continue addition patent provides us market exclusivity nuvaring expire april company anticipates significant decline us nuvaring sales thereafter table contents key products generate significant amount companys profits cash flows events adversely affect markets leading products could material negative impact results operations cash flows companys ability generate profits operating cash flow depends largely upon continued profitability companys key products januvia janumet keytruda gardasilgardasil isentress result companys dependence key products event adversely affects products markets products could significant adverse impact results operations cash flows events could include loss patent protection increased costs associated manufacturing generic overthecounter availability companys product competitive product discovery previously unknown side effects results postapproval trials increased competition introduction new effective treatments discontinuation removal market product reason events could material adverse effect sales products example company anticipates sales zepatier materially unfavorably affected increasing competition declining patient volumes company also anticipates sales zostavax materially unfavorably affected due competition companys research development efforts may succeed developing commercially successful products company may able acquire commercially successful products ways consequence company may able replace sales successful products lost patent protection like major pharmaceutical companies order remain competitive company must continue launch new products year expected declines sales products loss market exclusivity mean companys future success dependent pipeline new products including new products may develop collaborations joint ventures products able obtain license acquisition accomplish company commits substantial effort funds resources research development dedicated resources various collaborations third parties high rate failure inherent research development process new drugs result high risk funds invested company research programs generate financial returns risk profile compounded fact research long investment cycle bring pharmaceutical compound discovery phase market may take decade failure occur point process including later process significant funds invested description research development process see item business research development phase testing highly regulated phase substantial risk company encounter serious obstacles achieve goals therefore company may abandon product invested substantial amounts time resources risks encountered research development process include following preclinical testing new compound may yield disappointing results competing products manufacturers may reach market first clinical trials new drug may successful new drug may effective may harmful side effects new drug may approved regulators intended use may possible obtain patent new drug payers may refuse cover reimburse new product sales new product may disappointing company state certainty whether products development approved launched whether able develop license otherwise acquire compounds product candidates products whether products launched commercially successful company must maintain continuous flow successful new products successful new indications brand extensions existing products sufficient cover substantial research development costs replace sales lost profitable products lose market exclusivity displaced competing products therapies failure short term long term would material adverse effect companys business results operations cash flow financial position prospects table contents companys success dependent successful development marketing new products subject substantial risks products appear promising development may fail reach market fail succeed numerous reasons including following findings ineffectiveness superior safety efficacy competing products harmful side effects clinical preclinical testing failure receive necessary regulatory approvals including delays approval new products new indications uncertainties time required obtain regulatory approvals benefitrisk standards applied regulatory agencies determining whether grant approvals failure certain markets obtain reimbursement commensurate level innovation clinical benefit presented product lack economic feasibility due manufacturing costs factors preclusion commercialization proprietary rights others future certain pipeline programs cancelled company believes commercial prospects reduced company may recognize material noncash impairment charges programs measured fair value capitalized connection acquisitions failure successfully develop market new products short term long term would material adverse effect companys business results operations cash flow financial position prospects companys products including products development marketed unless company obtains maintains regulatory approval companys activities including research preclinical testing clinical trials manufacturing marketing products subject extensive regulation numerous federal state local governmental authorities united states including fda foreign regulatory authorities including eu japan united states fda particular importance company administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals many cases fda requirements increased amount time money necessary develop new products bring market united states regulation outside united states also primarily focused drug safety effectiveness many cases cost reduction fda foreign regulatory authorities substantial discretion require additional testing delay withhold registration marketing approval otherwise preclude distribution sale product even company successful developing new products able market products unless obtained required regulatory approvals jurisdiction proposes market new products obtained company must maintain approval long plans market new products jurisdiction approval required companys failure obtain approval significant delays approval process failure maintain approval jurisdiction prevent selling new products jurisdiction approval obtained ever company would able realize revenues new products jurisdiction approval developments following regulatory approval may adversely affect sales companys products even product reaches market certain developments following regulatory approval including results postapproval phase trials studies may decrease demand companys products including following rereview products already marketed recall loss marketing approval products already marketed table contents changing government standards public expectations regarding safety efficacy labeling changes greater scrutiny advertising promotion past several years clinical trials postmarketing surveillance certain marketed drugs company competitors within industry raised concerns led recalls withdrawals adverse labeling marketed products clinical trials postmarketing surveillance certain marketed drugs also raised concerns among prescribers patients relating safety efficacy pharmaceutical products general negatively affected sales products addition increased scrutiny outcomes clinical trials led increased volatility market reaction matters often attract litigation even basis litigation groundless considerable resources may needed respond addition following wake product withdrawals significant safety issues health authorities fda ema japans pharmaceutical medical device agency increased focus safety assessing benefitrisk balance drugs health authorities appear become cautious making decisions approvability new products indications rereviewing select products already marketed adding uncertainties regulatory processes also greater regulatory scrutiny especially united states advertising promotion particular directtoconsumer advertising previously unknown side effects discovered increase negative publicity regarding known side effects companys products could significantly reduce demand product require company take actions could negatively affect sales including removing product market restricting distribution applying labeling changes current environment pharmaceutical companies operate company risk product liability consumer protection claims civil criminal governmental actions related products research andor marketing activities company faces intense competition lower cost generic products general company faces increasing competition lowercost generic products patent rights protect products varying strengths durations addition countries patent protection significantly weaker united states eu united states eu political pressure reduce spending prescription drugs led legislation measures encourage use generic biosimilar products although companys policy actively protect patent rights generic challenges companys products arise time companys patents may prevent emergence generic competition products loss patent protection product typically followed promptly generic substitutes reducing companys sales product availability generic substitutes companys drugs may adversely affect results operations cash flow addition proposals emerge time time united states countries legislation encourage early rapid approval generic drugs proposal enacted law could worsen substantial negative effect companys sales potentially business cash flow results operations financial position prospects company faces intense competition competitors products addition factors could certain circumstances lead noncash impairment charges companys products face intense competition competitors products competition may increase new products enter market event competitors products may safer effective convenient use effectively marketed sold companys products alternatively case generic competition including generic availability competitors branded products may equally safe effective products sold substantially lower price companys products result company fails maintain competitive position could material adverse effect business cash flow results operations financial position prospects addition products measured fair value capitalized connection acquisitions experience difficulties market negatively impact product cash flows company may recognize material non cash impairment charges respect value products table contents company faces continued pricing pressure respect products company faces continued pricing pressure globally particularly mature markets managed care organizations government agencies programs could negatively affect companys sales profit margins united states include practices managed care groups institutional governmental purchasers ii us federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act aca iii state activities aimed increasing price transparency changes health care system enacted part health care reform united states well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries could result pricing pressures addition us larger customers may future ask receive higher rebates drugs certain highly competitive categories company must also compete placed formularies managed care organizations exclusion product formulary lead reduced usage managed care organization order provide information companys pricing practices company recently posted website pricing action transparency report united states years report provides companys average annual list price net price increases across companys us portfolio dating back report shows companys average annual net price increases taking sales deductions rebates discounts returns account across us human health portfolio low midsingle digits average net price across companys portfolio declined reflecting specific inyear dynamics including impact loss patent protection three major merck medicines additionally weighted average annual discount rate steadily increasing time reflecting competitive market branded medicines impact aca companys gross us sales reduced result rebates discounts returns outside united states numerous major markets including eu japan pervasive government involvement funding health care regard fix pricing reimbursement pharmaceutical vaccine products consequently markets company subject government decision making budgetary actions respect products company expects pricing pressures continue future health care industry united states continue subject increasing regulation political action company believes health care industry continue subject increasing regulation well political legal action future proposals reform health care system considered executive branch congress state legislatures united states enacted major health care reform legislation form aca various insurance market reforms advanced state federal insurance exchanges launched respect effect law pharmaceutical industry law increased mandated medicaid rebate expanded rebate medicaid managed care utilization increased types entities eligible federal b drug discount program law also requires pharmaceutical manufacturers pay point service discount medicare part beneficiaries medicare part coverage gap ie socalled donut hole companys revenue reduced million due requirement beginning point service discount increase point service discount coverage gap result balanced budget act addition point service discount extended biosimilar products also pharmaceutical manufacturers required pay annual nontax deductible health care reform fee total annual industry fee billion billion fee assessed company proportion share prior year branded pharmaceutical sales certain government programs medicare medicaid company recorded million costs annual fee january centers medicare medicaid services cms issued medicaid rebate final rule implements provisions aca effective april rule provides comprehensive guidance calculation average manufacturer price best price two metrics utilized determine rebates drug table contents manufacturers required pay state medicaid programs impact changes resulting issuance rule material merck time however company still awaiting guidance cms two aspects rule deferred later implementation include definition constitutes product line extension delay participation us territories medicaid drug rebate program april company evaluate financial impact two elements become effective company predict likelihood future changes health care industry general pharmaceutical industry particular impact may companys results operations financial condition business company increasingly dependent sophisticated software applications computing infrastructure company experienced network cyberattack led disruption worldwide operations including manufacturing research sales operations company could target future cyberattacks company increasingly dependent sophisticated software applications complex information technology systems computing infrastructure collectively systems conduct critical operations disruption degradation manipulation systems intentional accidental means could impact key business processes cyberattacks companys systems could result exposure confidential information modification critical data andor failure critical operations misuse systems could result disclosure sensitive personal information theft trade secrets intellectual property confidential business information company continues leverage new innovative technologies across enterprise improve efficacy efficiency business processes use create new risks june company experienced network cyberattack led disruption worldwide operations including manufacturing research sales operations companys manufacturing sites operational manufacturing active pharmaceutical ingredient api formulating packaging shipping product companys external manufacturing impacted throughout time merck continued fulfill orders ship product due cyberattack anticipated company unable fulfill orders certain products certain markets unfavorable effect sales approximately million addition company recorded manufacturingrelated expenses primarily unfavorable manufacturing variances materials production costs well expenses related remediation efforts marketing administrative expenses research development expenses aggregated million net insurance recoveries approximately million due residual backlog orders company anticipates sales unfavorably affected certain markets approximately million cyberattack merck expect significant impairment value intangible assets related marketed products inventories result cyberattack company insurance coverage insuring costs resulting cyberattacks received proceeds however may disputes insurers availability insurance coverage claims related incident additionally temporary production shutdown cyberattack contributed companys inability meet higher expected demand gardasil resulted mercks decision borrow doses gardasil us centers disease control prevention pediatric vaccine stockpile company subsequently replenished portion borrowed doses net effect borrowing subsequent partial replenishment reduction sales million company anticipates replenish remaining borrowed doses second half company implemented variety measures enhance systems guard similar attacks future also pursuing enterprisewide effort enhance company 's resiliency future cyberattacks including incidents similar june attack objective efforts protect future cyberattacks also improve speed companys recovery attacks enable continued business operations greatest extent possible recovery period although aggregate impact cyberattacks network disruptions including june cyberattack companys operations financial condition material date company continues table contents target events nature expects continue company monitors data information technology personnel usage company systems reduce risks continues ongoing basis current potential threats assurance companys efforts protect data systems successful preventing disruptions operations including manufacturing research sales operations disruption could result loss revenue loss critical sensitive information companys companys third party providers databases systems could also result financial legal business reputational harm company potentially substantial remediation costs changes laws regulations could materially adversely affect companys business aspects companys business including research development manufacturing marketing pricing sales litigation intellectual property rights subject extensive legislation regulation changes applicable federal state laws agency regulations could material adverse effect companys business particular significant uncertainty future aca health care laws general united states company participating debate monitoring proposed changes could affect business company unable predict likelihood changes aca depending nature repeal replacement aca actions could material adverse effect companys results operations financial condition business uncertainty global economic conditions together austerity measures taken certain governments could negatively affect companys operating results uncertainty global economic geopolitical conditions may result slowdown global economy could affect companys business reducing prices drug wholesalers retailers hospitals government agencies managed health care providers may able willing pay companys products reducing demand companys products could turn negatively impact companys sales result material adverse effect companys business cash flow results operations financial position prospects global efforts toward health care cost containment continue exert pressure product pricing market access united states pricing pressures continue many companys products several international markets governmentmandated pricing actions reduced prices generic patented drugs addition austerity measures negatively affected companys revenue performance company anticipates pricing actions including biennial price reductions japan occur austerity measures continue negatively affect revenue performance credit economic conditions worsen resulting economic currency impacts affected markets globally could material adverse effect companys results company significant global operations expose additional risks adverse event could material negative impact companys results operations extent companys operations outside united states significant risks inherent conducting global business include changes medical reimbursement policies programs pricing restrictions key markets multiple regulatory requirements could restrict companys ability manufacture sell products key markets trade protection measures import export licensing requirements including imposition trade sanctions similar restrictions united states governments foreign exchange fluctuations table contents diminished protection intellectual property countries possible nationalization expropriation addition may changes companys business political position instability disruption destruction significant geographic region regardless cause including war terrorism riot civil insurrection social unrest natural manmade disasters including famine flood fire earthquake storm disease example companys lone manufacturing plant puerto rico negatively affected hurricane maria june united kingdom uk held referendum voters approved exit eu commonly referred brexit result referendum british government begun negotiating terms uks future relationship eu although unknown terms possible greater restrictions imports exports uk eu countries increased regulatory complexities cross boarder labor issues could adversely impact companys business operations uk failure attract retain highly qualified personnel could affect ability successfully develop commercialize products companys success largely dependent continued ability attract retain highly qualified scientific technical management personnel well personnel expertise clinical research development governmental regulation commercialization competition qualified personnel pharmaceutical industry intense company sure able attract retain quality personnel costs materially increase past company experienced difficulties delays manufacturing certain products including vaccines merck past experienced difficulties manufacturing certain products including vaccines addition network cyberattack experienced company june led disruption companys operations including manufacturing operations company may future experience difficulties delays inherent manufacturing products failure company vendors suppliers comply current good manufacturing practices applicable regulations quality assurance guidelines could lead manufacturing shutdowns product shortages delays product manufacturing ii construction delays related construction new facilities expansion existing facilities including intended support future demand companys products iii manufacturing distribution problems including changes manufacturing production sites limits manufacturing capacity due regulatory requirements changes types products produced physical limitations could impact continuous supply manufacturing difficulties result product shortages leading lost sales reputational harm company company may able realize expected benefits investments emerging markets company taking steps increase sales emerging markets however guarantee companys efforts expand sales markets succeed countries within emerging markets may especially vulnerable periods global financial instability may limited resources spend health care order company successfully implement emerging markets strategy must attract retain qualified personnel company may also required increase reliance thirdparty agents within less developed markets addition many countries currencies fluctuate substantially currencies devalue company offset devaluations companys financial performance within countries could adversely affected addition china commercial economic conditions may adversely affect companys growth prospects market company continues believe china represents important growth opportunity events coupled heightened scrutiny health care industry may continue impact product pricing market access generally company anticipates reported inquiries made various governmental authorities involving multinational pharmaceutical companies china may continue table contents reasons sales within emerging markets carry significant risks however failure maintain companys presence emerging markets could material adverse effect business financial condition results companys operations company exposed market risk fluctuations currency exchange rates interest rates company operates multiple jurisdictions virtually sales denominated currencies local jurisdiction additionally company entered enter acquisition licensing borrowings financial transactions may give rise currency interest rate exposure since company certainty foresee mitigate adverse fluctuations fluctuations currency exchange rates interest rates could negatively affect companys results operations financial position cash flows occurred respect venezuela order mitigate adverse impact market fluctuations company time time enter hedging agreements hedging agreements currency options forwards interest rate swaps may limit exposure exchange rate interest rate fluctuations attempts mitigate risks may costly always successful company subject evolving complex tax laws may result additional liabilities may affect results operations company subject evolving complex tax laws jurisdictions operates significant judgment required determining companys tax liabilities companys tax returns periodically examined various tax authorities company believes accrual tax contingencies adequate open years based past experience interpretations tax law judgments potential actions tax authorities however due complexity tax contingencies ultimate resolution tax matters may result payments greater less amounts accrued addition company may affected changes tax laws tax rate changes new tax laws revised tax law interpretations domestic foreign jurisdictions december us tax cuts jobs act tcja became law final impact tcja company may differ estimates reported possibly materially due factors changes interpretations assumptions made additional guidance may issued actions taken company result tcja among others pharmaceutical products develop unexpected safety efficacy concerns unexpected safety efficacy concerns arise respect marketed products whether scientifically justified leading product recalls withdrawals declining sales well product liability consumer fraud andor claims including potential civil criminal governmental actions reliance third party relationships outsourcing arrangements could adversely affect companys business company depends third parties including suppliers alliances pharmaceutical biotechnology companies third party service providers key aspects business including development manufacture commercialization products support information technology systems failure third parties meet contractual regulatory obligations company development factors materially disrupt relationships company third parties could material adverse effect companys business negative events animal health industry could negative impact future results operations future sales key animal health products could adversely affected number risk factors including certain risks specific animal health business example outbreak disease carried animals bovine spongiform encephalopathy mad cow disease could lead widespread death precautionary table contents destruction well reduced consumption demand animals could adversely impact companys results operations also outbreak highly contagious diseases near companys main production sites could require company immediately halt production vaccines sites force company incur substantial expenses procuring raw materials vaccines elsewhere risks specific animal health include epidemics pandemics government procurement pricing practices weather global agribusiness economic events animal health segment companys business becomes significant impact events future results operations would also become significant biologics vaccines carry unique risks uncertainties could negative impact future results operations successful development testing manufacturing commercialization biologics vaccines particularly human animal health vaccines long expensive uncertain process unique risks uncertainties biologics vaccines including may limited access supply normal diseased tissue samples cell lines pathogens bacteria viral strains biological materials addition government regulations multiple jurisdictions united states eu could result restricted access transport use materials company loses access sufficient sources materials tighter restrictions imposed use materials company may able conduct research activities planned may incur additional development costs development manufacturing marketing biologics vaccines subject regulation fda ema regulatory bodies regulations often complex extensive regulations applicable pharmaceutical products example united states bla including preclinical clinical trial data extensive data regarding manufacturing procedures required human vaccine candidates fda approval generally required release manufactured commercial lot manufacturing biologics vaccines especially large quantities often complex may require use innovative technologies handle living microorganisms lot approved biologic vaccine must undergo thorough testing identity strength quality purity potency manufacturing biologics requires facilities specifically designed validated purpose sophisticated quality assurance quality control procedures necessary slight deviations anywhere manufacturing process including filling labeling packaging storage shipping quality control testing may result lot failures product recalls spoilage changes made manufacturing process company may required provide preclinical clinical data showing comparable identity strength quality purity potency products changes biologics vaccines frequently costly manufacture production ingredients derived living animal plant material biologics vaccines made synthetically particular keeping demand vaccines may difficult due complexity producing vaccines use biologically derived ingredients lead variability manufacturing process could lead allegations harm including infections allergic reactions allegations would reviewed standard investigation process could lead closure product facilities due possible contamination events could result substantial costs product liability insurance products may limited cost prohibitive unavailable result number factors product liability insurance become less available cost increased significantly company subject substantial number product liability claims see item financial statements supplementary data note contingencies environmental liabilities information companys current product liability litigation respect product liability company selfinsures substantially risk availability commercial insurance become restrictive company evaluated risks determined cost obtaining product liability insurance outweighs likely table contents benefits coverage available insurance certain product liabilities effective august including liability legacy merck products first sold date company continually assess efficient means address risk however guarantee insurance coverage obtained obtained sufficient fully cover product liabilities may arise social media platforms present risks challenges inappropriate andor unauthorized use certain media vehicles could cause brand damage information leakage could lead legal implications including improper collection andor dissemination personally identifiable information addition negative inaccurate posts comments company products social networking web site could damage companys reputation brand image goodwill disclosure nonpublic companysensitive information companys workforce others external media channels could lead information loss although internal company social media policy guides employees appropriate personal professional use social media company processes place may completely secure protect information identifying new points entry social media continues expand also presents new challenges cautionary factors may affect future results cautionary statements private securities litigation reform act report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words anticipates expects plans estimates forecasts projects words similar meaning negative variations foregoing one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product development product approvals product potential development programs one must carefully consider statement understand many factors could cause actual results differ materially companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement company cautions place undue reliance forwardlooking statements although possible predict identify factors may include following competition generic andor biosimilar products companys products lose patent protection increased brand competition therapeutic areas important companys longterm business performance difficulties uncertainties inherent new product development outcome lengthy complex process new product development inherently uncertain drug candidate fail stage process one latestage product candidates could fail receive regulatory approval new product candidates may appear promising development fail reach market efficacy safety concerns inability obtain necessary regulatory approvals difficulty excessive cost manufacture andor infringement patents intellectual property rights others furthermore sales new products may prove disappointing fail reach anticipated levels pricing pressures united states abroad including rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement pricing general changes government laws regulations including laws governing intellectual property enforcement thereof affecting companys business table contents efficacy safety concerns respect marketed products whether scientifically justified leading product recalls withdrawals declining sales significant changes customer relationships changes behavior spending patterns purchasers health care products services including delaying medical procedures rationing prescription medications reducing frequency physician visits foregoing health care insurance coverage legal factors including product liability claims antitrust litigation governmental investigations including tax disputes environmental concerns patent disputes branded generic competitors could preclude commercialization products negatively affect profitability existing products cyberattacks companys information technology systems could disrupt companys operations lost market opportunity resulting delays uncertainties approval process fda foreign regulatory authorities increased focus privacy issues countries around world including united states eu legislative regulatory landscape privacy data protection continues evolve increasing amount focus privacy data protection issues potential affect directly companys business including recently enacted laws majority states united states requiring security breach notification changes tax laws including changes related taxation foreign earnings changes accounting pronouncements promulgated standardsetting regulatory bodies including financial accounting standards board sec adverse company economic factors company control including changes inflation interest rates foreign currency exchange rates list considered exhaustive statement potential risks uncertainties see risk factors item b unresolved staff comments none item properties companys corporate headquarters located kenilworth new jersey companys us commercial operations headquartered upper gwynedd pennsylvania companys us pharmaceutical business conducted divisional headquarters located upper gwynedd pennsylvania kenilworth new jersey companys vaccines business conducted divisional headquarters located upper gwynedd pennsylvania mercks animal health global headquarters located madison new jersey principal us research facilities located rahway kenilworth new jersey west point pennsylvania palo alto california boston massachusetts elkhorn nebraska animal health principal research facilities outside united states located switzerland china mercks manufacturing operations headquartered whitehouse station new jersey company also production facilities human health products nine locations united states puerto rico outside united states subsidiaries company owns interest manufacturing plants properties japan singapore south africa countries western europe central south america asia capital expenditures billion billion billion united states amounted billion billion million abroad expenditures amounted million million million company subsidiaries principal facilities manufacturing plants titles consider satisfactory company believes properties good operating condition machinery equipment well maintained plants manufacture products suitable intended purposes capacities projected capacities adequate current projected needs existing table contents company products capacity plants converted needed modification requirements newly introduced future products item legal proceedings information called item incorporated herein reference item financial statements supplementary data note contingencies environmental liabilities item mine safety disclosures applicable table contents executive officers registrant ages february officers listed serve pleasure board directors none officers elected pursuant arrangement understanding officer persons name age offices business experience kenneth c frazier chairman president chief executive officer since december executive vice president president merck manufacturing division since march senior sanat chattopadhyay vice president operations merck manufacturing division november march executive vice president chief financial officer global services since april executive vice president chief financial officer april april corporate vice president president robert davis medical products baxter international inc march richard r deluca jr executive vice president president merck animal health since september executive vice president chief patient officer strategic communications global public policy population health since july executive vice president strategic communications global public policy population health january july president merck vaccines julie l gerberding january january mirian graddickweir executive vice president human resources since november executive vice president general counsel since july executive vice president chief michael j holston ethics compliance officer june july senior vice president finance global controller since march assistant controller november rita karachun march roger perlmutter md phd executive vice president president merck research laboratories since april adam h schechter executive vice president president global human health since may senior vice president chief ethics compliance officer since march senior vice president deputy general counsel chief ethics compliance officer hewlettpackard company january ashley watson march february mr holston notified company resign position company effective april table contents part ii item market registrants common equity related stockholder matters issuer purchases equity securities principal market trading companys common stock new york stock exchange nyse symbol mrk common stock market price information set forth table based historical nyse market prices following table also sets forth calendar periods indicated cash dividends paid per common share high low sales prices companys common stock reported nyse cash dividends paid per common share year th q rd q nd q st q common stock market prices th q rd q nd q st q high low high low january approximately shareholders record companys common stock issuer purchases equity securities three months ended december follows issuer purchases equity securities millions total number average price approximate dollar value shares shares paid per may yet purchased period purchased share plans programs october october november november december december total shares purchased period made part plan approved board directors march purchase billion merck shares november board directors authorized additional purchases billion mercks common stock treasury shares approximated table contents performance graph following graph assumes investment december reinvestment dividends companys common shares sp index composite peer group major pharmaceutical companies abbvie inc amgen inc astrazeneca plc bristolmyers squibb company johnson johnson eli lilly company glaxosmithkline plc novartis ag pfizer inc roche holding ag sanofi sa comparison fiveyear cumulative total return merck co inc composite peer group sp index end period value cagr merck peer grp sp merck peer grp sp compound annual growth rate peer group average calculated market cap weighted basis performance graph deemed incorporated reference filing securities act securities exchange act except extent company specifically incorporates reference addition performance graph deemed soliciting material filed sec subject regulation c provided regulation sk liabilities section securities exchange act except extent company specifically requests information treated soliciting material specifically incorporates reference filing securities act exchange act table contents item selected financial data following selected financial data read conjunction item managements discussion analysis financial condition results operations consolidated financial statements notes thereto contained item financial statements supplementary data report merck co inc subsidiaries millions except per share amounts results year sales materials production marketing administrative research development restructuring costs income expense net income taxes taxes income net income less net income attributable noncontrolling interests net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders cash dividends declared cash dividends declared per common share capital expenditures depreciation average common shares outstanding millions average common shares outstanding assuming dilution millions yearend position working capital property plant equipment net total assets longterm debt total equity yearend statistics number stockholders record number employees amounts include provisional net tax charge related enactment us tax legislation charge related formation collaboration astrazeneca amounts include charge related settlement worldwide patent litigation related keytruda amounts include net charge related settlement vioxx shareholder class action litigation foreign exchange losses related venezuela gains dispositions businesses assets favorable benefit certain tax items amounts reflect divestiture mercks consumer care business october including gain sale well gain recognized option exercise astrazeneca gains dispositions businesses assets loss extinguishment debt table contents item managements discussion analysis financial condition results operations description mercks business merck co inc merck company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health products companys operations principally managed products basis include four operating segments pharmaceutical animal health healthcare services alliances segments pharmaceutical segment reportable segment pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities december merck sanofi pasteur sa sanofi terminated equallyowned joint venture sanofi pasteur msd spmsd developed marketed vaccines europe beginning merck recording vaccine sales incurring costs result operating vaccines business european markets previously part spmsd joint venture accounted equity method affiliate company also animal health segment discovers develops manufactures markets animal health products including vaccines company sells veterinarians distributors animal producers companys healthcare services segment provides services solutions focus engagement health analytics clinical services improve value care delivered patients overview merck continued bring innovation patients physicians expanding focus oncology advancing programs late stage pipeline throughout keytruda companys antipd programmed death receptor therapy received approval several additional indications globally including us food drug administration fda approval combination pemetrexed carboplatin commonly used chemotherapy regimen firstline treatment metastatic nonsquamous nonsmallcell lung cancer nsclc irrespective pdl expression keytruda antipd treatment approved firstline setting monotherapy combination therapy appropriate patients metastatic nsclc addition lynparza oral poly adpribose polymerase parp inhibitor developed collaboration received fda approval treatment patients germline brca mutated hernegative metastatic breast cancer previously treated chemotherapy additionally november fda approved prevymis prophylaxis prevention cytomegalovirus cmv infection disease december fda approved steglatro steglujan segluromet treatment type diabetes january prevymis also approved european union eu worldwide sales billion increase compared sales growth driven primarily launches keytruda zepatier bridion well positive performance mercks animal health business addition revenue benefited sale vaccines markets previously part nowterminated spmsd vaccines joint venture growth areas largely offset effects generic biosimilar competition resulted sales declines products including zetia vytorin cubicin remicade augmenting mercks portfolio pipeline external innovation remains important component companys overall strategy july merck astrazeneca entered global strategic oncology collaboration codevelop cocommercialize astrazenecas lynparza multiple cancer types lynparza oral parp inhibitor currently approved certain types ovarian breast cancer companies develop commercialize lynparza monotherapy combination trials potential medicines independently merck astrazeneca develop commercialize lynparza combinations respective pd pdl medicines companies also jointly develop commercialize astrazenecas selumetinib oral potent selective inhibitor mek part mitogenactivated protein kinase mapk pathway currently table contents developed multiple indications including thyroid cancer addition october merck acquired rigontec gmbh rigontec leader accessing retinoic acidinducible gene pathway part innate immune system novel distinct approach cancer immunotherapy induce immediate longterm antitumor immunity also march merck acquired controlling interest valle sa valle leading privately held producer animal health products brazil merck continues prioritize resources maximize opportunities ongoing upcoming product launches keytruda launching around world multiple indications merck achieved multiple additional regulatory milestones keytruda including approval fda combination therapy appropriate patients metastatic nsclc noted well monotherapy approval treatment certain patients recurrent locally advanced metastatic gastric gastroesophageal junction adenocarcinoma treatment certain patients locally advanced metastatic urothelial carcinoma type bladder cancer treatment adult pediatric patients classical hodgkin lymphoma chl treatment adult pediatric patients unresectable metastatic microsatellite instabilityhigh msih mismatch repair deficient solid tumors keytruda also received approval eu treatment certain patients chl urothelial carcinoma merck continues evaluate pipeline focusing research efforts opportunities believes greatest potential address unmet medical needs addition recent regulatory approvals discussed company continued advance programs latestage pipeline several regulatory submissions mk doravirine investigational nonnucleoside reverse transcriptase inhibitor treatment hiv infection mka doravirine lamivudine tenofovir disoproxil fumarate currently review fda addition fda accepted review supplemental biologics license application bla keytruda treatment adult pediatric patients refractory primary mediastinal bcell lymphoma pmbcl refractory relapsed two prior lines therapy additionally steglatro steglujan segluromet review eu companys phase oncology programs include keytruda therapeutic areas breast colorectal esophageal gastric head neck hepatocellular nasopharyngeal renal smallcell lung cancers lynparza pancreatic prostate cancer selumetinib thyroid cancer additionally company candidates phase clinical development several therapeutic areas see research development company continues support innovation strategy remaining disciplined prioritizing resources wherever possible fund investment many opportunities mercks pipeline believes help drive longterm growth also fund nearterm opportunities grow revenue research development expenses reflect increased clinical development spending company continues invest pipeline november mercks board directors raised companys quarterly dividend per share per share company returned billion shareholders dividends share repurchases earnings per common share assuming dilution attributable common shareholders eps compared eps years reflect impact acquisition divestiturerelated costs includes charge related uprifosbuvir clinical development program well restructuring costs certain items include provisional net tax charge related recent enactment us tax legislation aggregate charge related formation collaboration astrazeneca nongaap eps exclude items see nongaap income nongaap eps cyberattack june company experienced network cyberattack led disruption worldwide operations including manufacturing research sales operations companys manufacturing sites operational manufacturing active pharmaceutical ingredient api formulating packaging shipping product companys external manufacturing impacted throughout time merck continued fulfill orders ship product due cyberattack anticipated company unable fulfill orders certain products certain markets unfavorable effect sales approximately million addition table contents company recorded manufacturingrelated expenses primarily unfavorable manufacturing variances materials production costs well expenses related remediation efforts marketing administrative expenses research development expenses aggregated approximately million net insurance recoveries approximately million due residual backlog orders certain products company anticipates sales unfavorably affected certain markets approximately million cyberattack merck expect significant impairment value intangible assets related marketed products inventories result cyberattack referenced company insurance coverage insuring costs resulting cyberattacks received insurance proceeds however may disputes insurers availability insurance coverage claims related incident additionally temporary production shutdown cyberattack contributed companys inability meet higher expected demand gardasil resulted mercks decision borrow doses gardasil us centers disease control prevention cdc pediatric vaccine stockpile company subsequently replenished portion borrowed doses net effect borrowing subsequent partial replenishment reduction sales million company anticipates replenish remaining borrowed doses second half hurricane maria september hurricane maria made direct landfall puerto rico company one plant puerto rico makes limited number pharmaceutical products company also works contract manufacturers island mercks plant sustain substantial damage production activities plant resumed power restored facility yet fully reliable plant continues prepared use alternative sources power water company making progress fully restore normal operations despite significant damage islands infrastructure supply chains within puerto rico improving yet fully restored immaterial impact sales company expects immaterial impact sales operating results sales worldwide sales billion increase compared sales growth driven primarily higher sales recently launched products including keytruda zepatier bridion additionally sales benefited december termination spmsd marketed vaccines major european markets merck began recording vaccine sales markets previously part spmsd joint venture resulting incremental vaccine sales approximately million higher sales pneumovax adempas well animal health products also contributed revenue growth increases largely offset effects generic competition certain products including zetia lost us market exclusivity december vytorin lost us market exclusivity april cubicin due us patent expiration june cancidas lost eu patent protection april revenue growth also offset continued biosimilar competition remicade ongoing generic erosion products including singulair nasonex collectively sales decline attributable products affected generic biosimilar competition billion lower sales products within diversified brands franchise includes certain products approaching expiration marketing exclusivity longer protected patents developed markets including dulera inhalation aerosol well lower combined sales diabetes franchise januvia janumet declines sales isentressisentress hd also partially offset revenue growth additionally sales reduced million due borrowing company made cdc pediatric vaccine stockpile doses gardasil discussed also anticipated company unable fulfill orders certain products certain markets due cyberattack unfavorable effect sales approximately million sales united states billion decline compared billion decrease driven primarily effects generic competition zetia vytorin cubicin declines products within diversified brands including nasonex dulera inhalation aerosol lower sales januviajanumet gardasilgardasil isentressisentress hd zostavax also contributed us sales decline table contents declines partially offset higher sales keytruda zepatier bridion pneumovax along higher sales animal health products international sales billion increase compared billion primarily reflecting growth keytruda zepatier higher sales vaccines due termination spmsd joint venture well higher sales animal health products sales growth partially offset ongoing biosimilar competition remicade well generic erosion cancidas products within diversified brands international sales represented total sales respectively global efforts toward health care cost containment continue exert pressure product pricing market access worldwide united states pricing pressures continue many companys products several international markets governmentmandated pricing actions reduced prices generic patented drugs addition austerity measures negatively affected companys revenue performance company anticipates pricing actions including biennial price reductions japan occur austerity measures continue negatively affect revenue performance worldwide sales billion increase compared foreign exchange unfavorably affected global sales performance includes lower benefit revenue hedging activities compared revenue growth primarily reflects higher sales keytruda launch hcv treatment zepatier growth vaccine products including gardasilgardasil varivax pneumovax also contributing sales growth higher sales hospital acute care products including bridion noxafil growth within diabetes franchise januvia janumet well higher sales animal health products particularly bravecto increases largely offset sales declines attributable ongoing effects generic biosimilar competition certain products including remicade nasonex along products within diversified brands declines isentress dulera inhalation aerosol also partially offset revenue growth sales performance reflects decline approximately million due reduced operations company venezuela result economic conditions volatility country table contents sales companys products follows millions us intl total us intl total us intl total primary care womens health cardiovascular zetia vytorin atozet adempas diabetes januvia janumet general medicine womens health nuvaring implanonnexplanon follistim aq hospital specialty hepatitis zepatier hiv isentressisentress hd hospital acute care bridion noxafil invanz cancidas cubicin primaxin immunology remicade simponi oncology keytruda emend temodar diversified brands respiratory singulair nasonex dulera cozaarhyzaar arcoxia fosamax vaccines gardasilgardasil proquadmmr iivarivax pneumovax rotateq zostavax pharmaceutical total pharmaceutical segment sales segment sales total segment sales us plus international may equal total due rounding sales cubicin represent sales subsequent cubist acquisition date december merck sanofi terminated equallyowned joint venture spmsd marketed vaccines major european markets see note accordingly vaccine sales include sales european markets previously part spmsd amounts include sales vaccines sold spmsd results reflected equity income affiliates included income expense net amounts however include supply sales spmsd pharmaceutical primarily reflects sales human health pharmaceutical products including products within franchises listed separately represents nonreportable segments animal health healthcare services alliances primarily comprised miscellaneous corporate revenues including revenue hedging activities well thirdparty manufacturing sales also includes million million respectively related sale marketing rights certain productstable contents pharmaceutical segment primary care womens health cardiovascular combined global sales zetia marketed countries outside united states ezetrol vytorin marketed outside united states inegy atozet marketed certain countries outside united states medicines lowering ldl cholesterol billion decline compared sales decline driven lower volumes pricing zetia vytorin united states result generic competition agreement generic manufacturer launched generic version zetia united states december us patent exclusivity periods zetia vytorin otherwise expired april accordingly company experiencing rapid substantial declines us zetia vytorin sales expects declines continue company lose market exclusivity major european markets ezetrol april inegy april anticipates sales declines markets thereafter sales ezetrol inegy markets million million respectively combined worldwide sales zetia vytorin atozet billion growth compared reflecting volume growth europe higher pricing united states largely offset lower sales venezuela due reduced operations company country lower volumes united states reflecting part generic competition zetia pursuant collaboration bayer ag bayer see note consolidated financial statements merck lead commercial rights adempas cardiovascular drug treatment pulmonary arterial hypertension countries outside americas bayer lead rights americas including united states companies share profits equally collaboration merck began promoting distributing adempas europe transition bayer merck territories including japan continued merck recorded sales adempas million million million includes sales mercks marketing territories well mercks share profits sale adempas bayers marketing territories diabetes worldwide combined sales januvia janumet medicines help lower blood sugar levels adults type diabetes billion decline compared including favorable effect foreign exchange sales decline driven primarily ongoing pricing pressure partially offset continued volume growth globally combined global sales januvia janumet billion increase compared sales growth driven primarily higher volumes united states europe canada partially offset pricing pressures united states europe lower sales venezuela due companys reduced operations country april merck announced fda issued complete response letter crl regarding mercks supplemental new drug applications nda januvia janumet janumet xr sitagliptin metformin hcl extendedrelease applications merck seeking include data tecos trial evaluating cardiovascular outcomes sitagliptin prescribing information sitagliptincontaining medicines merck taking actions respond crl december fda approved steglatro ertugliflozin tablets oral sodiumglucose cotransporter sglt inhibitor fixeddose combination steglujan ertugliflozin sitagliptin tablets fixeddose combination sglt inhibitor dipeptidyl peptidase inhibitor januvia sitagliptin fda also approved fixeddose combination segluromet ertugliflozin metformin hydrochloride steglatro steglujan segluromet indicated improve glycemic control adults type diabetes mellitus products part worldwide except japan collaboration merck pfizer inc pfizer codevelopment copromotion ertugliflozin result fda approval merck make million payment pfizer accrued fourth quarter amount capitalized amortized estimated useful life subject impairment testing merck exclusively promote steglatro two fixeddose combination products united states merck pfizer share revenues certain costs basis merck share pfizer may entitled additional milestone payments january committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending approval ertugliflozin two fixed dose combination products chmp positive opinion considered european commission ec approval products eu received merck make additional million milestone payment pfizer table contents general medicine womens health worldwide sales nuvaring vaginal contraceptive product million decline compared including favorable effect foreign exchange sales decline driven primarily lower sales united states reflecting lower volumes partially offset higher pricing lower demand europe global sales nuvaring million increase compared including unfavorable effect foreign exchange sales growth largely reflects higher pricing united states partially offset volume declines europe patent provides us market exclusivity nuvaring expire april company anticipates significant decline us nuvaring sales thereafter worldwide sales implanonnexplanon singlerod subdermal contraceptive implants grew million increase compared primarily reflecting higher pricing volume growth united states global sales implanonnexplanon million increase compared including unfavorable effect foreign exchange sales growth reflects higher demand united states partially offset declines international markets particularly venezuela hospital specialty hepatitis global sales zepatier treatment chronic hepatitis c hcv infection billion million sales growth driven primarily higher sales europe united states japan following product launch merck also launched zepatier international markets company beginning experience unfavorable effects increasing competition declining patient volumes anticipates sales zepatier future materially adversely affected factors hiv worldwide sales isentressisentress hd hiv integrase inhibitor use combination antiretroviral agents treatment hiv infection billion decline compared sales decline primarily reflects lower demand united states europe due competitive pressures may fda approved isentress hd oncedaily dose isentress july ec granted marketing authorization oncedaily dose isentress marketed isentress mg global sales isentress billion decline compared including unfavorable effect foreign exchange sales decline driven primarily lower volumes united states well lower demand pricing europe due competitive pressures partially offset favorable adjustment discount reserves united states hospital acute care global sales bridion reversal two types neuromuscular blocking agents used surgery million growth compared driven strong global demand particularly united states worldwide sales million growth compared including favorable effect foreign exchange sales growth reflects volume growth markets including united states approved fda december partially offset decline venezuela due reduced operations company country worldwide sales noxafil prevention invasive fungal infections million increase compared primarily reflecting higher demand pricing united states well volume growth europe global sales noxafil grew million driven primarily higher pricing united states volume growth europe reflecting ongoing positive impact approval new formulations higher demand asia pacific region foreign exchange unfavorably affected global sales performance global sales invanz treatment certain infections million increase compared driven primarily higher sales united states reflecting higher pricing partially offset lower demand well higher demand brazil worldwide sales invanz million decline compared including unfavorable effect foreign exchange sales performance reflects higher pricing united states largely offset decline venezuela patent provided us table contents market exclusivity invanz expired november company anticipates significant decline us invanz sales future periods global sales cancidas antifungal product sold primarily outside united states million decline compared driven primarily generic competition certain european markets eu compound patent cancidas expired april accordingly company experiencing significant decline cancidas sales european markets expects decline continue worldwide sales cancidas million decline compared reflecting unfavorable effect foreign exchange pricing declines europe offset higher volumes china global sales cubicin iv antibiotic complicated skin skin structure infections bacteremia caused designated susceptible organisms million decline compared billion decline compared us composition patent cubicin expired june accordingly company experiencing rapid substantial decline us cubicin sales result generic competition expects decline continue company anticipates lose market exclusivity cubicin european markets early november merck announced fda approved prevymis letermovir prophylaxis prevention cmv infection disease adult cmvseropositive recipients r allogeneic hematopoietic stem cell transplant result fda approval merck made million million milestone payment aicuris amount capitalized amortized estimated useful life subject impairment testing january prevymis approved ec result merck make additional million milestone payment aicuris merck also filed prevymis regulatory approval markets including japan immunology sales remicade treatment inflammatory diseases marketed company europe russia turkey million decline compared billion decline compared foreign exchange unfavorably affected sales performance company lost market exclusivity remicade major european markets longer market exclusivity marketing territories company experiencing pricing volume declines markets result biosimilar competition expects declines continue sales simponi oncemonthly subcutaneous treatment certain inflammatory diseases marketed company europe russia turkey million growth compared including favorable effect foreign exchange sales growth primarily reflects higher demand europe sales simponi million increase compared including unfavorable effect foreign exchange sales growth driven primarily higher volumes europe reflecting part ongoing positive impact ulcerative colitis indication oncology sales keytruda antipd therapy billion billion million yearoveryear increases driven volume growth markets particularly united states europe japan company continues launch keytruda multiple new indications globally us sales keytruda billion million million sales united states continue build across multiple approved indications particular treatment nsclc reflecting continued adoption keytruda firstline setting monotherapy patients metastatic nsclc whose tumors high pdl expression well uptake keytruda combination pemetrexed carboplatin commonly used chemotherapy regimen firstline treatment metastatic nonsquamous nsclc without pdl expression indications including melanoma head neck cancer bladder cancer also contributed growth sales growth international markets reflects positive performance melanoma indications well greater contribution treatment patients nsclc reimbursement established additional markets first second line settings march fda approved keytruda treatment adult pediatric patients chl refractory treatment relapsed three prior lines therapy may ec approved keytruda treatment adult patients relapsed refractory chl failed autologous stem cell transplant brentuximab vedotin transplantineligible failed brentuximab vedotin table contents may fda approved keytruda combination pemetrexed carboplatin firstline treatment metastatic nonsquamous nsclc irrespective pdl expression keytruda antipd treatment approved firstline setting monotherapy combination therapy appropriate patients metastatic nsclc october keytruda approved fda monotherapy firstline setting patients metastatic nsclc whose tumors high pdl expression egfr alk genomic tumor aberrations keytruda monotherapy also indicated secondline greater treatment setting patients metastatic nsclc whose tumors express pdl disease progression platinumcontaining chemotherapy patients egfr alk genomic tumor aberrations disease progression fdaapproved therapy aberrations prior receiving keytruda additionally january ec approved keytruda firstline treatment metastatic nsclc adults whose tumors high pdl expression egfr alk positive tumor mutations also may fda approved keytruda treatment certain patients locally advanced metastatic urothelial carcinoma type bladder cancer firstline setting keytruda approved treatment patients locally advanced metastatic urothelial carcinoma ineligible cisplatincontaining chemotherapy secondline setting keytruda approved treatment patients locally advanced metastatic urothelial carcinoma disease progression following platinumcontaining chemotherapy within months neoadjuvant adjuvant treatment platinumcontaining chemotherapy september ec approved keytruda use monotherapy treatment locally advanced metastatic urothelial carcinoma adults received prior platinumcontaining chemotherapy well adults eligible cisplatincontaining chemotherapy additionally may fda approved keytruda firstofitskind indication treatment adult pediatric patients previously treated unresectable metastatic msih mismatch repair deficient solid tumors unique indication keytruda first cancer therapy approved use based biomarker regardless tumor type september fda approved keytruda treatment patients recurrent locally advanced metastatic gastric gastroesophageal junction adenocarcinoma whose tumors express pdl december merck announced pivotal phase keynote trial investigating keytruda secondline treatment patients advanced gastric gastroesophageal junction adenocarcinoma meet primary endpoint overall survival os patients whose tumors expressed pdl additionally progression free survival pfs pdl positive population show statistical significance safety profile observed keynote consistent observed previously reported studies keytruda new safety signals identified current indication remains unchanged company continues evaluate keytruda gastric gastroesophageal junction adenocarcinoma keynote phase clinical trial studying keytruda monotherapy combination chemotherapy firstline treatment patients pdl positive advanced gastric gastroesophageal junction cancer keynote phase trial studying keytruda combination chemotherapy neoadjuvantadjuvant setting august merck announced fda approved keytruda treatment patients recurrent metastatic head neck squamous cell carcinoma hnscc disease progression platinumcontaining chemotherapy july merck announced pivotal phase keynote trial investigating keytruda previously treated patients recurrent metastatic hnscc meet prespecified primary endpoint os safety profile observed keynote consistent observed previously reported studies keytruda new safety signals identified current indication remains unchanged clinical trials continue including keynote phase clinical trial keytruda firstline treatment recurrent metastatic hnscc result additional approvals received noted keytruda approved united states eu monotherapy treatment certain patients nsclc melanoma chl urothelial carcinoma keytruda also approved united states monotherapy treatment certain patients hnscc gastric gastroesophageal junction adenocarcinoma msih mismatch repair deficient cancer combination pemetrexed carboplatin certain patients nsclc keytruda also approved japan treatment radically unresectable melanoma pdl positive unresectable advanced recurrent nsclc table contents relapsed refractory chl radically unresectable urothelial carcinoma keytruda clinical development program includes studies across broad range cancer types see research development january merck entered settlement license agreement resolve worldwide patent infringement litigation related keytruda see note consolidated financial statements pursuant settlement company pay royalties net sales keytruda net sales keytruda lynparza oral parp inhibitor developed part collaboration formed july astrazeneca see note consolidated financial statements currently approved certain types ovarian breast cancer january fda approved lynparza use patients brcamutated hernegative metastatic breast cancer previously treated chemotherapy neoadjuvant adjuvant metastatic setting result approval merck make million milestone payment astrazeneca see note consolidated financial statements also january japanese ministry health labour welfare approved lynparza use maintenance therapy patients platinumsensitive relapsed ovarian cancer regardless brca mutation status responded last platinumbased chemotherapy lynparza first parp inhibitor approved japan diversified brands mercks diversified brands include human health pharmaceutical products approaching expiration marketing exclusivity longer protected patents developed markets continue core part companys offering markets around world respiratory worldwide sales singulair onceaday oral medicine chronic treatment asthma relief symptoms allergic rhinitis million decline compared million decrease compared foreign exchange unfavorably affected global sales performance favorably affected global sales performance sales declines driven lower volumes japan result generic competition patents provided market exclusivity singulair japan expired result company experiencing significant decline singulair sales japan expects decline continue company longer market exclusivity singulair major market global sales nasonex inhaled nasal corticosteroid treatment nasal allergy symptoms million decline compared million decline compared foreign exchange favorably affected global sales performance company experiencing substantial decline us nasonex sales result generic competition expects decline continue decline global nasonex sales also driven lower volumes pricing europe ongoing generic erosion lower sales venezuela due reduced operations company country global sales dulera inhalation aerosol combination medicine treatment asthma million decline compared driven lower sales united states reflecting ongoing competitive pricing pressure well lower demand worldwide sales dulera inhalation aerosol million decline compared including unfavorable effect foreign exchange decline driven lower sales united sales reflecting competitive pricing pressure partially offset higher demand vaccines december merck sanofi terminated equallyowned joint venture spmsd developed marketed vaccines europe accordingly vaccine sales include sales merck vaccines european markets previously part spmsd joint venture whereas sales periods prior prior vaccine sales european markets sold spmsd joint venture results reflected equity income affiliates included income expense net see note consolidated financial statements supply sales spmsd however included vaccine sales periods prior incremental vaccine sales resulting termination spmsd joint venture approximately million approximately million relate gardasilgardasil table contents worldwide sales gardasilgardasil vaccines help prevent certain cancers diseases caused certain types human papillomavirus hpv billion growth compared sales growth driven primarily higher sales europe resulting termination spmsd joint venture noted well higher demand asia pacific due part launch china partially offset lower sales united states lower sales united states reflect timing public sector purchases addition company made request borrow doses gardasil cdc pediatric vaccine stockpile cdc granted companys decision borrow doses cdc driven part temporary shutdown resulting cyberattack occurred june well overall higher demand expected result borrowing company reversed sales related borrowed doses recognized corresponding liability company subsequently replenished nearly half doses borrowed stockpile net effect borrowing subsequent partial replenishment reduction sales million company anticipates replenish remaining borrowed doses second half result recognition sales reversal remaining liability additionally october fda approved dose vaccination regimen gardasil use girls boys years age cdcs advisory committee immunization practices acip voted recommend dose vaccination regimen certain year olds company experiencing impact transition dose vaccine regimen dose vaccination regimen however increased patient starts helping offset negative effects transition mercks sales gardasilgardasil billion growth compared sales growth driven primarily higher volumes pricing united states well higher demand asia pacific region partially offset decline government tenders brazil company party certain thirdparty license agreements respect gardasilgardasil including crosslicense settlement agreement glaxosmithkline result agreements company pays royalties worldwide gardasilgardasil sales vary country included materials production costs global sales proquad pediatric combination vaccine help protect measles mumps rubella varicella million million million increase compared driven primarily higher pricing volumes united states well volume growth international markets particularly europe sales growth compared driven primarily higher demand pricing united states worldwide sales mmr ii vaccine help protect measles mumps rubella million million million sales growth compared largely attributable higher sales europe resulting termination spmsd joint venture sales performance compared driven higher demand resulting measles outbreaks united states global sales varivax vaccine help prevent chickenpox varicella million million million sales decline compared driven primarily lower volumes brazil due loss government tender well lower sales united states reflecting lower demand partially offset higher pricing higher sales europe resulting termination spmsd joint venture partially offset decline sales growth compared driven primarily higher sales united states reflecting effects public sector purchasing higher pricing partially offset lower demand volume growth brazil reflecting timing government tenders also contributed sales increase compared worldwide sales pneumovax vaccine help prevent pneumococcal disease million increase compared driven primarily higher demand pricing united states well higher sales europe resulting termination spmsd joint venture mercks sales pneumovax million increase compared driven primarily higher volumes pricing united states higher demand asia pacific region foreign exchange unfavorably affected sales performance favorably affected sales performance global sales rotateq vaccine help protect rotavirus gastroenteritis infants children million increase compared driven primarily higher sales europe resulting termination spmsd joint venture mercks sales rotateq million increase compared including unfavorable effect foreign exchange sales performance driven table contents primarily effects public sector purchasing united states well volume growth several international markets worldwide sales zostavax vaccine help prevent shingles herpes zoster adults years age older million decline compared including favorable effect foreign exchange sales decline driven primarily lower demand united states reflecting approval competitors vaccine received preferential recommendation acip october prevention shingles zostavax company anticipates competition material adverse effect sales zostavax future periods us sales decline largely offset growth europe resulting termination spmsd joint venture volume growth asia pacific region mercks sales zostavax million decline compared including unfavorable effect foreign exchange decline driven primarily lower volumes united states partially offset higher pricing united states higher demand asia pacific region segments companys segments animal health healthcare services alliances segments material separate reporting animal health animal health includes pharmaceutical vaccine products prevention treatment control disease major farm companion animal species animal health sales affected competition frequent introduction generic products worldwide sales animal health products billion billion billion global sales animal health products grew compared primarily reflecting higher sales companion animal products largely driven growth bravecto line products kill fleas ticks dogs cats weeks reflecting growth oral formulation continued uptake topical formulation launched animal health sales growth also driven higher sales ruminant poultry swine products worldwide sales animal health products increased compared including unfavorable effect foreign exchange sales growth reflects volume growth across species areas particularly products companion animals driven primarily higher sales bravecto well poultry swine products march merck acquired controlling interest valle leading privately held producer animal health products brazil see note consolidated financial statements costs expenses millions change change materials production marketing administrative research development restructuring costs income expense net materials production materials production costs billion billion billion costs include expenses amortization intangible assets recorded connection business acquisitions totaled billion billion billion costs also include intangible asset impairment charges million million million respectively related marketed products intangibles recorded connection business acquisitions see note consolidated financial statements costs also include million intangible asset impairment charge related licensing agreement company may recognize additional noncash impairment charges future related intangible assets measured fair value capitalized connection business acquisitions charges could material addition expenses include million amortization purchase accounting adjustments cubists table contents inventories also included materials production costs expenses associated restructuring activities amounted million million million respectively primarily reflecting accelerated depreciation asset writeoffs related planned sale closure manufacturing facilities separation costs associated manufacturingrelated headcount reductions incurred reflected restructuring costs discussed gross margin compared improvements gross margin reflect lower net impact amortization intangible assets intangible asset impairment charges restructuring costs noted reduced gross margin percentage points percentage points percentage points gross margin improvement compared also reflects favorable effects product mix manufacturingrelated costs associated cyberattack partially offset gross margin improvement improvement gross margin compared also driven lower inventory writeoffs favorable effects foreign exchange marketing administrative marketing administrative expenses billion increase compared higher administrative costs including costs associated company operating vaccines business european markets previously part spmsd joint venture remediation costs related cyberattack higher promotional expenses related product launches partially offset lower restructuring acquisition divestiture related costs lower selling expenses favorable effect foreign exchange expenses billion decline compared driven largely lower acquisition divestiturerelated costs favorable effects foreign exchange lower administrative expenses legal defense costs well lower selling costs higher promotional spending largely related product launches higher restructuring costs partially offset decline expenses include restructuring costs million million million respectively related primarily accelerated depreciation facilities closed divested separation costs associated sales force reductions incurred reflected restructuring costs discussed expenses also include acquisition divestiturerelated costs million million million respectively consisting integration transaction certain costs related business acquisitions divestitures acquisition divestiturerelated costs include costs related acquisition cubist see note consolidated financial statements research development research development rd expenses billion increase compared increase driven primarily charge related formation collaboration astrazeneca unfavorable effect changes estimated fair value measurement liabilities contingent consideration higher clinical development spending largely offset lower inprocess research development iprd impairment charges lower restructuring costs rd expenses billion compared billion increase driven primarily higher iprd impairment charges increased clinical development spending higher restructuring licensing costs partially offset reduction expenses associated decrease estimated fair value measurement liabilities contingent consideration well favorable effects foreign exchange rd expenses comprised costs directly incurred merck research laboratories mrl companys research development division focuses human healthrelated activities billion billion billion also included rd expenses costs incurred divisions support rd activities including depreciation production general administrative well licensing activity certain costs operating segments including pharmaceutical animal health segments aggregate billion billion billion respectively additionally rd expenses include billion aggregate charge related formation collaboration astrazeneca see note consolidated financial statements rd expenses also include iprd impairment charges million billion million respectively see research development company may recognize additional noncash impairment charges future related cancellation delay pipeline programs measured fair value capitalized connection business acquisitions charges could material addition rd expenses include expense income related changes estimated fair value measurement liabilities contingent consideration recorded connection table contents acquisitions company recorded charges million increase estimated fair value liabilities contingent consideration company recorded reduction expenses million million respectively decrease estimated fair value liabilities contingent consideration related discontinuation delay certain programs see note consolidated financial statements rd expenses also reflect million million million respectively accelerated depreciation asset abandonment costs associated restructuring activities restructuring costs company incurs substantial costs restructuring program activities related mercks productivity cost reduction initiatives well connection integration certain acquired businesses company commenced actions global restructuring programs designed streamline cost structure actions programs include elimination positions sales administrative headquarters organizations well sale closure certain manufacturing research development sites consolidation office facilities company also continues reduce global real estate footprint improve efficiency manufacturing supply network restructuring costs primarily representing separation related costs associated restructuring activities million million million respectively separation costs million million million respectively incurred associated actual headcount reductions well estimated expenses existing severance programs headcount reductions probable could reasonably estimated merck eliminated approximately positions positions positions related restructuring activities also included restructuring costs asset abandonment shutdown related costs well employeerelated costs curtailment settlement termination charges associated pension postretirement benefit plans sharebased compensation plan costs segment reporting restructuring costs unallocated expenses additional costs associated companys restructuring activities included materials production marketing administrative research development discussed company recorded aggregate pretax costs million billion billion related restructuring program activities see note consolidated financial statements company substantially completed actions programs approximately million additional pretax costs expected incurred relating anticipated employee separations remaining assetrelated costs income expense net income expense net million expense million expense billion expense details components income expense net see note consolidated financial statements segment profits millions pharmaceutical segment profits nonreportable segment profits income taxes segment profits comprised segment sales less standard costs certain operating expenses directly incurred segment components equity income loss affiliates certain depreciation amortization expenses internal management reporting presented chief operating decision maker merck allocate materials production costs standard costs majority research development expenses general administrative expenses cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits also excluded determination segment profits acquisition divestiturerelated costs including amortization purchase accounting adjustments intangible asset impairment charges changes estimated fair value measurement liabilities contingent consideration restructuring costs portion equity income additionally segment profits reflect expenses table contents corporate manufacturing cost centers miscellaneous income expense unallocated items including loss extinguishment debt charge related settlement worldwide keytruda patent litigation gains divestitures well net charge related settlement vioxx shareholder class action litigation foreign exchange losses related devaluation companys net monetary assets venezuela reflected table also included miscellaneous corporate profits losses well operating profits losses related thirdparty manufacturing sales pharmaceutical segment profits grew compared primarily reflecting higher sales favorable effects product mix pharmaceutical segment profits grew compared primarily reflecting higher sales taxes income effective income tax rates reflect impacts acquisition divestiturerelated costs include billion iprd impairment charges well restructuring costs beneficial impact foreign earnings addition effective income tax rate includes provisional net charge billion related enactment us tax legislation known tax cuts jobs act tcja see note consolidated financial statements effective income tax rate also reflects unfavorable impact billion aggregate pretax charge recorded connection formation collaboration astrazeneca tax benefit recognized partially offset favorable impact net benefit million related settlement certain federal income tax issues see note consolidated financial statements benefit million related settlement state income tax issue effective income tax rate reflects favorable impact net benefit million related settlement certain federal income tax issues impact net charge related settlement vioxx shareholder class action litigation fully deductible combined us federal state tax rates favorable impact tax legislation enacted fourth quarter well unfavorable effect nontax deductible foreign exchange losses related venezuela see note consolidated financial statements net income earnings per common share net income attributable merck co inc billion billion billion eps nongaap income nongaap eps nongaap income nongaap eps alternative views companys performance merck providing management believes information enhances investors understanding companys results permits investors understand management assesses performance nongaap income nongaap eps exclude certain items nature items impact analysis underlying business performance trends excluded items considered nonrecurring consist acquisition divestiturerelated costs restructuring costs certain items excluded items significant components understanding assessing financial performance nongaap income nongaap eps important internal measures company senior management receives monthly analysis operating results includes nongaap eps management uses measures internally planning forecasting purposes measure performance company along metrics senior managements annual compensation derived part using nongaap income nongaap eps since nongaap income nongaap eps measures determined accordance gaap standardized meaning prescribed gaap therefore may comparable calculation similar measures companies information nongaap income nongaap eps considered addition substitute superior net income eps prepared accordance generally accepted accounting principles united states gaap table contents reconciliation gaap financial measures nongaap financial measures follows millions except per share amounts income taxes reported gaap increase decrease excluded items acquisition divestiturerelated costs restructuring costs items aggregate charge related formation oncology collaboration astrazeneca charge related settlement worldwide keytruda patent litigation foreign currency devaluation related venezuela net charge related settlement vioxx shareholder class action litigation gain sale certain migraine clinical development programs gain divestiture certain ophthalmic products nongaap income taxes taxes income reported gaap estimated tax benefit excluded items provisional net tax charge related enactment tcja net tax benefits settlements certain federal income tax issues tax benefit related settlement state income tax issue nongaap taxes income nongaap net income less net income attributable noncontrolling interests nongaap net income attributable merck co inc eps assuming dilution reported gaap eps difference nongaap eps assuming dilution estimated tax impact excluded items determined applying statutory rate originating territory nongaap adjustments represents difference calculated gaap eps calculated nongaap eps may different amount calculated dividing impact excluded items weightedaverage shares applicable year acquisition divestiturerelated costs nongaap income nongaap eps exclude impact certain amounts recorded connection business acquisitions divestitures amounts include amortization intangible assets amortization purchase accounting adjustments inventories well intangible asset impairment charges expense income related changes estimated fair value measurement contingent consideration also excluded integration transaction certain costs associated business acquisitions divestitures restructuring costs nongaap income nongaap eps exclude costs related restructuring actions see note consolidated financial statements amounts include employee separation costs accelerated depreciation associated facilities closed divested accelerated depreciation costs represent difference depreciation expense recognized revised useful life asset based upon anticipated date site closed divested equipment disposed depreciation expense determined utilizing useful life prior restructuring actions restructuring costs also include asset abandonment shutdown related costs well employeerelated costs curtailment settlement termination charges associated pension postretirement benefit plans sharebased compensation costs table contents certain items nongaap income nongaap eps exclude certain items items adjusted evaluating individual basis considering quantitative qualitative aspects typically consist items unusual nature significant results particular period indicative future operating results excluded nongaap income nongaap eps aggregate charge related formation collaboration astrazeneca see note consolidated financial statements provisional net tax charge related enactment tcja net benefit related settlement certain federal income tax issues benefit related settlement state income tax issue see note consolidated financial statements excluded nongaap income nongaap eps charge settle worldwide patent litigation related keytruda see note consolidated financial statements excluded nongaap income nongaap eps foreign exchange losses related devaluation companys net monetary assets venezuela see note consolidated financial statements net charge related previously disclosed settlement vioxx shareholder class action litigation gain sale certain migraine clinical development programs see note consolidated financial statements gain divestiture companys remaining ophthalmics business international markets see note consolidated financial statements well net tax benefit related settlement certain federal income tax issues see note consolidated financial statements research development chart reflecting companys current research pipeline february set forth item business research development research development update company currently several candidates regulatory review united states internationally keytruda approved antipd therapy clinical development expanded indications different cancer types december fda accepted review supplemental bla keytruda treatment adult pediatric patients refractory pmbcl relapsed two prior lines therapy fda granted priority review status prescription drug user fee action pdufa target action date april additionally keytruda received breakthrough therapy designation fda combination axitnib firstline treatment patients advanced metastatic renal cell carcinoma treatment highrisk earlystage triplenegative breast cancer combination neoadjuvant chemotherapy treatment merkel cell carcinoma also january merck eisai co ltd eisai announced receipt breakthrough therapy designation fda eisais multiple receptor tyrosine kinase inhibitor lenvima lenvatinib combination keytruda potential treatment patients advanced andor metastatic renal cell carcinoma lenvima keytruda combination therapy jointly developed eisai merck marks th breakthrough therapy designation granted keytruda fdas breakthrough therapy designation intended expedite development review candidate planned use alone combination treat serious lifethreatening disease condition preliminary clinical evidence indicates drug may demonstrate substantial improvement existing therapies one clinically significant endpoints january merck announced pivotal phase keynote trial investigating keytruda combination pemetrexed alimta cisplatin carboplatin firstline treatment patients metastatic nonsquamous nsclc met dual primary endpoints os pfs based interim analysis conducted independent data monitoring committee treatment keytruda combination pemetrexed plus platinum chemotherapy resulted significantly longer os pfs pemetrexed plus platinum chemotherapy alone results keynote presented upcoming medical meeting submitted regulatory authorities fda placed full clinical hold keynote keynote partial clinical hold cohort keynote three combination studies keytruda lenalidomide pomalidomide versus lenalidomide pomalidomide alone blood cancer multiple myeloma decision followed review data data monitoring committee deaths observed keytruda arms keynote table contents keynote fda determined data available time indicated risks keytruda plus pomalidomide lenalidomide outweighed potential benefit patients multiple myeloma patients enrolled keynote keynote keytrudalenalidomidedexamethasone cohort keynote discontinued investigational treatment keytruda clinical hold apply studies keytruda keytruda clinical development program consists clinical trials including trials combine keytruda cancer treatments studies encompass cancer types including bladder colorectal esophageal gastric head neck hepatocellular hodgkin lymphoma nonhodgkin lymphoma melanoma nasopharyngeal nsclc ovarian pmbcl prostate renal smallcell lung triplenegative breast many currently phase clinical development trials planned cancers mk ertugliflozin investigational oral sglt inhibitor development help improve glycemic control adults type diabetes two fixeddose combination products mka ertugliflozin januvia mkb ertugliflozin metformin review eu january chmp ema adopted positive opinion recommending approval medicines chmp positive opinion considered ec ertugliflozin two fixeddose combination products approved fda december mkj investigational fixeddose combination sitagliptin ipragliflozin review japan pharmaceuticals medical devices agency mk developed commercialization japan collaboration astellas pharma inc astellas ipragliflozin sglt inhibitor co developed astellas kotobuki pharmaceutical co ltd kotobuki approved use japan copromoted merck kotobuki mk doravirine investigational nonnucleoside reverse transcriptase inhibitor treatment hiv infection january merck announced fda accepted review two ndas doravirine ndas include data doravirine oncedaily tablet use combination antiretroviral agents use doravirine lamivudine tenofovir disoproxil fumarate oncedaily fixeddose combination single tablet complete regimen mka pdufa action date applications october v investigational pediatric hexavalent combination vaccine dtapipvhibhepb review fda developed approved commercialized joint venture merck sanofi vaccine designed help protect six important diseases diphtheria tetanus pertussis whooping cough polio poliovirus types invasive disease caused haemophilus influenzae type b hib hepatitis b fda issued crl respect bla v companies working provide additional data requested fda v marketed vaxelis eu addition candidates regulatory review company several drug candidates phase clinical development addition keytruda programs discussed mka combination relebactam investigational betalactamase inhibitor imipenemcilastatin approved carbapenem antibiotic fda designated combination qualified infectious disease product designated fast track status treatment hospitalacquired bacterial pneumonia ventilatorassociated bacterial pneumonia complicated intraabdominal infections complicated urinary tract infections mk lynparza olaparib oral parp inhibitor currently approved certain types ovarian breast cancer july merck astrazeneca entered global strategic oncology collaboration codevelop cocommercialize astrazenecas lynparza multiple cancer types see note consolidated financial statements mk selumetinib oral potent selective inhibitor mek part mitogenactivated protein kinase mapk pathway currently developed multiple cancer types additionally february fda granted orphan drug designation selumetinib treatment neurofibromatosis type development selumetinib part global strategic oncology collaboration merck astrazeneca reference v investigational rvsvzebov ebola vaccine candidate studied large scale phase clinical trials november merck newlink genetics announced exclusive licensing collaboration agreement investigational ebola vaccine december merck announced application emergency use assessment listing eual v accepted review world health organization table contents according eual process designed expedite availability vaccines needed public health emergencies another outbreak ebola decision grant v eual status based data regarding quality safety efficacyeffectiveness well riskbenefit analysis emergency use eual designation allows emergency use vaccine remains investigational yet licensed commercial distribution july merck announced fda granted v breakthrough therapy designation ema granted vaccine candidate prime priority medicines status december end study results ring vaccination trial reported lancet supporting july interim assessment v offers substantial protection ebola virus disease reported cases among vaccinated individuals days vaccination randomized nonrandomized clusters results ongoing studies included first regulatory filing anticipated first half mk vericiguat investigational treatment heart failure studied patients suffering chronic heart failure development vericiguat part worldwide strategic collaboration merck bayer see note consolidated financial statements v inactivated varicella zoster virus vaccine development prevention herpes zoster company completed phase trial autologous hematopoietic cell transplant patients another phase trial patients solid tumor malignancies undergoing chemotherapy hematological malignancies study autologous hematopoietic cell transplant patients met primary endpoints merck presented results study american society blood marrow transplantation meetings february study patients solid tumor malignancies undergoing chemotherapy met primary endpoints primary efficacy endpoint met patients hematologic malignancies merck present results study upcoming scientific meeting due competitive environment development v currently hold mk selective nonnarcotic orallyadministered pxreceptor agonist developed treatment refractory chronic cough merck plans initiate phase clinical trial first half mk originally developed afferent pharmaceuticals afferent acquired company see note consolidated financial statements upon initiation phase clinical trial merck make million milestone payment accrued estimated fair value time acquisition company also discontinued certain drug candidates february merck announced stopping protocol also known apecs study phase study evaluating verubecestat mk investigational small molecule inhibitor betasite amyloid precursor protein cleaving enzyme bace people prodromal alzheimers disease decision stop study follows recommendation external data monitoring committee edmc assessed overall benefitrisk recent interim safety analysis edmc concluded unlikely positive benefitrisk could established trial continued result company recorded iprd impairment charge discussed merck announced submit applications regulatory approval mk anacetrapib companys investigational cholesteryl ester transfer protein cetp inhibitor decision followed thorough review clinical profile anacetrapib including discussions external experts also merck made strategic decision discontinue development investigational combination regimens mkb grazoprevirruzasviruprifosbuvir mkc ruzasviruprifosbuvir treatment chronic hcv infection decision made based review available phase efficacy data consideration evolving marketplace growing number treatment options available patients chronic hcv infection including zepatier currently marketed company treatment adult patients chronic hcv infection result decision company recorded iprd impairment charge discussed company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development companys research development model designed increase productivity improve probability success prioritizing companys research development resources candidates company believes capable providing unambiguous promotable advantages patients payers delivering maximum value approved medicines vaccines new indications new formulations merck pursuing emerging product table contents opportunities independent therapeutic area modality small molecule biologics vaccines building biologics capabilities company committed ensuring externally sourced programs remain important component pipeline strategy focus supplementing internal research licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well access new technologies company also reviews pipeline examine candidates may provide value outlicensing company continues evaluate certain latestage clinical development platform technology assets determine outlicensing sale potential companys clinical pipeline includes candidates multiple disease areas including cancer cardiovascular diseases diabetes infectious diseases neurosciences obesity pain respiratory diseases vaccines acquired inprocess research development connection business acquisitions company recorded fair value inprocess research projects time acquisition yet reached technological feasibility december balance iprd billion million million million respectively iprd projects received marketing approval major market company began amortizing assets based estimated useful lives iprd projects remain development subject inherent risks uncertainties drug development possible company able successfully develop complete iprd programs profitably commercialize underlying product candidates time periods receive approvals fda regulatory agencies subject uncertainty significant delays approval process companys failure obtain approval would delay prevent company realizing revenues products additionally certain iprd programs fail abandoned development company realize future cash flows estimated recorded iprd acquisition date company may also recover research development expenditures made since acquisition develop programs circumstances occur companys future operating results could adversely affected company may recognize impairment charges charges could material company recorded million iprd impairment charges within research development expenses amount million resulted strategic decision discontinue development investigational combination regimens mkb grazoprevirruzasviruprifosbuvir mkc ruzasviruprifosbuvir treatment chronic hcv infection decision made based review available phase efficacy data consideration evolving marketplace growing number treatment options available patients chronic hcv infection including zepatier currently marketed company treatment adult patients chronic hcv infection result decision company recorded iprd impairment charge writeoff remaining intangible asset related uprifosbuvir company previously recorded impairment charge uprifosbuvir described iprd impairment charges also include charge million writeoff intangible asset related verubecestat investigational small molecule inhibitor betasite amyloid precursor protein cleaving enzyme bace resulting decision february stop phase study evaluating verubecestat people prodromal alzheimers disease decision stop study followed recommendation edmc assessed overall benefitrisk interim safety analysis edmc concluded unlikely positive benefitrisk could established trial continued company recorded billion iprd impairment charges amount billion relates clinical development program uprifosbuvir nucleotide prodrug evaluated treatment hcv company determined changes product profile well changes mercks expectations pricing market opportunity taken together constituted triggering event required company evaluate uprifosbuvir intangible asset impairment utilizing market participant assumptions considering different scenarios company concluded best estimate fair value intangible asset related uprifosbuvir million resulting recognition pretax impairment charge noted iprd impairment charges also include charges million million related discontinuation table contents programs obtained connection acquisitions ccam biotherapeutics ltd oncoethix respectively resulting unfavorable efficacy data additional million relates programs obtained connection smartcells acquisition following decision terminate lead compound due lack efficacy pursue backup compound reduced projected future cash flows iprd impairment charges also include million related inlicensed program house dust mite allergies business reasons returned licensor remaining iprd impairment charges primarily relate deprioritized pipeline programs deemed alternative use period including million impairment charge investigational candidate contraception discontinuation delay certain clinical development programs resulted reduction related liabilities contingent consideration see note consolidated financial statements company recorded million iprd impairment charges million related surotomycin clinical development program company received unfavorable efficacy data clinical trial surotomycin evaluation data combined assessment commercial opportunity surotomycin resulted discontinuation program iprd impairment charge noted additional research development required remaining programs reach technological feasibility costs complete research projects depend whether projects brought final stages development ultimately submitted fda regulatory agencies approval acquisitions research collaborations license agreements merck continues remain focused pursuing opportunities potential drive near longterm growth certain recent transactions described merck actively monitoring landscape growth opportunities meet companys strategic criteria february merck viralytics limited viralytics announced definitive agreement pursuant merck acquire viralytics australian publicly traded company focused oncolytic immunotherapy treatments range cancers aud per share proposed acquisition values total issued shares viralytics approximately aud million million upon completion transaction merck gain full rights cavatax cva viralyticss investigational oncolytic immunotherapy cavatax based viralyticss proprietary formulation oncolytic virus coxsackievirus type shown preferentially infect kill cancer cells cavatax currently evaluated multiple phase phase clinical trials intratumoral intravenous agent including combination keytruda previous agreement merck viralytics study investigating use keytruda cavatax combination melanoma prostate lung bladder cancers transaction remains subject viralyticss shareholder vote customary regulatory approvals merck anticipates transaction close second quarter october merck acquired rigontec rigontec leader accessing retinoic acidinducible gene pathway part innate immune system novel distinct approach cancer immunotherapy induce immediate longterm antitumor immunity rigontecs lead candidate rgt currently phase development evaluating treatment patients various tumors terms agreement merck made upfront cash payment million million may make additional contingent payments million million related achievement research milestones regulatory approvals million related achievement commercial targets transaction accounted acquisition asset upfront payment reflected within research development expenses july merck astrazeneca entered global strategic oncology collaboration codevelop cocommercialize astrazenecas lynparza olaparib multiple cancer types lynparza oral parp inhibitor currently approved certain types ovarian breast cancer companies jointly developing commercializing lynparza monotherapy combination trials potential medicines independently merck astrazeneca develop commercialize lynparza combinations respective pd pdl medicines keytruda pembrolizumab imfinzi durvalumab companies also jointly develop commercialize astrazenecas selumetinib oral potent selective inhibitor mek part mitogenactivated protein kinase mapk pathway currently developed multiple indications including thyroid cancer terms agreement astrazeneca merck share development commercialization costs table contents lynparza selumetinib monotherapy nonpdlpd combination therapy opportunities gross profits lynparza selumetinib product sales generated monotherapies combination therapies shared equally merck fund development commercialization costs keytruda combination lynparza selumetinib astrazeneca fund development commercialization costs imfinzi combination lynparza selumetinib part agreement merck made upfront payment astrazeneca billion making payments million multiyear period certain license options million paid december million paid million paid company recorded aggregate charge billion research development expenses related upfront payment future license options payments addition merck pay astrazeneca additional billion contingent upon successful achievement future regulatory salesbased milestones total aggregate consideration billion capital expenditures capital expenditures billion billion billion expenditures united states billion billion million merck plans invest approximately billion five years capital projects including approximately billion united states depreciation expense billion billion billion billion billion billion respectively applied locations united states total depreciation expense included accelerated depreciation million million million respectively associated restructuring activities see note consolidated financial statements analysis liquidity capital resources mercks strong financial profile enables fund research development focus external alliances support inline products maximize upcoming launches providing significant cash returns shareholders selected data millions working capital total debt total liabilities equity cash provided operations total debt decline working capital compared primarily reflects reclassification billion notes due first half longterm debt shortterm debt billion upfront option payments related formation astrazeneca collaboration discussed well million paid redeem debt connection tender offers discussed cash provided operating activities billion billion billion decline cash provided operating activities reflects billion payment related settlement certain federal income tax issues see note consolidated financial statements payments billion related formation collaboration astrazeneca see note consolidated financial statements million payment made company related settlement worldwide keytruda patent litigation see note consolidated financial statements cash provided operating activities reflects net payment approximately million fund vioxx shareholder class action litigation settlement covered insurance proceeds cash provided operating activities continues companys primary source funds finance operating needs capital expenditures treasury stock purchases dividends paid shareholders cash provided investing activities billion compared use cash investing activities billion change driven primarily lower purchases securities investments higher proceeds sales securities investments lower use cash acquisitions businesses cash used investing activities billion compared billion lower use cash driven primarily cash used acquisition cubist well lower purchases securities investments partially offset lower proceeds sales securities investments use cash acquisitions afferent staywell company llc table contents cash used financing activities billion compared billion increase cash used financing activities driven primarily proceeds issuance debt well higher purchases treasury stock lower proceeds exercise stock options partially offset lower payments debt cash used financing activities billion compared billion driven primarily lower proceeds issuance debt partially offset decrease shortterm borrowings lower payments debt lower purchases treasury stock higher proceeds exercise stock options company recorded charges million related devaluation net monetary assets venezuela large majority cash see note consolidated financial statements december total worldwide cash investments billion including billion cash cash equivalents shortterm investments billion longterm investments substantial majority cash investments held foreign subsidiaries prior enactment tcja would subject significant tax payments cash investments repatriated form dividends accordance tcja company recorded provisional amount taxes unremitted earnings december previously deemed indefinitely reinvested outside united states see note consolidated financial statements result tcja repatriation foreign earnings future little incremental us tax consequences companys contractual obligations december follows payments due period millions total thereafter purchase obligations loans payable current portion longterm debt longterm debt interest related debt obligations unrecognized tax benefits transition tax related enactment tcja operating leases includes future inventory purchases company committed connection certain divestitures january billion notes matured repaid december companys consolidated balance sheet reflects liabilities unrecognized tax benefits interest penalties billion including million reflected current liability due high degree uncertainty regarding timing future cash outflows liabilities unrecognized tax benefits beyond one year reasonable estimate period cash settlement years beyond made connection enactment tcja company required pay onetime transition tax company elected pay period eight years permitted tcja see note consolidated financial statements purchase obligations enforceable legally binding obligations purchases goods services including minimum inventory contracts research development advertising amounts reflected research development obligations include contingent milestone payments related collaborative arrangements acquisitions contingent milestone payments considered contractual obligations contingent upon successful achievement developmental regulatory approval commercial milestones december company million accrued milestone payments related collaborations pfizer bayer astrazeneca see note consolidated financial statements well connection certain licensing arrangements payable addition december company million current liabilities contingent consideration related business acquisitions expected paid see note consolidated financial statements also excluded research development obligations potential future funding commitments approximately million investments research venture capital funds loans payable current portion long term debt reflects million longdated notes subject repayment option holders required funding obligations relating companys pension postretirement benefit plans expected material however company currently anticipates contributing table contents approximately million us pension plans million international pension plans million postretirement benefit plans november company launched tender offers certain outstanding notes debentures company paid million aggregate consideration applicable purchase price together accrued interest redeem million principal amount debt validly tendered connection tender offers november company issued billion principal amount senior unsecured notes consisting million principal amount notes due million principal amount notes due company used net proceeds offering billion general corporate purposes company billion fiveyear credit facility matures june facility provides backup liquidity companys commercial paper borrowing facility used general corporate purposes company drawn funding facility december company filed securities registration statement us securities exchange commission sec automatic shelf registration process available wellknown seasoned issuers effective three years february merck issued billion aggregate principal amount senior unsecured notes company used portion net proceeds offering billion repay commercial paper issued substantially finance companys acquisition cubist remaining net proceeds used general corporate purposes including repurchases companys common stock repayment outstanding commercial paper borrowings debt maturities also february company redeemed billion legacy cubist debt acquired acquisition see note consolidated financial statements effective november company executed full unconditional guarantee existing debt subsidiary merck sharp dohme corp msd msd executed full unconditional guarantee existing debt company excluding commercial paper including payments principal interest guarantees extend debt issued subsequent date company continues maintain conservative financial profile company places cash investments instruments meet high credit quality standards specified investment policy guidelines guidelines also limit amount credit exposure one issuer company participate offbalance sheet arrangements involving unconsolidated subsidiaries provide financing potentially expose company unrecorded financial obligations november board directors declared quarterly dividend per share companys common stock paid january january board directors declared quarterly dividend per share companys common stock second quarter payable april november mercks board directors authorized additional purchases billion mercks common stock treasury treasury stock purchase authorization time limit made time openmarket transactions block transactions exchange privately negotiated transactions company purchased billion common stock million shares treasury december companys share repurchase authorization billion includes billion authorized repurchases remaining program announced march company purchased billion billion common stock respectively authorized share repurchase programs financial instruments market risk disclosures company manages impact foreign exchange rate movements interest rate movements earnings cash flows fair values assets liabilities operational means use various financial instruments including derivative instruments significant portion companys revenues earnings foreign affiliates exposed changes foreign exchange rates objectives accounting related companys foreign currency risk management program well interest rate risk management activities discussed table contents foreign currency risk management company established revenue hedging balance sheet risk management net investment hedging programs protect volatility future foreign currency cash flows changes fair value caused volatility foreign exchange rates objective revenue hedging program reduce variability caused changes foreign exchange rates would affect us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen achieve objective company hedge portion forecasted foreign currency denominated thirdparty intercompany distributor entity sales forecasted sales expected occur planning cycle typically two years future company layer hedges time increasing portion forecasted sales hedged gets closer expected date forecasted sales portion forecasted sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments company manages anticipated transaction exposure principally purchased local currency put options forward contracts purchased collar options merck principally sells foreign currency revenue hedging program uniform weakening us dollar would yield largest overall potential loss market value hedge instruments market value mercks hedges would declined estimated million million december respectively uniform weakening us dollar market value determined using foreign exchange option pricing model holding factors except exchange rates constant although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows company manages operating activities net asset positions local subsidiary order mitigate effects exchange monetary assets liabilities company also uses balance sheet risk management program mitigate exposure net monetary assets denominated currency subsidiarys functional currency effects volatility foreign exchange instances merck principally utilizes forward exchange contracts offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts partially offset effects exchange exposures deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument cash flows contracts reported operating activities consolidated statements cash flows sensitivity analysis changes value us dollar foreign currency denominated derivatives investments monetary assets liabilities indicated us dollar uniformly weakened currency exposures company december income taxes would declined approximately million million respectively company net short payable position relative major foreign currencies consideration forward contracts uniform weakening us dollar yield largest overall potential net loss earnings due exchange measurement assumes change one foreign currency relative us dollar would affect foreign currencies relative us dollar although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows since january venezuela designated hyperinflationary result local foreign operations remeasured us dollars impact recorded results operations upon evaluation evolving economic conditions venezuela volatility country combined decline transactions settled official cencoex rate company determined unlikely outstanding net monetary assets would settled cencoex rate accordingly company recorded charges million within income expense net devalue net monetary assets venezuela amount represented companys estimate us dollar amount would ultimately collected recorded additional exchange losses million aggregate reflecting ongoing effect translating transactions net monetary assets consistent rates table contents company may also use forward exchange contracts hedge net investment foreign operations movements exchange rates forward contracts designated hedges net investment foreign operation company hedges portion net investment certain foreign operations measures ineffectiveness based upon changes spot foreign exchange rates recorded income expense net effective portion unrealized gains losses contracts recorded foreign currency translation adjustment within comprehensive income oci remains accumulated comprehensive income aoci either sale complete substantially complete liquidation subsidiary cash flows contracts reported investing activities consolidated statement cash flows foreign exchange risk also managed use foreign currency debt companys senior unsecured eurodenominated notes designated effective economic hedges net investment foreign operation accordingly foreign currency transaction gains losses due spot rate fluctuations eurodenominated debt instruments included foreign currency translation adjustment within oci interest rate risk management company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk december company party payfloating receivefixed interest rate swap contracts designated fair value hedges fixedrate notes notional amounts match amount hedged fixedrate notes detailed table millions number interest rate total swap notional debt instrument par value debt swaps held amount notes due notes due notes due notes due notes due notes due interest rate swap contracts designated hedges fair value changes notes attributable changes benchmark london interbank offered rate libor swap rate fair value changes notes attributable changes libor swap rate recorded interest expense offset fair value changes swap contracts cash flows contracts reported operating activities consolidated statement cash flows companys investment portfolio includes cash equivalents shortterm investments market values significantly affected changes interest rates market value companys medium longterm fixedrate investments modestly affected changes us interest rates changes medium longterm us interest rates significant impact market value companys fixedrate borrowings generally longer maturities sensitivity analysis measure potential changes market value mercks investments debt change interest rates indicated one percentage point increase interest rates december would positively affected net aggregate market value instruments billion one percentage point decrease december would negatively affected net aggregate market value billion billion respectively fair value mercks debt determined using pricing models reflecting one percentage point shifts appropriate yield curves fair values mercks investments determined using combination pricing duration models critical accounting policies companys consolidated financial statements prepared conformity gaap accordingly include certain amounts based managements best estimates judgments estimates used accounting amounts recorded connection acquisitions including initial fair value determinations assets liabilities primarily iprd intangible assets contingent consideration well subsequent fair value table contents measurements additionally estimates used determining items provisions sales discounts returns depreciable amortizable lives recoverability inventories including produced preparation product launches amounts recorded contingencies environmental liabilities reserves pension postretirement benefit plan assumptions sharebased compensation assumptions restructuring costs impairments longlived assets including intangible assets goodwill investments taxes income uncertainty inherent estimates actual results may differ estimates application following accounting policies result accounting estimates potential significant impact financial statements acquisitions dispositions determine whether transactions accounted acquisitions disposals assets businesses company makes certain judgments include assessment inputs processes outputs associated acquired set activities company determines substantially fair value gross assets included transaction concentrated single asset group similar assets assets would represent business considered business assets transaction need include input substantive process together significantly contribute ability create outputs business combination acquisition method accounting requires assets acquired liabilities assumed recorded date acquisition respective fair values limited exceptions assets acquired liabilities assumed business combination arise contingencies recognized fair value fair value reasonably estimated acquisition date fair value asset acquired liability assumed arises contingency determined asset liability recognized probable reasonably estimable criteria met asset liability recognized fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date accordingly company may required value assets fair value measures reflect companys intended use assets excess purchase price consideration transferred estimated fair values net assets acquired recorded goodwill transaction costs costs restructure acquired company expensed incurred operating results acquired business reflected companys consolidated financial statements date acquisition fair values intangible assets including acquired iprd determined utilizing information available near acquisition date based expectations assumptions deemed reasonable management given considerable judgment involved determining fair values company typically obtains assistance thirdparty valuation specialists significant items amounts allocated acquired iprd capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project merck make separate determination useful life asset generally determined period substantial majority cash flows expected generated begin amortization certain companys business acquisitions involve potential future payment consideration contingent upon achievement performance milestones including product development milestones royalty payments future product sales fair value contingent consideration liabilities determined acquisition date using unobservable inputs inputs include estimated amount timing projected cash flows probability success achievement contingent event riskadjusted discount rate used present value probability weighted cash flows subsequent acquisition date reporting period contingent consideration liability remeasured current fair value changes either expense income recorded earnings changes inputs may result significantly different fair value adjustment judgments made determining estimated fair values assigned assets acquired liabilities assumed business combination well asset lives materially affect companys results operations fair values identifiable intangible assets related currently marketed products product rights primarily determined using income approach fair value estimated based assets discounted projected net cash flows companys estimates market participant net cash flows consider historical projected pricing margins expense levels performance competing products applicable relevant industry therapeutic area growth drivers factors current expected trends technology product life cycles time investment required develop products technologies ability obtain marketing regulatory approvals ability manufacture commercialize products extent timing potential table contents new product introductions companys competitors life assets underlying patent net cash flows probabilityadjusted appropriate consider uncertainties associated underlying assumptions well risk profile net cash flows utilized valuation probabilityadjusted future net cash flows product discounted present value utilizing appropriate discount rate fair values identifiable intangible assets related iprd also determined using income approach fair value estimated based assets probabilityadjusted future net cash flows reflect different stages development product associated probability successful completion net cash flows discounted present value using appropriate discount rate company determines transaction accounted acquisition business transaction accounted asset acquisition rather business combination therefore goodwill recorded asset acquisition acquired iprd alternative future use charged expense contingent consideration recognized acquisition date revenue recognition revenues sales products recognized title risk loss passes customer typically time delivery recognition revenue also requires reasonable assurance collection sales proceeds completion performance obligations domestically sales discounts issued customers pointofsale intermediary wholesaler known chargebacks form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale addition revenues recorded net time value money discounts customers collection accounts receivable expected excess one year provision aggregate customer discounts covers chargebacks rebates chargebacks discounts occur contracted customer purchases directly intermediary wholesaler contracted customer generally purchases product contracted price plus markup wholesaler wholesaler turn charges company back difference price initially paid wholesaler contract price paid wholesaler customer provision chargebacks based expected sellthrough levels companys wholesale customers contracted customers well estimated wholesaler inventory levels rebates amounts owed based upon definitive contractual agreements legal requirements private sector public sector medicaid medicare part benefit providers final dispensing product pharmacy benefit plan participant provision based expected payments driven patient usage contract performance benefit provider customers company uses historical customer segment mix adjusted known events order estimate expected provision amounts accrued aggregate customer discounts evaluated quarterly basis comparison information provided wholesalers health maintenance organizations pharmacy benefit managers customers amounts accrued adjustments recorded trends significant events indicate change estimated provision appropriate company continually monitors provision aggregate customer discounts material adjustments estimates associated aggregate customer discount provision summarized information changes aggregate customer discount accrual related us sales follows millions balance january current provision adjustments prior years payments balance december accruals chargebacks reflected direct reduction accounts receivable accruals rebates current liabilities accrued balances relative provisions included accounts receivable accrued table contents current liabilities million billion respectively december million billion respectively december company maintains returns policy allows us pharmaceutical customers return product within specified period prior subsequent expiration date generally three six months months product expiration estimate provision returns based upon historical experience actual returns additionally company considers factors levels inventory distribution channel product dating expiration period whether products discontinued entrance market additional generic competition changes formularies launch overthecounter products among others product returns provision us pharmaceutical sales percentage us net pharmaceutical sales distribution programs us wholesalers company encourages wholesalers align purchases underlying demand maintain inventories specified levels terms programs allow wholesalers earn fees upon providing visibility inventory levels well achieving certain performance parameters inventory management customer service levels reducing shortage claims reducing product returns information provided wholesaler distribution programs includes items sales trends inventory onhand onorder quantity product returns wholesalers generally provide mentioned data company regulatory requirement report lot level information manufacturers level information needed determine remaining shelf life original sale date inventory given current wholesaler inventory levels generally less month company believes collection order lot information across wholesale customers would limited use estimating sales discounts returns inventories produced preparation product launches company capitalizes inventories produced preparation product launches sufficient support estimated initial market demand typically capitalization inventory begin related product candidates phase clinical trials considered high probability regulatory approval company monitors status respective product within regulatory approval process however company generally disclose specific timing regulatory approval company aware specific risks contingencies normal regulatory approval process specific issues identified research process relating safety efficacy manufacturing marketing labeling related inventory would generally capitalized expiry dates inventory affected stage completion company manages levels inventory stage optimize shelf life inventory relation anticipated market demand order avoid product expiry issues inventories capitalized anticipated future sales shelf lives support realization inventory value inventory shelf life sufficient meet initial product launch requirements inventories produced preparation product launches capitalized december million contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well certain additional matters see note consolidated financial statements company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable significant factors considered review legal defense reserves follows actual costs incurred company development companys legal defense strategy structure light scope litigation number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials associated litigation amount legal defense reserves december approximately million million respectively represents companys best estimate table contents minimum amount defense costs incurred connection outstanding litigation however events additional trials events could arise course litigation could affect ultimate amount legal defense costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine increase reserves time future based upon factors set forth believes would appropriate company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents legitimate claim contribution asserted liability initially accrued based upon estimated transaction costs manage site accruals adjusted site investigations feasibility studies related cost assessments remedial techniques completed extent potentially responsible parties may jointly severally liable expected contribute determined company also remediating environmental contamination resulting past industrial activity certain sites takes active role identifying accruing costs past merck performed worldwide survey assess sites potential contamination resulting past industrial activities assessment indicated physical investigation warranted investigation performed providing better evaluation need remedial action need identified remedial action initiated definitive information became available course investigations andor remedial efforts site estimates refined accruals established adjusted accordingly estimates related accruals continue refined annually company believes compliance issues associated applicable environmental laws regulations would material adverse effect company expenditures remediation environmental liabilities million estimated million aggregate years managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively liabilities undiscounted consider potential recoveries parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial position results operations liquidity capital resources year sharebased compensation company expenses sharebased payment awards employees including grants stock options requisite service period based grant date fair value awards company determines fair value certain sharebased awards using blackscholes optionpricing model uses historical current market data estimate fair value method incorporates various assumptions riskfree interest rate expected volatility expected dividend yield expected life options total pretax sharebased compensation expense million million million december million total pretax unrecognized compensation expense related nonvested stock option restricted stock unit performance share unit awards recognized weighted average period years segment reporting sharebased compensation costs unallocated expenses pensions postretirement benefit plans net periodic benefit cost pension plans totaled million million million net periodic benefit credit postretirement benefit plans million million million pension postretirement benefit plan information financial reporting purposes calculated using actuarial assumptions including discount rate plan benefit obligations expected rate return plan assets changes net periodic benefit cost year year pension plans largely attributable changes discount rate affecting net loss amortization increase net periodic benefit credit postretirement benefit plans compared largely attributable changes retiree medical benefits approved company december partially offset lower returns plan assets table contents company reassesses benefit plan assumptions regular basis pension postretirement benefit plans discount rate evaluated measurement dates modified reflect prevailing market rate portfolio highquality fixedincome debt instruments would provide future cash flows needed pay benefits included benefit obligation come due discount rates companys us pension postretirement benefit plans ranged december compared range december expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid developing expected rate return company considers longterm compound annualized returns historical market data current market conditions actual returns companys plan assets using reference information company develops forwardlooking return expectations asset category weightedaverage expected longterm rate return target portfolio allocated across investment categories expected portfolio performance reflects contribution active management appropriate expected rate return companys us pension postretirement benefit plans range compared range decrease primarily due modest shift asset allocation company established investment guidelines us pension postretirement plans create asset allocation expected deliver rate return sufficient meet longterm obligation plan given acceptable level risk target investment portfolio companys us pension postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios equity weighting consistent longterm nature plans benefit obligations expected annual standard deviation returns target portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests nonus pension plans targeted investment portfolio varies based duration pension liabilities local government rules regulations although significant percentage plan assets invested us equities concentration risk mitigated use strategies diversified within management guidelines actuarial assumptions based upon managements best estimates judgment reasonably possible change plus minus basis points discount rate assumption assumptions held constant would estimated million favorable unfavorable impact companys net periodic benefit cost reasonably possible change plus minus basis points expected rate return assumption assumptions held constant would estimated million favorable unfavorable impact mercks net periodic benefit cost required funding obligations relating companys pension postretirement benefit plans expected material preceding hypothetical changes discount rate expected rate return assumptions would impact companys funding requirements net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions recorded component accumulated comprehensive income aoci expected returns pension plans based calculated marketrelated value assets methodology asset gainslosses resulting actual returns differ companys expected returns recognized marketrelated value assets ratably fiveyear period also net loss amounts aoci excess certain thresholds amortized net periodic benefit cost average remaining service life employees restructuring costs restructuring costs recorded connection restructuring programs designed streamline companys cost structure result company made estimates judgments regarding future plans including future termination benefits exit costs incurred restructuring actions take place accruing costs company recognize amount within range costs best estimate within range amount within range better estimate amount company recognizes minimum amount within range connection actions management also assesses recoverability longlived assets employed business certain instances asset lives shortened based changes expected useful lives affected assets severance related costs reflected within restructuring table contents costs assetrelated charges reflected within materials production costs marketing administrative expenses research development expenses depending upon nature asset impairments longlived assets company assesses changes economic regulatory legal conditions makes assumptions regarding estimated future cash flows evaluating value companys property plant equipment goodwill intangible assets company periodically evaluates whether current facts circumstances indicate carrying values longlived assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows assets appropriate asset groupings compared carrying value determine whether impairment exists asset determined impaired loss measured based difference assets fair value carrying value quoted market prices available company estimate fair value using discounted value estimated future cash flows approach goodwill represents excess consideration transferred fair value net assets businesses acquired assigned reporting units company tests goodwill impairment least annual basis frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value reporting unit less carrying amount factors considered assessment include general macroeconomic conditions conditions specific industry market cost factors could significant effect earnings cash flows overall financial performance reporting unit whether sustained declines companys share price additionally company evaluates extent fair value exceeded carrying value reporting unit last date valuation performed company concludes likely fair value reporting unit less carrying amount quantitative fair value test performed acquired intangible assets excluding iprd initially recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives events circumstances warrant review company assess recoverability future operations using pretax undiscounted cash flows derived lowest appropriate asset groupings impairments recognized operating results extent carrying value intangible asset exceeds fair value determined based net present value estimated future cash flows iprd company acquires business combinations represents fair value assigned incomplete research projects time acquisition reached technological feasibility amounts capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment project company tests iprd impairment least annually frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value iprd intangible asset less carrying amount company concludes likely fair value less carrying amount quantitative test compares fair value iprd intangible asset carrying value performed impairment testing purposes company may combine separately recorded iprd intangible assets one unit account based relevant facts circumstances generally company combine iprd intangible assets testing purposes operate single asset essentially inseparable fair value less carrying amount impairment loss recognized within companys operating results judgments made evaluating impairment longlived intangibles materially affect companys results operations impairments investments company reviews investments impairments based determination whether decline market value investment carrying value otherthantemporary company considers available evidence evaluating potential impairments investments including duration extent fair value less cost equity securities companys ability intent hold investments debt securities otherthan temporary impairment occurred company expect recover entire amortized cost basis debt security company intend sell impaired debt security likely required sell debt security recovery amortized cost basis amount table contents otherthantemporary impairment recognized earnings limited portion attributed credit loss remaining portion otherthantemporary impairment related factors recognized oci taxes income companys effective tax rate based pretax income statutory tax rates tax planning opportunities available various jurisdictions company operates estimated effective tax rate year applied companys quarterly operating results event significant unusual onetime item recognized expected recognized companys quarterly operating results tax attributable item would separately calculated recorded time unusual onetime item company considers resolution prior year tax matters items significant judgment required determining companys tax provision evaluating tax positions recognition measurement tax position based managements best judgment given facts circumstances information available reporting date company evaluates tax positions determine whether benefits tax positions likely sustained upon audit based technical merits tax position tax positions likely sustained upon audit company recognizes largest amount benefit greater likely realized upon ultimate settlement financial statements tax positions likely sustained upon audit company recognize portion benefit financial statements likely threshold met period tax position taken company may subsequently recognize benefit tax position tax matter effectively settled statute limitations expires likely threshold met subsequent period see note consolidated financial statements tax regulations require items included tax return different times items reflected financial statements timing differences create deferred tax assets liabilities deferred tax assets generally represent items used tax deduction credit tax return future years company already recorded tax benefit financial statements company establishes valuation allowances deferred tax assets amount expected future taxable income likely support use deduction credit deferred tax liabilities generally represent tax expense recognized financial statements payment deferred expense company already taken deduction tax return yet recognized expense financial statements recently issued accounting standards discussion recently issued accounting standards see note consolidated financial statements cautionary factors may affect future results report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words anticipates expects plans estimates forecasts projects words similar meaning negative variations foregoing one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product development product approvals product potential development programs one must carefully consider statement understand many factors could cause actual results differ materially companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement one carefully evaluate statements light factors including risk factors described companys filings securities exchange commission especially forms q k item risk factors annual report company discusses detail various important risk factors could cause actual results differ expected historic results company notes factors investors permitted private securities litigation reform act one understand possible predict identify table contents factors consequently reader consider list complete statement potential risks uncertainties item quantitative qualitative disclosures market risk information required item incorporated reference discussion financial instruments market risk disclosures item managements discussion analysis financial condition results operations table contents item financial statements supplementary data financial statements consolidated balance sheet merck co inc subsidiaries december related consolidated statements income comprehensive income equity cash flows three years period ended december notes consolidated financial statements report dated february pricewaterhousecoopers llp independent registered public accounting firm follows consolidated statement income merck co inc subsidiaries years ended december millions except per share amounts sales costs expenses materials production marketing administrative research development restructuring costs income expense net income taxes taxes income net income less net income attributable noncontrolling interests net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders consolidated statement comprehensive income merck co inc subsidiaries years ended december millions net income attributable merck co inc comprehensive income loss net taxes net unrealized loss derivatives net reclassifications net unrealized loss investments net reclassifications benefit plan net gain loss prior service credit cost net amortization cumulative translation adjustment comprehensive income attributable merck co inc accompanying notes integral part consolidated financial statements table contents consolidated balance sheet merck co inc subsidiaries december millions except per share amounts assets current assets cash cash equivalents shortterm investments accounts receivable net allowance doubtful accounts inventories excludes inventories classified assets see note current assets total current assets investments property plant equipment cost land buildings machinery equipment office furnishings construction progress less accumulated depreciation goodwill intangibles net assets liabilities equity current liabilities loans payable current portion longterm debt trade accounts payable accrued current liabilities income taxes payable dividends payable total current liabilities longterm debt deferred income taxes noncurrent liabilities merck co inc stockholders equity common stock par value authorized shares issued shares paidin capital retained earnings accumulated comprehensive loss less treasury stock cost shares shares total merck co inc stockholders equity noncontrolling interests total equity accompanying notes integral part consolidated financial statement table contents consolidated statement equity merck co inc subsidiaries years ended december millions except per share amounts accumulated non common paidin retained comprehensive treasury controlling stock capital earnings loss stock interests total balance january net income attributable merck co inc comprehensive income net taxes cash dividends declared common stock per share treasury stock shares purchased changes noncontrolling ownership interests net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december net income attributable merck co inc comprehensive loss net taxes cash dividends declared common stock per share treasury stock shares purchased changes noncontrolling ownership interests net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december net income attributable merck co inc comprehensive income net taxes cash dividends declared common stock per share treasury stock shares purchased acquisition valle sa net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december accompanying notes integral part consolidated financial statement table contents consolidated statement cash flows merck co inc subsidiaries years ended december millions cash flows operating activities net income adjustments reconcile net income net cash provided operating activities depreciation amortization intangible asset impairment charges provisional charge onetime transition tax related enactment us tax legislation charge future payments related astrazeneca collaboration license options charge related settlement worldwide keytruda patent litigation foreign currency devaluation related venezuela net charge related settlement vioxx shareholder class action litigation equity income affiliates dividends distributions equity method affiliates deferred income taxes sharebased compensation net changes assets liabilities accounts receivable inventories trade accounts payable accrued current liabilities income taxes payable noncurrent liabilities net cash provided operating activities cash flows investing activities capital expenditures purchases securities investments proceeds sales securities investments acquisition cubist pharmaceuticals inc net cash acquired acquisitions businesses net cash acquired dispositions businesses net cash divested net cash provided used investing activities cash flows financing activities net change shortterm borrowings payments debt proceeds issuance debt purchases treasury stock dividends paid stockholders proceeds exercise stock options net cash used financing activities effect exchange rate changes cash cash equivalents net decrease increase cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year accompanying notes integral part consolidated financial statement table contents notes consolidated financial statements merck co inc subsidiaries millions except per share amounts nature operations merck co inc merck company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health products companys operations principally managed products basis include four operating segments pharmaceutical animal health healthcare services alliances segments pharmaceutical segment reportable segment pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities december merck sanofi pasteur sa sanofi terminated equallyowned joint venture sanofi pasteur msd spmsd developed marketed vaccines europe beginning merck recording vaccine sales incurring costs result operating vaccines business european markets previously part spmsd joint venture accounted equity method affiliate company also animal health segment discovers develops manufactures markets animal health products including vaccines company sells veterinarians distributors animal producers companys healthcare services segment provides services solutions focus engagement health analytics clinical services improve value care delivered patients summary accounting policies principles consolidation consolidated financial statements include accounts company subsidiaries controlling interest maintained intercompany balances transactions eliminated controlling interest determined majority ownership interest absence substantive thirdparty participating rights case variable interest entities majority exposure expected losses residual returns consolidated subsidiaries merck ownership less outside shareholders interests shown noncontrolling interests equity investments affiliates company significant influence controlling interest interests entities owned equally company third party shared control carried equity basis acquisitions business combination acquisition method accounting requires assets acquired liabilities assumed recorded date acquisition respective fair values limited exceptions assets acquired liabilities assumed business combination arise contingencies generally recognized fair value fair value determined asset liability recognized probable reasonably estimable criteria met asset liability recognized fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date accordingly company may required value assets fair value measures reflect companys intended use assets excess purchase price consideration transferred estimated fair values net assets acquired recorded goodwill transaction costs costs restructure acquired company expensed incurred operating results acquired business reflected companys consolidated financial statements date acquisition company determines assets acquired meet definition business acquisition method accounting transaction accounted acquisition assets rather business combination therefore goodwill recorded table contents foreign currency translation net assets international subsidiaries local currencies determined functional currencies translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recorded foreign currency translation account included accumulated comprehensive income loss aoci reflected separate component equity subsidiaries operate highly inflationary economies subsidiaries us dollar determined functional currency nonmonetary foreign currency assets liabilities translated using historical rates monetary assets liabilities translated current rates us dollar effects rate changes included income expense net cash equivalents cash equivalents comprised certain highly liquid investments original maturities less three months inventories inventories valued lower cost market cost substantial majority domestic pharmaceutical vaccine inventories determined using lastin firstout lifo method financial reporting tax purposes cost inventories determined using firstin firstout fifo method inventories consist currently marketed products well certain inventories produced preparation product launches considered high probability regulatory approval evaluating recoverability inventories produced preparation product launches company considers likelihood revenue obtained future sale related inventory together status product within regulatory approval process investments investments marketable debt equity securities classified availableforsale reported fair value fair values companys investments determined using quoted market prices active markets identical assets liabilities quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities changes fair value considered temporary reported net tax comprehensive income oci declines fair value equity securities considered otherthan temporary impairment losses charged income expense net company considers available evidence evaluating potential impairments investments including duration extent fair value less cost equity securities companys ability intent hold investments debt securities otherthantemporary impairment occurred company expect recover entire amortized cost basis debt security company intend sell impaired debt security likely required sell debt security recovery amortized cost basis amount otherthantemporary impairment recognized earnings recorded income expense net limited portion attributed credit loss remaining portion otherthantemporary impairment related factors recognized oci realized gains losses debt equity securities included income expense net revenue recognition revenues sales products recognized title risk loss passes customer typically upon delivery recognition revenue also requires reasonable assurance collection sales proceeds completion performance obligations domestically sales discounts issued customers pointofsale intermediary wholesaler known chargebacks form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale addition revenues recorded net time value money discounts collection accounts receivable expected excess one year accruals chargebacks reflected direct reduction accounts receivable accruals rebates recorded current liabilities accrued balances relative provisions chargebacks rebates included accounts receivable accrued current liabilities million billion respectively december million billion respectively december company recognizes revenue sales vaccines federal government placement vaccine stockpiles accordance securities exchange commission sec interpretation commission guidance regarding accounting sales vaccines bioterror countermeasures federal government placement pediatric vaccine stockpile strategic national stockpile interpretation allows companies recognize revenue sales vaccines us government stockpiles even though sales might meet criteria revenue recognition accounting guidance table contents depreciation depreciation provided estimated useful lives assets principally using straightline method tax purposes accelerated tax methods used estimated useful lives primarily range years buildings years machinery equipment office furnishings depreciation expense billion billion billion advertising promotion costs advertising promotion costs expensed incurred company recorded advertising promotion expenses billion billion billion respectively software capitalization company capitalizes certain costs incurred connection obtaining developing internaluse software including external direct costs material services payroll costs employees directly involved software development capitalized software costs included property plant equipment amortized beginning software project substantially complete asset ready intended use capitalized software costs associated projects amortized years including companys ongoing multiyear implementation enterprisewide resource planning system million million net accumulated amortization december respectively capitalized software costs amortized periods ranging years costs incurred preliminary project stage postimplementation stage well maintenance training costs expensed incurred goodwill goodwill represents excess consideration transferred fair value net assets businesses acquired goodwill assigned reporting units evaluated impairment least annual basis frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value reporting unit less carrying amount company concludes likely fair value reporting unit less carrying amount quantitative fair value test performed acquired intangibles acquired intangibles include products product rights tradenames patents initially recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives ranging years see note company periodically evaluates whether current facts circumstances indicate carrying values acquired intangibles may recoverable circumstances determined exist estimate undiscounted future cash flows assets appropriate asset groupings compared carrying value determine whether impairment exists asset determined impaired loss measured based difference carrying value intangible asset fair value determined based net present value estimated future cash flows acquired inprocess research development acquired inprocess research development iprd company acquires business combinations represents fair value assigned incomplete research projects time acquisition reached technological feasibility amounts capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project merck make determination useful life intangible asset generally determined period substantial majority cash flows expected generated begin amortization company tests iprd impairment least annually frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value iprd intangible asset less carrying amount company concludes likely fair value less carrying amount quantitative test compares fair value iprd intangible asset carrying value performed fair value less carrying amount impairment loss recognized operating results contingent consideration certain companys business acquisitions involve potential future payment consideration contingent upon achievement performance milestones including product development milestones royalty payments future product sales fair value contingent consideration liabilities determined acquisition date using unobservable inputs inputs include estimated amount timing projected cash flows probability success achievement contingent event riskadjusted discount rate used present value probability weighted cash flows subsequent acquisition date table contents reporting period contingent consideration liability remeasured current fair value changes either expense income recorded earnings research development research development expensed incurred nonrefundable advance payments goods services used future research development activities expensed activity performed goods received rather payment made research development expenses include restructuring costs iprd impairment charges periods addition research development expenses include expense income related changes estimated fair value measurement liabilities contingent consideration collaborative arrangements merck entered collaborative arrangements provide company varying rights develop produce market products together collaborative partners cost reimbursements collaborative partners recognized incurred included materials production costs marketing administrative expenses research development expenses based underlying nature related activities subject reimbursement merck principal sales transactions third parties company recognizes sales materials production costs marketing administrative expenses gross basis company records profit sharing amounts received collaborative partners alliance revenue within sales profit sharing amounts pays collaborative partners within materials production costs terms collaboration agreements may require company make payments based upon achievement certain developmental regulatory approval commercial milestones upfront milestone payments payable merck collaborative partners prior regulatory approval expensed incurred included research development expenses payments due collaborative partners upon subsequent regulatory approval capitalized amortized estimated useful life corresponding intangible asset materials production costs provided future cash flows support amounts capitalized salesbased milestones payable merck collaborative partners accrued probable achieved capitalized subject cumulative amortization catchup amortization catch calculated either time first regulatory approval indications unapproved time collaboration formed time formation collaboration approved products related intangible asset recognized amortized materials production costs remaining useful life subject impairment testing sharebased compensation company expenses sharebased payments employees requisite service period based grantdate fair value awards restructuring costs company records liabilities costs associated exit disposal activities period liability incurred accordance existing benefit arrangements employee termination costs accrued restructuring actions probable estimable accruing costs company recognize amount within range costs best estimate within range amount within range better estimate amount company recognizes minimum amount within range costs onetime termination benefits employee required render service termination order receive benefits recognized ratably future service period contingencies legal defense costs company records accruals contingencies legal defense costs expected incurred connection loss contingency probable liability incurred amount reasonably estimated taxes income deferred taxes recognized future tax effects temporary differences financial income tax reporting based enacted tax laws rates company evaluates tax positions determine whether benefits tax positions likely sustained upon audit based technical merits tax position tax positions likely sustained upon audit company recognizes largest amount benefit greater likely realized upon ultimate settlement financial statements tax positions likely sustained upon audit company recognize portion benefit financial statements company recognizes interest penalties associated uncertain tax positions component taxes income consolidated statement income table contents use estimates consolidated financial statements prepared conformity accounting principles generally accepted united states gaap accordingly include certain amounts based managements best estimates judgments estimates used accounting amounts recorded connection acquisitions including initial fair value determinations assets liabilities primarily iprd intangible assets contingent consideration well subsequent fair value measurements additionally estimates used determining items provisions sales discounts returns depreciable amortizable lives recoverability inventories including produced preparation product launches amounts recorded contingencies environmental liabilities reserves pension postretirement benefit plan assumptions sharebased compensation assumptions restructuring costs impairments longlived assets including intangible assets goodwill investments taxes income uncertainty inherent estimates actual results may differ estimates reclassifications certain reclassifications made prior year amounts conform current year presentation recently issued accounting standards may financial accounting standards board fasb issued amended accounting guidance revenue recognition applied contracts customers objective new guidance improve comparability revenue recognition practices across entities provide useful information users financial statements improved disclosure requirements new standard permits two methods adoption retrospectively prior reporting period presented full retrospective method retrospectively cumulative effect adopting guidance recognized date initial application modified retrospective method new standard effective january adopted using modified retrospective method company anticipates recording cumulativeeffect adjustment upon adoption increasing retained earnings million adoption new guidance also result additional disclosures january fasb issued revised guidance accounting reporting financial instruments new guidance requires equity investments readily determinable fair values currently classified available sale measured fair value changes fair value recognized net income new guidance also simplifies impairment testing equity investments without readily determinable fair values changes certain disclosure requirements new standard effective january adopted using modified retrospective approach company anticipates recording cumulativeeffect adjustment upon adoption increasing retained earnings million august fasb issued guidance classification certain cash receipts payments statement cash flows intended reduce diversity practice new standard effective january adopted using retrospective application company anticipate changes presentation consolidated statement cash flows result adopting new standard october fasb issued guidance accounting income tax consequences intraentity transfers assets inventory existing guidance recognition current deferred income taxes intraentity asset transfer prohibited asset sold third party new guidance require recognition income tax consequences intraentity transfer asset exception inventory intraentity transfer occurs new standard effective january adopted using modified retrospective approach company anticipates recording cumulativeeffect adjustment upon adoption increasing retained earnings approximately million corresponding increase deferred tax assets subject finalization november fasb issued guidance requiring amounts generally described restricted cash restricted cash equivalents included cash cash equivalents reconciling beginningofperiod endofperiod total amounts shown statement cash flows new standard effective january adopted using retrospective application adoption new guidance material effect companys consolidated statement cash flows march fasb amended guidance related net periodic benefit cost defined benefit plans requires entities disaggregate current service cost component components net benefit cost present employee compensation costs income statement within operations subtotal table contents presented present components net benefit cost separately income statement outside income operations capitalize service cost component applicable entities must use retrospective transition method adopt requirement separate presentation income statement service costs components prospective transition method adopt requirement limit capitalization benefit costs service cost component company utilize practical expedient permits use amounts disclosed pension postretirement benefit plan note prior comparative periods estimation basis applying retrospective presentation requirements new standard effective january net periodic benefit cost credit service cost approximately million million years ended december respectively see note upon adoption amounts reclassified income expense net current classification within materials production costs marketing administrative expenses research development costs may fasb issued guidance clarifying account change terms conditions sharebased payment award modification new guidance modification accounting required fair value vesting conditions classification award equity liability changes result change terms conditions new standard effective january applied future sharebased payment award modifications occur february fasb issued new accounting guidance accounting reporting leases new guidance requires lessees recognize rightofuse asset lease liability recorded balance sheet leases leases meet definition shortterm lease leases classified either operating finance operating leases result straightline expense income statement similar current operating leases finance leases result expense recognized earlier years lease term similar current capital leases new guidance effective interim annual periods beginning adopted using modified retrospective approach require application new guidance beginning earliest comparative period presented early adoption permitted company currently evaluating impact adoption consolidated financial statements august fasb issued new guidance hedge accounting intended closely align hedge accounting companies risk management strategies simplify application hedge accounting increase transparency scope results hedging programs new guidance makes financial nonfinancial hedging strategies eligible hedge accounting amends presentation disclosure requirements changes companies assess effectiveness new guidance effective interim annual periods beginning modified retrospective basis early application permitted interim period company intends early adopt guidance january modified retrospective basis company anticipates recording cumulativeeffect adjustment upon adoption decreasing retained earnings million adoption new guidance result additional disclosures february fasb issued new guidance address narrowscope financial reporting issue arose consequence tcja existing guidance requires deferred tax liabilities assets adjusted change tax laws rates effect included income continuing operations reporting period includes enactment date guidance applicable even situations related income tax effects items accumulated comprehensive income originally recognized comprehensive income rather net income amounts related benefit plans hedging activity result tax effects items within accumulated comprehensive income reflect appropriate tax rate difference referred stranded tax effects new guidance allows reclassification amounts retained earnings thereby eliminating stranded tax effects new guidance effective interim annual periods company currently evaluating impact adoption consolidated financial statements june fasb issued amended guidance accounting credit losses financial instruments guidance introduces expected loss model estimating credit losses replacing incurred loss model new guidance also changes impairment model availableforsale debt securities requiring use allowance record estimated credit losses subsequent recoveries new guidance effective interim annual periods beginning earlier application permitted new guidance applied modified retrospective basis cumulativeeffect adjustment directly retained earnings beginning period adoption company currently evaluating impact adoption consolidated financial statements table contents january fasb issued guidance provides elimination step goodwill impairment test new guidance impairment charges recognized extent carrying amount reporting unit exceeds fair value certain limitations new guidance effective interim annual periods early adoption permitted company anticipate adoption new guidance material effect consolidated financial statements acquisitions divestitures research collaborations license agreements company continues pursue acquisition businesses establishment external alliances research collaborations licensing agreements complement internal research capabilities arrangements often include upfront payments well expense reimbursements payments third party milestone royalty profit share arrangements contingent upon occurrence certain future events linked success asset development company also reviews marketed products pipeline examine candidates may provide value outlicensing part portfolio assessment process may also divest certain assets pro forma financial information acquired businesses presented historical financial results acquired entity significant compared companys financial results recently announced transaction february merck viralytics limited viralytics announced definitive agreement pursuant merck acquire viralytics australian publicly traded company focused oncolytic immunotherapy treatments range cancers aud per share proposed acquisition values total issued shares viralytics approximately aud million million upon completion transaction merck gain full rights cavatax cva viralyticss investigational oncolytic immunotherapy transaction remains subject viralyticss shareholder vote customary regulatory approvals merck anticipates transaction close second quarter transactions october merck acquired rigontec gmbh rigontec rigontec leader accessing retinoic acidinducible gene pathway part innate immune system novel distinct approach cancer immunotherapy induce immediate longterm antitumor immunity rigontecs lead candidate rgt currently phase development evaluating treatment patients various tumors terms agreement merck made upfront cash payment million million may make additional contingent payments million million related achievement research milestones regulatory approvals million related achievement commercial targets transaction accounted acquisition asset upfront payment reflected within research development expenses july merck astrazeneca entered global strategic oncology collaboration codevelop cocommercialize astrazenecas lynparza olaparib multiple cancer types see note march merck acquired controlling interest valle sa valle leading privately held producer animal health products brazil valle extensive portfolio products spanning parasiticides antiinfectives vaccines include products livestock horses companion animals terms agreement merck acquired shares valle million total purchase price million placed escrow pending resolution certain contingent items transaction accounted acquisition business merck recognized intangible assets million related currently marketed products net deferred tax liabilities million net assets million noncontrolling interest million addition company recorded liabilities million contingencies identified acquisition date corresponding indemnification assets million representing amounts reimbursed merck contingent liabilities paid excess consideration transferred fair value net assets acquired million recorded goodwill goodwill allocated animal health segment deductible tax purposes estimated fair values identifiable intangible assets related currently marketed products determined using income approach probabilityadjusted future net cash flows product discounted present value utilizing discount rate actual cash flows likely different assumed intangible assets related currently marketed products amortized estimated useful lives table contents years fourth quarter merck acquired additional interest valle million reduced noncontrolling interest related valle transactions july merck acquired afferent pharmaceuticals afferent privately held pharmaceutical company focused development therapeutic candidates targeting px receptor treatment common poorlymanaged neurogenic conditions afferents lead investigational candidate mk formerly af selective nonnarcotic orallyadministered px antagonist evaluated treatment refractory chronic cough total consideration transferred million included cash paid outstanding afferent shares million well sharebased compensation payments settle equity awards attributable precombination service cash paid transaction costs behalf afferent addition former afferent shareholders eligible receive total additional million contingent upon attainment certain clinical development commercial milestones multiple indications candidates including mk transaction accounted acquisition business company determined fair value contingent consideration million acquisition date utilizing probabilityweighted estimated cash flow stream using appropriate discount rate dependent nature timing milestone payment merck recognized intangible asset iprd million net deferred tax liabilities million net assets million primarily consisting cash acquired excess consideration transferred fair value net assets acquired million recorded goodwill allocated pharmaceutical segment deductible tax purposes fair value identifiable intangible asset related iprd determined using income approach assets probabilityadjusted future net cash flows discounted present value using discount rate actual cash flows likely different assumed also july merck wholly owned subsidiary healthcare services solutions llc acquired majority ownership interest staywell company llc staywell portfolio company vestar capital partners vestar staywell health engagement company helps clients engage educate people improve health business results terms transaction merck paid million majority ownership interest additionally merck provided staywell million intercompany loan pay preexisting thirdparty debt merck option buy vestar option require merck buy vestars remaining ownership interest fair value beginning three years acquisition date transaction accounted acquisition business merck recognized intangible assets million deferred tax liabilities million net liabilities million noncontrolling interest million excess consideration transferred fair value net assets acquired million recorded goodwill largely attributable anticipated synergies expected arise acquisition goodwill allocated healthcare services segment deductible tax purposes intangible assets recognized primarily relate customer relationships amortized year useful life medical information solutions content amortized fiveyear useful life june merck moderna therapeutics moderna entered strategic collaboration license agreement develop commercialize novel messenger rna mrnabased personalized cancer vaccines development program entail multiple studies several types cancer include evaluation mrnabased personalized cancer vaccines combination mercks keytruda pursuant terms agreement merck made upfront cash payment moderna million recorded research development expenses following human proof concept studies merck right elect make additional payment moderna merck exercises right two companies equally share costs profits worldwide collaboration development personalized cancer vaccines moderna right elect copromote personalized cancer vaccines united states agreement entails exclusivity around combinations keytruda moderna merck ability combine mrnabased personalized cancer vaccines nonpd agents january merck acquired iomet pharma ltd iomet privately held ukbased drug discovery company focused development innovative medicines treatment cancer particular emphasis fields cancer immunotherapy cancer metabolism acquisition provides merck iomets preclinical pipeline ido indoleaminedioxygenase tdo tryptophandioxygenase dualacting idotdo inhibitors transaction accounted acquisition business total purchase consideration transaction included cash payment million future additional milestone payments million contingent upon certain clinical regulatory milestones achieved company determined fair value table contents contingent consideration million acquisition date utilizing probabilityweighted estimated cash flow stream adjusted expected timing payment utilizing discount rate merck recognized intangible assets iprd million net deferred tax assets million excess consideration transferred fair value net assets acquired million recorded goodwill allocated pharmaceutical segment deductible tax purposes fair values identifiable intangible assets related iprd determined using income approach assets probabilityadjusted future net cash flows discounted present value also using discount rate actual cash flows likely different assumed july merck made million payment result achievement clinical development milestone accrued estimated fair value time acquisition noted transactions december company divested remaining ophthalmics portfolio international markets mundipharma ophthalmology products limited merck received consideration approximately million recognized gain million recorded income expense net july merck acquired ccam biotherapeutics ltd ccam privately held biopharmaceutical company focused discovery development novel cancer immunotherapies total purchase consideration transaction included upfront payment million cash potential future additional payments associated attainment certain clinical development regulatory commercial milestones transaction accounted acquisition business merck recognized intangible asset iprd million related cm monoclonal antibody well liability contingent consideration million goodwill million net assets million result unfavorable efficacy data company determined would discontinue development pipeline program accordingly company recorded iprd impairment charge million related cm reversed related liability contingent consideration fair value million time program discontinuation iprd impairment charge income related reduction liability contingent consideration recorded research development expenses also july merck allergan plc allergan entered agreement pursuant allergan acquired exclusive worldwide rights mk mk mercks investigational small molecule oral calcitonin generelated peptide cgrp receptor antagonists developed treatment prevention migraine terms agreement allergan acquired rights upfront payments million million paid august upon closing transaction remaining million paid april company recorded gain million within income expense net related transaction allergan fully responsible development cgrp programs well manufacturing commercialization upon approval launch products agreement merck entitled receive potential development commercial milestone payments royalties tiered doubledigit rates based commercialization programs merck recognized gains million within income expense net resulting payments allergan achievement research development milestones february merck ngm biopharmaceuticals inc ngm privately held biotechnology company entered multiyear collaboration research discover develop commercialize novel biologic therapies across wide range therapeutic areas terms agreement merck made upfront payment ngm million included research development expenses purchased equity stake ngm million merck committed million fund ngms efforts initial fiveyear term collaboration potential additional funding certain conditions met prior merck initiating phase study licensed program ngm may elect either receive milestone royalty payments certain cases cofund development participate global cost revenue share arrangement agreement also provides ngm option participate copromotion cofunded program united states merck option extend research agreement two additional twoyear terms january merck acquired cubist pharmaceuticals inc cubist leader development therapies treat serious infections caused broad range bacteria total consideration transferred billion included cash paid outstanding cubist shares billion well sharebased compensation payments settle equity awards attributable precombination service cash paid transaction costs behalf cubist sharebased compensation payments settle nonvested equity awards attributable postcombination service table contents recognized transaction expense addition company assumed outstanding convertible debt cubist fair value approximately billion acquisition date merck redeemed debt february transaction accounted acquisition business estimated fair value assets acquired liabilities assumed cubist follows estimated fair value january cash cash equivalents accounts receivable inventories current assets property plant equipment identifiable intangible assets products product rights year weightedaverage useful life iprd noncurrent assets current liabilities deferred income tax liabilities longterm debt noncurrent liabilities total identifiable net assets goodwill consideration transferred included current liabilities noncurrent liabilities contingent consideration million million respectively goodwill recognized largely attributable anticipated synergies expected arise acquisition allocated pharmaceutical segment goodwill deductible tax purposes estimated fair values identifiable intangible assets related currently marketed products determined using income approach companys estimates projected net cash flows considered historical projected pricing margins expense levels performance competing products applicable relevant industry therapeutic area growth drivers factors current expected trends technology product life cycles extent timing potential new product introductions companys competitors life assets underlying patent net cash flows probability adjusted appropriate consider uncertainties associated underlying assumptions well risk profile net cash flows utilized valuation probabilityadjusted future net cash flows product discounted present value utilizing discount rate actual cash flows likely different assumed company recorded fair value incomplete research project surotomycin mk time acquisition reached technological feasibility alternative future use second quarter company received unfavorable efficacy data clinical trial surotomycin evaluation data combined assessment commercial opportunity surotomycin resulted discontinuation program iprd impairment charge see note connection cubist acquisition liabilities recorded potential future consideration contingent upon achievement future salesbased milestones fair value contingent consideration liabilities determined acquisition date using unobservable inputs inputs include estimated amount timing projected cash flows probability success achievement contingent event riskadjusted discount rate used present value probabilityweighted cash flows changes inputs could result different fair value measurement transaction closed january accordingly results operations acquired business included companys results operations beginning date company incurred table contents million transaction costs directly related acquisition cubist including sharebased compensation costs severance costs legal advisory fees reflected marketing administrative expenses following unaudited supplemental pro forma data presents consolidated information acquisition cubist completed january years ended december sales net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders unaudited supplemental pro forma data reflects historical information merck cubist adjusted include additional amortization expense based fair value assets acquired additional interest expense would incurred borrowings used fund acquisition transaction costs associated acquisition related tax effects adjustments pro forma data considered indicative results would occurred acquisition consummated january indicative future results remicadesimponi subsidiary scheringplough entered licensing agreement centocor ortho biotech inc centocor johnson johnson jj company market remicade prescribed treatment inflammatory diseases scheringploughs subsidiary exercised option contract centocor license rights develop commercialize simponi fully human monoclonal antibody company marketing rights products throughout europe russia turkey remicade lost market exclusivity major european markets february company longer market exclusivity marketing territories company continues market exclusivity simponi marketing territories profits derived mercks distribution two products countries equally divided merck jj collaborative arrangements merck entered collaborative arrangements provide company varying rights develop produce market products together collaborative partners parties arrangements active participants exposed significant risks rewards dependent commercial success activities collaboration mercks significant collaborative arrangements discussed astrazeneca july merck astrazeneca entered global strategic oncology collaboration codevelop cocommercialize astrazenecas lynparza olaparib multiple cancer types lynparza oral poly adpribose polymerase parp inhibitor currently approved certain types ovarian breast cancer companies jointly developing commercializing lynparza monotherapy combination trials potential medicines independently merck astrazeneca develop commercialize lynparza combinations respective pd pdl medicines keytruda pembrolizumab imfinzi durvalumab companies also jointly develop commercialize astrazenecas selumetinib oral potent selective inhibitor mek part mitogenactivated protein kinase mapk pathway currently developed multiple indications including thyroid cancer terms agreement astrazeneca merck share development commercialization costs lynparza selumetinib monotherapy nonpdlpd combination therapy opportunities gross profits lynparza selumetinib product sales generated monotherapies combination therapies shared equally merck fund development commercialization costs keytruda combination lynparza selumetinib astrazeneca fund development commercialization costs imfinzi combination lynparza selumetinib astrazenca currently principal lynparza sales transactions merck recording share product sales lynparza net costs sales commercialization costs alliance revenue within pharmaceutical segment share development costs associated table contents collaboration part research development expenses reimbursements received astrazeneca research development expenses recognized reductions research development costs part agreement merck made upfront payment astrazeneca billion making payments million multiyear period certain license options million paid december million paid million paid company recorded aggregate charge billion research development expenses related upfront payment future license options payments addition merck pay astrazeneca additional billion contingent upon successful achievement future regulatory milestones billion salesbased milestones billion total aggregate consideration billion fourth quarter based performance lynparza since formation collaboration merck determined probable annual sales lynparza future would exceed million would trigger million salesbased milestone payment merck astrazeneca upon achievement sales milestone accordingly fourth quarter merck recorded million liability corresponding intangible asset also recognized million cumulative amortization expense within materials production costs remaining intangible asset amortized remaining estimated useful life years subject impairment testing remaining billion potential future salesbased milestone payments yet accrued deemed company probable time also january lynparza received approval united states treatment certain patients metastatic breast cancer triggering million milestone payment merck astrazeneca milestone payment capitalized amortized remaining useful life lynparza summarized information related collaboration follows year ended december alliance revenues net commercialization costs materials production costs marketing administrative expenses research development expenses receivables astrazeneca payables astrazeneca expenses include amounts attributed activities related collaboration rather amounts relating payments partners amounts materials production costs include amortization related intangible assets bayer ag company entered worldwide clinical development collaboration bayer ag bayer market develop soluble guanylate cyclase sgc modulators including bayers adempas riociguat approved treat pulmonary arterial hypertension chronic thromboembolic pulmonary hypertension two companies equally share costs profits collaboration implemented joint development commercialization strategy collaboration also includes clinical development bayers vericiguat phase trials worsening heart failure well optin rights early stage sgc compounds development bayer merck turn made available earlystage sgc compounds similar terms agreement bayer leads commercialization adempas americas merck leads commercialization rest world vericiguat potential optin products bayer lead commercialization rest world merck lead americas products candidates included agreement companies share development costs profits sales right copromote territories lead merck began promoting distributing adempas europe transition bayer merck territories including japan continued company determined probable annual sales adempas would exceed million triggering million payment merck bayer accordingly company recorded million liability corresponding intangible asset also recognized million cumulative amortization expense within materials production costs remaining intangible asset amortized table contents remaining estimated useful life subject impairment testing annual sales adempas exceeded million triggering million milestone payment merck bayer paid first quarter million additional potential future salesbased milestone payments yet accrued deemed company probable time summarized information related collaboration follows years ended december net product sales recorded merck mercks profit share sales bayer 's marketing territories total sales materials production costs marketing administrative expenses research development expenses receivables bayer payables bayer expenses include amounts attributed activities related collaboration rather amounts relating payments partners amounts materials production costs include amortization related intangible assets restructuring company incurs substantial costs restructuring program activities related mercks productivity cost reduction initiatives well connection integration certain acquired businesses company commenced actions global restructuring programs designed streamline cost structure actions programs include elimination positions sales administrative headquarters organizations well sale closure certain manufacturing research development sites consolidation office facilities company also continues reduce global real estate footprint improve efficiency manufacturing supply network company recorded total pretax costs million billion billion related restructuring program activities since inception programs december merck recorded total pretax accumulated costs approximately billion eliminated approximately positions comprised employee separations well elimination contractors vacant positions company estimates approximately twothirds cumulative pretax costs cash outlays primarily related employee separation expense approximately onethird cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested company substantially completed actions programs approximately million additional pretax costs expected incurred relating anticipated employee separations remaining assetrelated costs segment reporting restructuring charges unallocated expenses table contents following table summarizes charges related restructuring program activities type cost separation accelerated costs depreciation total year ended december materials production marketing administrative research development restructuring costs year ended december materials production marketing administrative research development restructuring costs year ended december materials production marketing administrative research development restructuring costs separation costs associated actual headcount reductions well headcount reductions probable could reasonably estimated positions eliminated restructuring program activities approximately accelerated depreciation costs primarily relate manufacturing research administrative facilities equipment sold closed part programs accelerated depreciation costs represent difference depreciation expense recognized revised useful life asset based upon anticipated date site closed divested equipment disposed depreciation expense determined utilizing useful life prior restructuring actions sites continue operate respective closure dates since future undiscounted cash flows sufficient recover respective book values merck recording accelerated depreciation revised useful life site assets anticipated site closure dates particularly related manufacturing locations may continue adjusted reflect changes resulting regulatory factors activity includes million million million respectively asset abandonment shutdown related costs additionally activity includes certain employeerelated costs associated pension postretirement benefit plans see note share based compensation activity also reflects net pretax losses resulting sales facilities related assets million million million table contents following table summarizes charges spending relating restructuring program activities separation accelerated costs depreciation total restructuring reserves january expenses payments receipts net noncash activity restructuring reserves december expenses payments receipts net noncash activity restructuring reserves december remaining cash outlays expected substantially completed end financial instruments derivative instruments hedging activities company manages impact foreign exchange rate movements interest rate movements earnings cash flows fair values assets liabilities operational means use various financial instruments including derivative instruments significant portion companys revenues earnings foreign affiliates exposed changes foreign exchange rates objectives accounting related companys foreign currency risk management program well interest rate risk management activities discussed foreign currency risk management company established revenue hedging balance sheet risk management net investment hedging programs protect volatility future foreign currency cash flows changes fair value caused volatility foreign exchange rates objective revenue hedging program reduce variability caused changes foreign exchange rates would affect us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen achieve objective company hedge portion forecasted foreign currency denominated thirdparty intercompany distributor entity sales forecasted sales expected occur planning cycle typically two years future company layer hedges time increasing portion forecasted sales hedged gets closer expected date forecasted sales portion forecasted sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments company manages anticipated transaction exposure principally purchased local currency put options forward contracts purchased collar options fair values derivative contracts recorded either assets gain positions liabilities loss positions consolidated balance sheet changes fair value derivative contracts recorded period either current earnings oci depending whether derivative designated part hedge transaction type hedge transaction derivatives designated cash flow hedges effective portion unrealized gains losses contracts recorded aoci reclassified sales hedged anticipated revenue recognized hedge relationship highly effective hedge ineffectiveness de minimis derivatives designated cash flow hedges serve economic hedges forecasted sales unrealized gains losses recorded sales period cash flows designated nondesignated contracts reported operating activities consolidated statement cash flows company enter derivatives trading speculative purposes company manages operating activities net asset positions local subsidiary order mitigate effects exchange monetary assets liabilities company also uses balance sheet risk management program mitigate exposure net monetary assets denominated currency subsidiarys table contents functional currency effects volatility foreign exchange instances merck principally utilizes forward exchange contracts offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts partially offset effects exchange exposures deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument cash flows contracts reported operating activities consolidated statement cash flows monetary assets liabilities denominated currency functional currency given subsidiary remeasured spot rates effect balance sheet date effects changes spot rates reported income expense net forward contracts designated hedges marked market income expense net accordingly fair value changes forward contracts help mitigate changes value remeasured assets liabilities attributable changes foreign currency exchange rates except extent spotforward differences differences significant due shortterm nature contracts typically average maturities inception less one year company may also use forward exchange contracts hedge net investment foreign operations movements exchange rates forward contracts designated hedges net investment foreign operation company hedges portion net investment certain foreign operations measures ineffectiveness based upon changes spot foreign exchange rates recorded income expense net effective portion unrealized gains losses contracts recorded foreign currency translation adjustment within oci remains aoci either sale complete substantially complete liquidation subsidiary cash flows contracts reported investing activities consolidated statement cash flows foreign exchange risk also managed use foreign currency debt companys senior unsecured eurodenominated notes designated effective economic hedges net investment foreign operation accordingly foreign currency transaction gains losses due spot rate fluctuations eurodenominated debt instruments included foreign currency translation adjustment within oci included cumulative translation adjustment pretax losses million pretax gains million million eurodenominated notes interest rate risk management company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk december company party payfloating receivefixed interest rate swap contracts designated fair value hedges fixedrate notes notional amounts match amount hedged fixedrate notes detailed table number interest rate total swap notional debt instrument par value debt swaps held amount notes due notes due notes due notes due notes due notes due interest rate swap contracts designated hedges fair value changes notes attributable changes benchmark london interbank offered rate libor swap rate fair value changes notes attributable changes libor swap rate recorded interest expense offset fair value changes swap contracts cash flows contracts reported operating activities consolidated statement cash flows table contents presented table fair value derivatives gross basis segregated derivatives designated hedging instruments designated hedging instruments december fair value fair value derivative derivative us dollar us dollar balance sheet caption asset liability notional asset liability notional derivatives designated hedging instruments interest rate swap contracts assets interest rate swap contracts accrued current liabilities interest rate swap contracts noncurrent liabilities foreign exchange contracts current assets foreign exchange contracts assets foreign exchange contracts accrued current liabilities foreign exchange contracts noncurrent liabilities derivatives designated hedging instruments foreign exchange contracts current assets foreign exchange contracts accrued current liabilities noted company records derivatives gross basis consolidated balance sheet company master netting agreements several financial institution counterparties see concentrations credit risk following table provides information companys derivative positions subject master netting arrangements presented net basis allowing right offset counterparty cash collateral exchanged per master agreements related credit support annexes december asset liability asset liability gross amounts recognized consolidated balance sheet gross amount subject offset master netting arrangements offset consolidated balance sheet cash collateral received posted net amounts table contents table provides information location pretax gain loss amounts derivatives designated fair value hedging relationship ii designated foreign currency cash flow hedging relationship iii designated foreign currency net investment hedging relationship iv designated hedging relationship years ended december derivatives designated fair value hedging relationship interest rate swap contracts amount loss gain recognized income expense net derivatives amount gain loss recognized income expense net hedged item derivatives designated foreign currency cash flow hedging relationships foreign exchange contracts amount gain reclassified aoci sales amount loss gain recognized oci derivatives derivatives designated foreign currency net investment hedging relationships foreign exchange contracts amount gain recognized income expense net derivatives amount loss gain recognized oci derivatives derivatives designated hedging relationship foreign exchange contracts amount loss gain recognized income expense net derivatives amount gain recognized sales million million million ineffectiveness hedge respectively ineffectiveness hedge represents amount excluded hedge effectiveness testing derivative contracts mitigate changes value remeasured foreign currency denominated monetary assets liabilities attributable changes foreign currency exchange rates december company estimates million pretax net unrealized losses derivatives maturing within next months hedge foreign currency denominated sales period reclassified aoci sales amount ultimately reclassified sales may differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity table contents investments debt equity securities information investments debt equity securities december follows gross unrealized gross unrealized fair amortized fair amortized value cost gains losses value cost gains losses corporate notes bonds us government agency securities assetbacked securities foreign government bonds mortgagebacked securities commercial paper equity securities availableforsale debt securities included shortterm investments totaled billion december remaining debt securities billion mature within five years december debt securities pledged collateral fair value measurements fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date company uses fair value hierarchy maximizes use observable inputs minimizes use unobservable inputs measuring fair value three levels inputs used measure fair value level highest priority level lowest level quoted prices unadjusted active markets identical assets liabilities level observable inputs level prices quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities level unobservable inputs supported little market activity level assets liabilities whose values determined using pricing models discounted cash flow methodologies similar techniques significant unobservable inputs well assets liabilities determination fair value requires significant judgment estimation inputs used measure financial assets liabilities fall within one level described categorization based lowest level input significant fair value measurement instrument table contents financial assets liabilities measured fair value recurring basis financial assets liabilities measured fair value recurring basis december summarized fair value measurements using fair value measurements using quoted prices significant quoted prices significant active significant active significant markets observable unobservable markets observable unobservable identical assets inputs inputs identical assets inputs inputs level level level total level level level total assets investments corporate notes bonds us government agency securities assetbacked securities foreign government bonds mortgagebacked securities commercial paper equity securities assets us government agency securities corporate notes bonds mortgagebacked securities assetbacked securities foreign government bonds equity securities derivative assets purchased currency options forward exchange contracts interest rate swaps total assets liabilities liabilities contingent consideration derivative liabilities forward exchange contracts interest rate swaps written currency options total liabilities primarily assetbacked securities highlyrated standard poors rating aaa moodys investors service rating aaa secured primarily auto loan credit card student loan receivables weightedaverage lives primarily years less mortgagebacked securities represent aaarated securities issued unconditionally guaranteed payment principal interest us government agencies investments included assets restricted use primarily payment benefits employee benefit plans fair value determination derivatives includes impact credit risk counterparties derivatives companys credit risk effects significant transfers level level december cash cash equivalents billion include billion cash equivalents would considered level fair value hierarchy table contents contingent consideration summarized information changes liabilities contingent consideration follows fair value january changes estimated fair value additions payments fair value december recorded research development expenses materials production costs income expense net includes cumulative translation adjustments includes million recorded current liability amounts expected paid within next months changes estimated fair value contingent consideration primarily relate changes liabilities recorded connection termination spmsd joint venture clinical progression program related afferent acquisition changes estimated fair value contingent consideration largely attributable reversal liabilities related programs obtained connection acquisitions ccam oncoethix smartcells see note additions contingent consideration reflected table relate termination spmsd joint venture see note acquisitions iomet afferent see note payments contingent consideration relate achievement clinical milestone connection acquisition iomet see note relate first commercial sale zerbaxa european union fair value measurements companys financial instruments cash cash equivalents receivables payables reflected balance sheet carrying value approximates fair value due shortterm nature estimated fair value loans payable longterm debt including current portion december billion compared carrying value billion december billion compared carrying value billion fair value estimated using recent observable market prices would considered level fair value hierarchy concentrations credit risk ongoing basis company monitors concentrations credit risk associated corporate government issuers securities financial institutions conducts business credit exposure limits established limit concentration single issuer institution cash investments placed instruments meet high credit quality standards specified companys investment policy guidelines majority companys accounts receivable arise product sales united states europe primarily due drug wholesalers retailers hospitals government agencies managed health care providers pharmacy benefit managers company monitors financial performance creditworthiness customers properly assess respond changes credit profile company also continues monitor global economic conditions including volatility associated international sovereign economies associated impacts financial markets business december companys total net accounts receivable outstanding one year approximately million company expect writeoffs adjustments accounts receivable would material adverse effect financial position liquidity results operations companys customers largest accounts receivable balances mckesson corporation amerisourcebergen corporation cardinal health inc zuellig pharma ltd asia pacific represented aggregate approximately total accounts receivable december company monitors creditworthiness customers grants credit terms normal course business bad debts minimal company normally require collateral security support credit sales derivative financial instruments executed international swaps derivatives association master agreements master agreements several companys financial institution counterparties also include table contents credit support annexes annexes contain provisions require collateral exchanged depending value derivative assets liabilities companys credit rating credit rating counterparty december company received cash collateral million million respectively various counterparties obligation return collateral recorded accrued current liabilities company advanced cash collateral counterparties december inventories inventories december consisted finished goods raw materials work process supplies total approximates current cost increase lifo costs recognized inventories assets inventories valued lifo method comprised approximately billion billion inventories december respectively amounts recognized assets comprised almost entirely raw materials work process inventories december amounts included billion billion respectively inventories expected sold within one year addition amounts included million december inventories produced preparation product launches goodwill intangibles following table summarizes goodwill activity segment pharmaceutical total balance january acquisitions impairments balance december acquisitions impairments balance december includes cumulative translation adjustments goodwill balances certain adjustments accumulated goodwill impairment losses december million million respectively additions goodwill pharmaceutical segment resulted primarily acquisitions afferent iomet see note additions goodwill within nonreportable segments primarily relate acquisition valle part animal health segment see note relate acquisition staywell part healthcare services segment see note impairments goodwill within nonreportable segments relate certain businesses within healthcare services segment table contents intangibles december consisted gross gross carrying accumulated carrying accumulated amount amortization net amount amortization net products product rights iprd tradenames acquired intangibles include products product rights tradenames patents initially recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives companys significant acquired intangibles related marketed products included product product rights december include zerbaxa billion sivextro million zetia million implanonnexplanon million dificid million gardasilgardasil million vytorin million bridion million simponi million company recognized intangible asset related adempas result collaboration bayer see note carrying value million december reflected table company recorded impairment charges related marketed products intangibles million million million respectively within material production costs company recorded intangible asset impairment charge million related intron treatment certain types cancers sales intron adversely affected availability new therapeutic options sales intron united states eroded rapidly previously anticipated company led changes cash flow assumptions intron revisions cash flows indicated intron intangible asset value fully recoverable undiscounted cash flows basis company utilized market participant assumptions determine best estimate fair value intangible asset related intron compared related carrying value resulted impairment charge noted intangible asset value intron december million remaining charges relate impairment customer relationship tradename developed technology intangibles certain businesses healthcare services segment company lowered cash flow projections zontivity product reduction thrombotic cardiovascular events patients history myocardial infarction peripheral arterial disease following several business decisions reduced sales expectations zontivity united states europe company utilized market participant assumptions considered several different scenarios determine fair value intangible asset related zontivity compared related carrying value resulted impairment charge million also company wroteoff million capitalized connection inlicensed products grastek ragwitek allergy immunotherapy tablets business reasons company returned licensor charges primarily relate impairment customer relationship tradename intangibles certain businesses within healthcare services segment iprd company acquires business combinations represents fair value assigned incomplete research projects time acquisition reached technological feasibility amounts capitalized iprd accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project company make separate determination useful life asset begin amortization million million million respectively iprd reclassified products product rights upon receipt marketing approval major market company recorded million iprd impairment charges within research development expenses amount million resulted strategic decision discontinue development investigational combination regimens mkb grazoprevirruzasviruprifosbuvir mkc ruzasviruprifosbuvir treatment chronic hepatitis c virus hcv infection decision made based review available phase efficacy data consideration evolving marketplace growing number treatment options available patients chronic hcv infection including zepatier currently marketed table contents company treatment adult patients chronic hcv infection result decision company recorded iprd impairment charge writeoff remaining intangible asset related uprifosbuvir company previously recorded impairment charge uprifosbuvir described iprd impairment charges also include charge million writeoff intangible asset related verubecestat investigational small molecule inhibitor betasite amyloid precursor protein cleaving enzyme bace resulting decision february stop phase study evaluating verubecestat people prodromal alzheimers disease decision stop study followed recommendation external data monitoring committee edmc assessed overall benefitrisk interim safety analysis edmc concluded unlikely positive benefitrisk could established trial continued company recorded billion iprd impairment charges amount billion relates clinical development program uprifosbuvir nucleotide prodrug evaluated treatment hcv company determined changes product profile well changes mercks expectations pricing market opportunity taken together constituted triggering event required company evaluate uprifosbuvir intangible asset impairment utilizing market participant assumptions considering different scenarios company concluded best estimate fair value intangible asset related uprifosbuvir million resulting recognition pretax impairment charge noted iprd impairment charges also include charges million million related discontinuation programs obtained connection acquisitions ccam oncoethix respectively resulting unfavorable efficacy data additional million relates programs obtained connection smartcells acquisition following decision terminate lead compound due lack efficacy pursue backup compound reduced projected future cash flows iprd impairment charges also include million related inlicensed program house dust mite allergies business reasons returned licensor remaining iprd impairment charges primarily relate deprioritized pipeline programs deemed alternative use period including million impairment charge investigational candidate contraception discontinuation delay certain clinical development programs resulted reduction related liabilities contingent consideration see note company recorded million iprd impairment charges million related surotomycin clinical development program company received unfavorable efficacy data clinical trial surotomycin evaluation data combined assessment commercial opportunity surotomycin resulted discontinuation program iprd impairment charge noted iprd projects remain development subject inherent risks uncertainties drug development possible company able successfully develop complete iprd programs profitably commercialize underlying product candidates company may recognize additional noncash impairment charges future related marketed products pipeline programs charges could material aggregate amortization expense primarily recorded within materials production costs billion billion billion estimated aggregate amortization expense next five years follows billion billion billion billion billion joint ventures equity method affiliates equity income affiliates reflects performance companys joint ventures equity method affiliates including spmsd termination december certain investment funds equity income affiliates million million million included income expense net see note investments affiliates accounted using equity method totaled million december million december table contents sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur sa established equallyowned joint venture spmsd market vaccines europe collaborate development combination vaccines distribution europe joint venture vaccine sales billion million december merck sanofi pasteur sanofi terminated spmsd ended joint vaccines operations europe terms termination merck acquired sanofis interest spmsd exchange consideration million comprised cash well future royalties net sales merck products previously sold joint venture december company determined fair value million date termination company accounted transaction step acquisition required merck remeasure ownership interest previously accounted equity method investment fair value acquisition date merck turn sold sanofi intellectual property rights held spmsd exchange consideration million comprised cash future royalties net sales sanofi products previously sold joint venture december company determined fair value million date termination excluded arrangement potential future sales vaxelis jointly developed investigational pediatric hexavalent combination vaccine approved european commission february european marketing rights vaxelis transferred separate equallyowned joint venture sanofi merck net impact termination spmsd joint venture follows products product rights year useful life accounts receivable income taxes payable deferred income tax liabilities net net assets acquired consideration payable sanofi net derecognition mercks previously held equity investment spmsd increase net assets mercks share restructuring costs related termination net gain termination spmsd joint venture recorded income expense net estimated fair values identifiable intangible assets related products product rights determined using income approach fair value estimated based market participant expectations assets projected net cash flows projected net cash flows discounted present value utilizing discount rate actual cash flows likely different assumed amount recorded products product rights million related gardasilgardasil fair value liabilities contingent consideration related mercks future royalty payments sanofi million reflected consideration payable sanofi net table determined acquisition date using unobservable inputs inputs include estimated amount timing projected cash flows riskadjusted discount rate used present value cash flows changes inputs could result different fair value measurement based existing accounting policy election merck record million estimated fair value contingent future royalties received sanofi sale sanofi products rather recognizing amounts sales occur royalties earned company incurred million transaction costs related termination spmsd included marketing administrative expenses pro forma financial information transaction presented results significant compared companys financial results table contents astrazeneca lp merck entered agreement astra ab astra develop market astra products royaltybearing license mercks total sales astra products reached level triggered first step establishment joint venture business carried astra merck inc ami merck astra owned share joint venture formed developed marketed astras new prescription medicines united states merck astra completed restructuring ownership operations joint venture whereby merck acquired astras interest ami renamed kbi inc kbi contributed kbis operating assets new us limited partnership astra pharmaceuticals lp partnership exchange limited partner interest astra contributed net assets wholly owned subsidiary astra usa inc partnership exchange general partner interest partnership renamed astrazeneca lp azlp upon astras merger zeneca group plc became exclusive distributor products kbi retained rights merck earned revenue based sales kbi products earned certain partnership returns azlp june astrazeneca exercised option purchase mercks interest kbi redeem mercks remaining interest azlp portion exercise price subject trueup based actual sales nexium prilosec closing june deferred recognized income contingency eliminated sales occurred deferred income amount fully recognized company began recognizing income corresponding receivable amounts due merck astrazeneca based sales performance nexium prilosec subject true june company recognized income million million million respectively income expense net related amounts receivable astrazeneca million december loans payable longterm debt commitments loans payable december included billion notes due million longdated notes subject repayment option holder loans payable december included million notes due million longdated notes subject repayment option holders weightedaverage interest rate commercial paper borrowings years ended december respectively table contents longterm debt december consisted notes due notes due notes due notes due notes due notes due notes due eurodenominated notes due eurodenominated notes due notes due notes due notes due floatingrate notes due eurodenominated notes due eurodenominated notes due eurodenominated notes due notes due notes due notes due debentures due notes due debentures due debentures due floatingrate borrowing due notes due notes due presented table includes million million december respectively borrowings variable rates resulted effective interest rates respectively exception debentures due notes listed table redeemable whole part mercks option time varying redemption prices november company launched tender offers certain outstanding notes debentures company paid million aggregate consideration applicable purchase price together accrued interest redeem million principal amount debt validly tendered connection tender offers recognized loss extinguishment debt million effective november company executed full unconditional guarantee existing debt subsidiary merck sharp dohme corp msd msd executed full unconditional guarantee existing debt company excluding commercial paper including payments principal interest guarantees extend debt issued subsequent date certain companys borrowings require merck comply financial covenants including requirement total debt capitalization ratio defined applicable agreements exceed december company compliance covenants table contents aggregate maturities longterm debt next five years follows billion billion billion billion billion company billion fiveyear credit facility matures june facility provides backup liquidity companys commercial paper borrowing facility used general corporate purposes company drawn funding facility rental expense operating leases net sublease income million million million minimum aggregate rental commitments noncancellable leases follows million million million million million thereafter million company significant capital leases contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well certain additional matters including governmental environmental matters opinion company unlikely resolution matters material companys financial position results operations cash flows given nature litigation discussed complexities involved matters company unable reasonably estimate possible loss range possible loss matters company knows among factors claims survive dispositive motion practice ii extent claims including size potential class particularly damages specified indeterminate iii discovery process affect litigation iv settlement posture parties litigation v factors may material effect litigation company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable companys decision obtain insurance coverage dependent market conditions including cost availability existing time decisions made company evaluated risks determined cost obtaining product liability insurance outweighs likely benefits coverage available insurance product liabilities effective august product liability litigation fosamax previously disclosed merck defendant product liability lawsuits united states involving fosamax fosamax litigation december approximately cases filed pending merck either federal state court approximately actions plaintiffs allege among things suffered osteonecrosis jaw onj generally subsequent invasive dental procedures tooth extraction dental implants andor delayed healing association use fosamax addition plaintiffs approximately actions generally allege sustained femur fractures andor bone injuries femur fractures association use fosamax cases alleging onj andor jaw related injuries august judicial panel multidistrict litigation jpml ordered certain fosamax product liability cases pending federal courts nationwide transferred consolidated one multidistrict litigation fosamax onj mdl coordinated pretrial proceedings december merck reached agreement principle plaintiffs steering committee psc fosamax onj mdl resolve pending onj cases appeal fosamax onj mdl state courts aggregate amount million merck psc subsequently formalized terms agreement table contents master settlement agreement onj master settlement agreement executed april included plaintiffs july merck elected proceed onj master settlement agreement reduced funding level million since participation level approximately merck fully funded onj master settlement agreement escrow agent agreement making settlement payments qualifying plaintiffs onj master settlement agreement effect cases alleging femur fractures discussed discovery currently ongoing approximately remaining onj cases pending various federal state courts company intends defend lawsuits cases alleging femur fractures march merck submitted motion transfer jpml seeking federal cases alleging femur fractures consolidated one multidistrict litigation coordinated pretrial proceedings motion transfer granted may federal cases involving allegations femur fracture transferred multidistrict litigation district new jersey femur fracture mdl bellwether case tried date femur fracture mdl glynn v merck jury returned verdict mercks favor addition june femur fracture mdl court granted mercks motion judgment matter law glynn case held plaintiffs failure warn claim preempted federal law glynn decision appealed plaintiff august femur fracture mdl court entered order requiring plaintiffs femur fracture mdl show cause cases asserting claims femur fracture injury took place prior september dismissed based courts preemption decision glynn case pursuant show cause order march femur fracture mdl court dismissed prejudice approximately cases preemption grounds plaintiffs approximately cases appealed decision us court appeals third circuit third circuit femur fracture mdl court also dismissed without prejudice another approximately cases pending plaintiffs appeal preemption ruling third circuit march third circuit issued decision reversing femur fracture mdl courts preemption ruling remanding appealed cases back femur fracture mdl court april merck filed petition seeking rehearing third circuits march decision denied april merck filed petition writ certiorari us supreme court august seeking review third circuits decision december supreme court invited solicitor general file brief case expressing views united states addition june femur fracture mdl court granted merck summary judgment gaynor v merck case found mercks updates january fosamax label regarding atypical femur fractures adequate matter law merck adequately communicated changes plaintiffs gaynor appeal femur fracture mdl courts findings respect adequacy label change appeal dismissal case based preemption grounds third circuit subsequently reversed dismissal march decision august merck filed motion requesting femur fracture mdl court enter order requiring plaintiffs femur fracture mdl claim fosamax label inadequate proximate cause alleged injuries show cause cases dismissed based courts preemption decision ruling gaynor case november court granted mercks motion entered requested show cause order plaintiffs responded appealed november show cause order december approximately cases pending femur fracture mdl following reinstatement cases appeal third circuit cases dismissed without prejudice also pending final resolution aforementioned appeal yet reinstated december approximately cases alleging femur fractures filed new jersey state court pending judge james hyland middlesex county parties selected initial group cases reviewed fact discovery two additional groups cases reviewed fact discovery selected november march respectively group cases reviewed fact discovery selected merck july merck continued select additional cases reviewed fact discovery table contents december approximately cases alleging femur fractures filed pending california state court femur fracture cases filed california state court coordinated single judge orange county california march court directed group discovery pool cases reviewed fact discovery subsequently scheduled galper v merck case plaintiffs selected first trial galper trial began february jury returned verdict mercks favor april plaintiff appealed verdict california appellate court oral argument plaintiffs appeal galper held november april california appellate court issued decision affirming lower courts judgment favor merck next femur fracture trial california scheduled begin april stayed plaintiffs request new trial date set additionally five femur fracture cases pending state courts discovery ongoing femur fracture mdl state courts femur fracture cases pending company intends defend lawsuits januviajanumet previously disclosed merck defendant product liability lawsuits united states involving januvia andor janumet december merck aware approximately product user claims alleging generally use januvia andor janumet caused development pancreatic cancer injuries complaints filed several different state federal courts claims filed consolidated multidistrict litigation proceeding us district court southern district california called incretinbased therapies products liability litigation mdl mdl includes federal lawsuits alleging pancreatic cancer due use following medicines januvia janumet byetta victoza latter two products manufactured pharmaceutical companies majority claims filed mdl filed superior court california county los angeles california state court november mdl california state court separate opinions granted summary judgment defendants grounds preemption approximately product user claims rulings resulted dismissal approximately product user claims plaintiffs appealed mdl california state court preemption rulings november us court appeals ninth circuit ninth circuit reversed trial courts ruling mdl remanded proceedings ninth circuit address substance defendants preemption argument instead ruled district court made various errors discovery jurisdiction returned us district court southern district california january preemption appeal california state court litigation fully briefed court yet scheduled oral argument december seven product users claims pending merck state courts california state court including four active product user claims pending illinois state court june illinois trial court denied mercks motion summary judgment grounds preemption merck sought permission appeal order interlocutory basis granted stay proceedings trial court september intermediate appellate court illinois denied mercks petition interlocutory review october merck filed petition illinois supreme court seeking leave appeal appellate courts denial illinois supreme court denied mercks petition certiorari review instead directed appellate court answer certified question result proceedings trial court remain stayed trials certain product users illinois delayed addition claims noted company agreed toll statute limitations approximately additional claims company intends continue defending lawsuits propeciaproscar previously disclosed merck defendant product liability lawsuits united states involving propecia andor proscar december approximately lawsuits filed plaintiffs allege experienced persistent sexual side effects following cessation treatment propecia andor proscar approximately plaintiffs also allege propecia proscar caused cause prostate cancer table contents testicular cancer male breast cancer lawsuits filed various federal courts state court new jersey federal lawsuits consolidated pretrial purposes federal multidistrict litigation judge brian cogan eastern district new york matters pending state court new jersey consolidated judge hyland middlesex county addition one matter pending state court california one matter pending state court ohio one matter appeal massachusetts supreme judicial court company intends defend lawsuits governmental proceedings previously disclosed company learned prosecution office milan italy investigating interactions companys italian subsidiary certain employees subsidiary certain italian health care providers company understands part larger investigation involving engagements various health care companies health care providers company cooperating investigation previously disclosed united kingdom uk competition markets authority cma issued statement objections company msd sharp dohme limited msd uk may statement objections cma alleges msd uk abused dominant position discount program remicade period march february company msd uk contesting cmas allegations previously disclosed company received investigative subpoena california insurance commissioners fraud bureau bureau seeking information january present related pricing promotion cubicin bureau investigating whether cubist pharmaceuticals inc company acquired unlawfully induced presentation false claims cubicin private insurers california insurance code false claims act company cooperating investigation previously disclosed company received civil investigative demand us attorneys office southern district new york requests information relating companys contracts services payments pharmacy benefit managers respect maxalt levitra january present company cooperating investigation previously disclosed company received subpoena office inspector general us department health human services behalf us attorneys office district maryland civil division us department justice requests information relating companys marketing singulair dulera inhalation aerosol certain marketing activities january present company cooperating investigation previously disclosed companys subsidiaries china received may continue receive inquiries regarding operations various chinese governmental agencies inquiries may related matters involving multinational pharmaceutical companies well chinese entities business companies companys policy cooperate authorities provide responses appropriate previously disclosed time time company receives inquiries subject preliminary investigation activities competition governmental authorities markets outside united states authorities may include regulators administrative authorities law enforcement similar officials preliminary investigation activities may include site visits formal informal requests demands documents materials inquiries interviews similar matters certain preliminary inquiries activities may lead commencement formal proceedings proceedings determined adversely company monetary fines andor remedial undertakings may required commercial litigation kdur antitrust litigation june january scheringplough corporation scheringplough settled patent litigation upshersmith inc upshersmith esi lederle inc lederle respectively relating generic versions scheringploughs longacting potassium chloride product supplement used cardiac patients lederle upshersmith filed abbreviated new drugapplications nda putative class nonclass action suits table contents filed behalf direct indirect purchasers kdur scheringplough upshersmith lederle consolidated multidistrict litigation us district court district new jersey february court denied companys motion summary judgment relating direct purchasers claims concerning settlement upshersmith granted companys motion summary judgment relating direct purchasers claims concerning settlement lederle previously disclosed february merck upshersmith reached settlement principle class direct purchasers optouts class merck contribute approximately million aggregate towards overall settlement april claims optouts dismissed prejudice pursuant written settlement agreement parties may merck class executed settlement agreement received preliminary approval court may october court entered final judgment order dismissal approving settlement agreement direct purchaser class dismissing claims class prejudice zetia antitrust litigation may schering corporation schering msp singapore company llc msp settled patent litigation glenmark pharmaceuticals inc usa glenmark pharmaceuticals ltd together glenmark relating generic version zetia pharmaceutical product containing ezetimibe used patients high cholesterol glenmark filed abbreviated nda january february putative class action suits filed behalf direct indirect purchasers zetia merck msd scheringplough schering msp glenmark us district courts eastern district virginia eastern district new york suits claim violations federal state antitrust laws well state statutory common law causes action suits seek unspecified damages sales force litigation previously disclosed may ms kelli smith filed complaint company us district court district new jersey behalf putative class female sales representatives putative subclass female sales representatives children claiming discriminatory policies practices selection promotion advancement b disparate pay c differential treatment hostile work environment e retaliation federal state discrimination laws plaintiffs sought granted leave file amended complaint january plaintiffs filed amended complaint adding four additional named plaintiffs october court denied companys motion dismiss strike class claims premature september plaintiffs filed additional motions including motion conditional certification equal pay act motion amend pleadings seeking add erisa constructive discharge claims company subsidiary named defendant motion equitable relief merck filed papers opposition motions april court granted plaintiffs motion conditional certification denied plaintiffs motions extend liability period equal pay act claims back june result liability period date back april earliest april magistrate judge granted plaintiffs request amend complaint add following company subsidiary corporate defendant ii erisa claim iii individual constructive discharge claim one named plaintiffs approximately individuals optedin action optin period closed august plaintiffs filed motion class certification motion seeks certify title vii pay discrimination class also seeks final collective action certification plaintiffs equal pay act claim parties currently engaged motion practice court qui tam litigation previously disclosed june us district court eastern district pennsylvania unsealed complaint filed company federal false claims act two former employees alleging among things company defrauded us government falsifying data connection clinical study conducted mumps component companys mmr ii vaccine complaint alleges fraud took place us government right participate take prosecution lawsuit notified court declined exercise right two former employees pursuing lawsuit without involvement us government addition previously disclosed two putative class action lawsuits behalf direct purchasers mmr ii vaccine charge company misrepresented efficacy mmr ii vaccine violation federal antitrust laws various state consumer protection laws pending eastern district pennsylvania september court denied mercks motion dismiss false claims act suit granted part denied part motion dismiss thenpending table contents antitrust suit result false claims act suit antitrust suits proceeded discovery company intends defend lawsuits merck kgaa litigation january protect longestablished brand rights united states company filed lawsuit merck kgaa darmstadt germany kgaa operating emd group united states alleging improperly uses name merck united states kgaa filed suit company france uk germany switzerland mexico india alleging breach parties coexistence agreement unfair competition andor trademark infringement december paris court first instance issued judgment finding certain activities company directed towards france constitute trademark infringement unfair competition activities found infringe company kgaa appealed decision appeal heard may june french appeals court held certain activities company directed france constituted unfair competition trademark infringement appeal pursued january uk high court issued judgment finding company breached co existence agreement infringed kgaas trademark rights result certain activities directed towards uk based use word merck promotional information activity noted uk decision finding based companys use sign merck connection sale products material pharmaceutical business transacted uk company kgaa appealed decision appeal heard june november uk court appeals affirmed decision coexistence agreement remitted rehearing issues trade mark infringement validity relief kgaa would entitled patent litigation time time generic manufacturers pharmaceutical products file abbreviated ndas fda seeking market generic forms companys products prior expiration relevant patents owned company protect patent rights company may file patent infringement lawsuits generic companies certain products company currently involved patent infringement litigation united states include noxafil nuvaring similar lawsuits defending companys patent rights may exist countries company intends vigorously defend patents believes valid infringement companies attempting market products prior expiration patents litigation assurance outcomes adverse could result significantly shortened periods exclusivity products respect products acquired acquisitions potentially significant intangible asset impairment charges noxafil august company filed lawsuit actavis laboratories fl inc actavis united states respect companys application fda seeking prepatent expiry approval sell generic version noxafil october district court held patent valid infringed actavis appealed decision march company filed lawsuit roxane laboratories inc roxane united states respect companys application fda seeking prepatent expiry approval sell generic version noxafil october parties reached settlement whereby roxane launch generic version upon expiry patent earlier certain conditions february company filed lawsuit par sterile products llc par pharmaceutical inc par pharmaceutical companies inc par pharmaceutical holdings inc collectively par united states respect companys application fda seeking prepatent expiry approval sell generic version noxafil injection october parties reached settlement whereby par launch generic version january earlier certain conditions nasonex nasonex lost market exclusivity united states prior april company filed patent infringement lawsuit apotex inc apotex corp apotex respect apotexs marketed product company believed infringing january company apotex settled matter apotex agreeing pay company million plus certain consideration nuvaring december company filed lawsuit subsidiary allergan plc united states respect companys application fda seeking prepatent expiry approval sell generic version nuvaring trial matter held january august district court ruled patent invalid company appealed decision october appellate court reversed district court decision found patent valid case remanded district court enjoined defendant table contents marketing generic version nuvaring patent expires september company filed lawsuit teva pharma united states respect companys application fda seeking prepatent expiry approval sell generic version nuvaring based ruling allergan plc matter district court dismissed companys lawsuit december following appellate reversal allergan plc matter defendant agreed enjoined marketing generic version nuvaring patent expires antipd antibody patent oppositions litigation previously disclosed ono pharmaceutical co ono european patent ep broadly claims use antipd antibody companys immunotherapy keytruda treatment cancer ono previously licensed commercial rights antipd antibody bristol myers squibb bms certain markets bms ono also european patent ep granted broadly claimed antipd antibodies could include keytruda previously disclosed company bms ono engaged worldwide litigation including united states validity infringement patent patent equivalents january company announced entered settlement license agreement bms ono resolving worldwide patent infringement litigation related use antipd antibody treatment cancer keytruda settlement license agreement company made onetime payment million recorded expense companys financial results bms pay royalties worldwide sales keytruda nonexclusive license market keytruda market approved global net sales keytruda company pay royalties net sales occurring january including december net sales occurring january including december parties also agreed dismiss claims worldwide relevant legal proceedings october pdl biopharma pdl filed lawsuit united states company alleging manufacture keytruda infringed us patent patent expired december patent claims platform technology used creation manufacture recombinant antibodies pdl seeking damages preexpiry infringement patent april parties reached settlement pursuant exchange lump sum pdl dismissed lawsuit prejudice granted company fully paidup nonexclusive license patent july company filed declaratory judgment action united states genentech city hope seeking ruling us patent cabilly iii patent claims platform technology used creation manufacture recombinant antibodies invalid keytruda bezlotoxumab infringe cabilly iii patent july company also filed petition uspto inter partes review ipr certain claims us patent cabilly ii patent claims platform technology used creation manufacture recombinant antibodies also owned genentech city hope invalid december uspto denied petition allowed company join ipr filed previously another party may parties reached settlement pursuant company dismissed lawsuit prejudice moved terminate ipr genentech city hope granted company fully paidup nonexclusive license cabilly ii cabilly iii patent gilead patent litigation opposition august gilead sciences inc gilead filed lawsuit us district court northern district california seeking declaration two company patents invalid infringed sale two sofosbuvir containing products solvadi harvoni company filed counterclaim sale products infringe two patents sought reasonable royalty past present future sales products march conclusion jury trial patents found invalid infringed jury awarded company million royalty sales products december conclusion jury trial court held bench trial equitable defenses raised gilead june court found gilead determined merck could collect jury award patents unenforceable respect gilead company appealed courts decision gilead also asked court overturn jurys decision validity court held hearing gileads motion august court subsequently rejected table contents gileads request gilead appealed hearing combined appeals case held february company pay net legal fees damages royalties receives ionis pharmaceuticals inc company idenix pharmaceuticals inc subsidiary pending litigation gilead united states uk norway canada germany france australia based different patent estates would also infringed gileads sales two products gilead opposed european patent european patent office epo trial united states held december jury returned verdict company awarding damages billion company submitted posttrial motions including issues enhanced damages future royalties gilead submitted posttrial motions judgment matter law hearing motions held september also september court denied companys motion enhanced damages granted motion prejudgment interest deferred motion future royalties february court granted gileads motion judgment matter law found patent invalid lack enablement company appeal decision australia company initially unsuccessful full federal court affirmed lower court decision company sought leave appeal high court australia review canada company initially unsuccessful federal court appeals affirmed lower court decision company sought leave supreme court canada review uk norway patent held invalid appeal filed epo opposition division revoked european patent company appealed decision cases france germany stayed pending final decision epo litigation various pending legal proceedings involving company principally product liability intellectual property lawsuits feasible predict outcome proceedings opinion company either likelihood loss remote reasonably possible loss associated resolution proceedings expected material companys financial position results operations cash flows either individually aggregate legal defense reserves legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable significant factors considered review legal defense reserves follows actual costs incurred company development companys legal defense strategy structure light scope litigation number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials associated litigation amount legal defense reserves december december approximately million million respectively represents companys best estimate minimum amount defense costs incurred connection outstanding litigation however events additional trials events could arise course litigation could affect ultimate amount legal defense costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine increase reserves time future based upon factors set forth believes would appropriate environmental matters previously disclosed mercks facilities oss netherlands inspected province brabant province pursuant dutch hazards major accidents decree sites environmental permits province issued penalties alleged violations regulations governing preventing managing accidents hazardous substances government also issued fine alleged environmental violations one oss facilities together totaled thousand company subsequently advised criminal investigation initiated based upon certain issues formed basis administrative enforcement action province company intends defend enforcement action may result investigation table contents may environmental protection agency epa conducted air compliance evaluation companys pharmaceutical manufacturing facility elkton virginia result investigation company issued notice noncompliance show cause notification relating certain federally enforceable requirements applicable elkton facility company advised epa enforcement action longer pursued company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents proceedings seek require operators hazardous waste disposal facilities transporters waste sites generators hazardous waste disposed sites clean sites reimburse government cleanup costs company made party proceedings alleged generator waste disposed sites case government alleges defendants jointly severally liable cleanup costs although joint several liability alleged proceedings frequently resolved allocation cleanup costs among parties nearly reflects relative contributions parties site situation companys potential liability varies greatly site site sites potential liability de minimis others final costs cleanup yet determined feasible predict outcome many proceedings brought federal state agencies private litigants opinion company proceedings ultimately result liability would material adverse effect financial position results operations liquidity capital resources company company taken active role identifying accruing costs amounts include reduction anticipated recoveries cleanup costs former site owners operators recalcitrant potentially responsible parties managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively liabilities undiscounted consider potential recoveries parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial position results operations liquidity capital resources year equity merck certificate incorporation authorizes shares common stock shares preferred stock capital stock summary common stock treasury stock transactions shares millions follows common treasury common treasury common treasury stock stock stock stock stock stock balance january purchases treasury stock issuances balance december issuances primarily reflect activity sharebased compensation plans sharebased compensation plans company sharebased compensation plans company grants restricted stock units rsus performance share units psus certain management level employees addition employees nonemployee directors may granted options purchase shares company common stock fair market value time grant plans approved companys shareholders table contents december million shares collectively authorized future grants companys sharebased compensation plans awards settled primarily treasury shares employee stock options granted purchase shares company stock fair market value time grant awards generally vest one third year threeyear period contractual term years rsus stock awards granted employees entitle holder shares common stock awards vest fair value stock option rsu awards determined fixed grant date based companys stock price psus stock awards ultimate number shares issued contingent companys performance preset objective set objectives fair value psu determined date grant based companys stock price rsus psus dividends declared vesting period payable employees upon vesting psu performance period number shares stock expected issued adjusted based probability achievement performance target final compensation expense recognized based ultimate number shares issued rsu psu distributions shares company stock end vesting performance period subject terms applicable awards psu awards generally vest three years prior rsu awards generally vested three years beginning awards granted rsu awards vest onethird year threeyear period total pretax sharebased compensation cost recorded million million million respectively related income tax benefits million million million respectively company uses blackscholes option pricing model determining fair value option grants applying model company uses historical data current market data estimate fair value options blackscholes model requires several assumptions including expected dividend yield riskfree interest rate volatility term options expected dividend yield based historical patterns dividend payments riskfree rate based rate grant date zerocoupon us treasury notes term equal expected term option expected volatility estimated using blend historical implied volatility historical component based historical monthly price changes implied volatility obtained market data companys traded options expected life represents amount time options granted expected outstanding based historical forecasted exercise behavior weighted average exercise price options granted per option respectively weighted average fair value options granted per option respectively determined using following assumptions years ended december expected dividend yield riskfree interest rate expected volatility expected life years summarized information relative stock option plan activity options thousands follows weighted weighted average average remaining aggregate number exercise contractual intrinsic options price term years value outstanding january granted exercised forfeited outstanding december exercisable december table contents additional information pertaining stock option plans provided table years ended december total intrinsic value stock options exercised fair value stock options vested cash received exercise stock options summary nonvested rsu psu activity shares thousands follows rsus psus weighted weighted average average number grant date number grant date shares fair value shares fair value nonvested january granted vested forfeited nonvested december december million total pretax unrecognized compensation expense related nonvested stock options rsu psu awards recognized weighted average period years segment reporting sharebased compensation costs unallocated expenses pension postretirement benefit plans company defined benefit pension plans covering eligible employees united states certain international subsidiaries addition company provides medical benefits principally eligible us retirees dependents postretirement benefit plans company uses december yearend measurement date pension plans postretirement benefit plans net periodic benefit cost net periodic benefit cost credit pension postretirement benefit plans consisted following components pension benefits us international postretirement benefits years ended december service cost interest cost expected return plan assets amortization unrecognized prior service cost net loss amortization termination benefits curtailments settlements net periodic benefit cost credit changes net periodic benefit cost credit year year pension plans largely attributable changes discount rate affecting net loss amortization increase net periodic benefit credit postretirement benefit plans compared largely attributable changes retiree medical benefits approved company december partially offset lower returns plan assets table contents connection restructuring actions see note termination charges recorded pension postretirement benefit plans related expanded eligibility certain employees exiting merck also connection restructuring activities curtailments recorded pension postretirement benefit plans settlements recorded certain us international pension plans reflected table obligations funded status summarized information changes plan assets benefit obligations funded status amounts recorded december follows pension benefits postretirement us international benefits fair value plan assets january actual return plan assets company contributions net effects exchange rate changes benefits paid settlements assets longer restricted payment postretirement benefits fair value plan assets december benefit obligation january service cost interest cost actuarial losses gains benefits paid effects exchange rate changes plan amendments curtailments termination benefits settlements benefit obligation december funded status december recognized assets accrued current liabilities noncurrent liabilities result certain allowable administrative actions occurred june million plan assets previously restricted payment postretirement benefits became available fund certain health welfare benefits actuarial losses primarily reflect changes discount rates december accumulated benefit obligation billion billion respectively pension plans billion billion respectively related us pension plans table contents information related funded status selected pension plans december follows us international pension plans projected benefit obligation excess plan assets projected benefit obligation fair value plan assets pension plans accumulated benefit obligation excess plan assets accumulated benefit obligation fair value plan assets plan assets entities required use fair value hierarchy maximizes use observable inputs minimizes use unobservable inputs measuring fair value three levels inputs used measure fair value level highest priority level lowest level quoted prices unadjusted active markets identical assets liabilities level observable inputs level prices quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities level unobservable inputs supported little market activity level assets whose values determined using pricing models discounted cash flow methodologies similar techniques significant unobservable inputs well instruments determination fair value requires significant judgment estimation december million million respectively approximately companys pension investments categorized level assets inputs used measure financial assets fall within one level described categorization based lowest level input significant fair value measurement instrument table contents fair values companys pension plan assets december asset category follows fair value measurements using fair value measurements using quoted prices significant quoted prices significant active significant active significant markets observable unobservable markets observable unobservable identical assets inputs inputs identical assets inputs inputs level level level total level level level total us pension plans assets cash cash equivalents investment funds developed markets equities emerging markets equities equity securities developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities investments net assets fair value hierarchy investments measured nav plan assets fair value international pension plans assets cash cash equivalents investment funds developed markets equities emerging markets equities government agency obligations corporate obligations fixed income obligations real estate equity securities developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities investments insurance contracts net assets fair value hierarchy investments measured nav plan assets fair value certain investments measured net asset value nav per share equivalent practical expedient classified fair value hierarchy fair value amounts presented table intended permit reconciliation fair value hierarchy fair value plan assets december plans level investments real estate funds generally valued market appraisals underlying investments funds plans level investments insurance contracts generally valued using crediting rate approximates market returns invest underlying securities whose market values unobservable determined using pricing models discounted cash flow methodologies similar techniques table contents table provides summary changes fair value including transfers andor financial assets measured fair value using significant unobservable inputs level companys pension plan assets insurance real insurance real contracts estate total contracts estate total us pension plans balance january actual return plan assets relating assets still held december relating assets sold year purchases sales net balance december international pension plans balance january actual return plan assets relating assets still held december purchases sales net transfers level balance december fair values companys postretirement benefit plan assets december asset category follows fair value measurements using fair value measurements using quoted prices significant quoted prices significant active significant active significant markets observable unobservable markets observable unobservable identical assets inputs inputs identical assets inputs inputs level level level total level level level total assets cash cash equivalents investment funds developed markets equities emerging markets equities government agency obligations equity securities developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities net assets fair value hierarchy investments measured nav plan assets fair value certain investments measured net asset value nav per share equivalent practical expedient classified fair value hierarchy fair value amounts presented table intended permit reconciliation fair value hierarchy fair value plan assets december company established investment guidelines us pension postretirement plans create asset allocation expected deliver rate return sufficient meet longterm obligation table contents plan given acceptable level risk target investment portfolio companys us pension postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios equity weighting consistent longterm nature plans benefit obligations expected annual standard deviation returns target portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests international pension plans targeted investment portfolio varies based duration pension liabilities local government rules regulations although significant percentage plan assets invested us equities concentration risk mitigated use strategies diversified within management guidelines expected contributions expected contributions approximately million us pension plans approximately million international pension plans approximately million postretirement benefit plans expected benefit payments expected benefit payments follows international pension postretirement us pension benefits benefits benefits expected benefit payments based assumptions used measure benefit obligations include estimated future employee service amounts recognized comprehensive income net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions net loss amounts excess certain thresholds amortized net periodic benefit cost average remaining service life employees following amounts reflected components oci pension plans postretirement us international benefit plans years ended december net loss gain arising period prior service cost credit arising period net loss amortization included benefit cost prior service credit cost amortization included benefit cost estimated net loss gain prior service cost credit amounts amortized aoci net periodic benefit cost million million respectively pension plans million million respectively relates us pension plans million million respectively postretirement benefit plans table contents actuarial assumptions company reassesses benefit plan assumptions regular basis weighted average assumptions used determining us pension postretirement benefit plan international pension plan information follows us pension postretirement benefit plans international pension plans december net periodic benefit cost discount rate expected rate return plan assets salary growth rate benefit obligation discount rate salary growth rate pension postretirement benefit plans discount rate evaluated measurement dates modified reflect prevailing market rate portfolio highquality fixedincome debt instruments would provide future cash flows needed pay benefits included benefit obligation come due expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid determined plan basis expected rate return within plan developed considering longterm historical returns data current market conditions actual returns plan assets using reference information longterm return expectations asset category weighted average expected return plans target portfolio developed according allocation among investment categories expected portfolio performance reflects contribution active management appropriate expected rate return companys us pension postretirement benefit plans range compared range decrease primarily due modest shift asset allocation increase weightedaverage expected return us pension postretirement benefit plan assets due relative weighting referenced plans assets health care cost trend rate assumptions postretirement benefit plans follows december health care cost trend rate assumed next year rate cost trend rate assumed decline year trend rate reaches ultimate trend rate one percentage point change health care cost trend rate would following effects one percentage point increase decrease effect total service interest cost components effect benefit obligation savings plans company also maintains defined contribution savings plans united states company matches percentage employees contributions consistent provisions plan employee eligible total employer contributions plans million million million respectively table contents income expense net income expense net consisted years ended december interest income interest expense exchange gains losses equity income affiliates net exchange losses related primarily venezuelan bolvar upon evaluation evolving economic conditions venezuela volatility country combined decline transactions settled official cencoex rate company determined unlikely outstanding net monetary assets would settled cencoex rate accordingly company recorded charges million devalue net monetary assets venezuela amounts represented companys estimate us dollar amount would ultimately collected recorded additional exchange losses million aggregate reflecting ongoing effect translating transactions net monetary assets consistent rates since january venezuela designated hyperinflationary result local foreign operations remeasured us dollars impact recorded results operations decline equity income affiliates compared driven primarily termination spmsd joint venture december partially offset higher equity income certain research investment funds decline equity income affiliates compared driven primarily lower equity income certain research investment funds net presented table includes gains million sale equity investments income million related astrazenecas option exercise see note million loss extinguishment debt see note net includes charge million settle worldwide patent litigation related keytruda see note gain million related settlement patent litigation gains million resulting receipt milestone payments outlicensed migraine clinical development programs see note million income related astrazenecas option exercise net includes million net charge related settlement vioxx shareholder class action litigation paid expense million contribution investments equity securities merck foundation partially offset million gain sale certain migraine clinical development programs see note million gain divestiture mercks remaining ophthalmics business international markets see note recognition million income related astrazenecas option exercise interest paid million million million table contents taxes income reconciliation effective tax rate us statutory rate follows amount tax rate amount tax rate amount tax rate us statutory rate applied income taxes differential arising provisional impact tcja impact purchase accounting adjustments including amortization valuation allowances restructuring state taxes us health care reform legislation foreign currency devaluation related venezuela foreign earnings tax settlements unremitted foreign earnings includes tax effect contingency reserves research credits losses foreign subsidiaries miscellaneous items companys effective tax rate reflects provisional impact tax cuts jobs act tcja enacted december among provisions tcja reduces us federal corporate statutory tax rate effective january requires companies pay onetime transition tax undistributed earnings certain foreign subsidiaries creates new taxes certain foreign sourced earnings company reflected impact tcja financial statements described however application certain provisions tcja remains subject interpretation instances company made reasonable estimate effects tcja onetime transition tax based companys post undistributed earnings profits ep substantial portion undistributed ep company previously provided deferred taxes earnings deemed merck retained indefinitely subsidiary companies reinvestment company recorded provisional amount onetime transition tax liability billion merck yet finalized calculation total post undistributed ep foreign subsidiaries transition tax based part amount undistributed ep held cash specified assets therefore amount may change company finalizes calculation post undistributed foreign ep finalizes amounts held cash specified assets provisional amount reduced reversal billion deferred taxes previously recorded connection merger scheringplough corporation certain undistributed foreign ep company anticipates able utilize certain foreign tax credits partially reduce transition tax payment resulting net transition tax payment billion permitted tcja company elected pay onetime transition tax period eight years current portion transition tax liability million included reduction prepaid income taxes included current assets remainder billion included noncurrent liabilities result tcja company made determination longer indefinitely reinvested respect undistributed earnings foreign subsidiaries provided deferred tax liability withholding tax would apply company remeasured deferred tax assets liabilities new federal statutory tax rate resulted provisional deferred tax benefit million deferred tax benefit calculation remains subject certain clarifications particularly related executive compensation benefits table contents beginning tcja includes tax global intangible lowtaxed income gilti defined tcja company allowed make accounting policy election account tax effects gilti tax either income tax provision future periods tax arises component deferred taxes related investments foreign subsidiaries company currently evaluating gilti provisions tcja implications tax provision finalized accounting policy election therefore company recorded deferred taxes gilti december foreign earnings tax rate differentials tax rate reconciliation primarily reflect impacts operations jurisdictions different tax rates united states particularly ireland switzerland well singapore puerto rico operate tax incentive grants begin expire earnings indefinitely reinvested thereby yielding favorable impact effective tax rate compared us statutory rate foreign earnings tax rate differentials include impact intangible asset impairment charges amortization purchase accounting adjustments restructuring costs items presented separately represent significant separately disclosed pretax cost charge substantial portion items relates jurisdictions lower tax rates united states therefore impact recording expense items lower tax rate jurisdictions unfavorable impact effective tax rate compared us statutory rate companys effective tax rate reflects impact protecting americans tax hikes act signed law december extending research credit permanently controlled foreign corporation lookthrough provisions five years income taxes consisted years ended december domestic foreign taxes income consisted years ended december current provision federal foreign state deferred provision federal foreign state table contents deferred income taxes december consisted assets liabilities assets liabilities intangibles inventory related accelerated depreciation unremitted foreign earnings pensions postretirement benefits compensation related unrecognized tax benefits net operating losses tax credit carryforwards subtotal valuation allowance total deferred taxes net deferred income taxes recognized assets deferred income taxes company net operating loss nol carryforwards several jurisdictions december million deferred taxes nol carryforwards relate foreign jurisdictions valuation allowances million established foreign nol carryforwards foreign deferred tax assets addition company million deferred tax assets relating various us tax credit carryforwards nol carryforwards expected fully utilized prior expiry income taxes paid billion billion billion respectively tax benefits relating stock option exercises million million million reconciliation beginning ending amount unrecognized tax benefits follows balance january additions related current year positions additions related prior year positions reductions tax positions prior years settlements lapse statute limitations balance december amounts reflect settlements irs discussed company recognize unrecognized tax benefits billion december income tax provision would reflect favorable net impact billion company examination numerous tax authorities various jurisdictions globally company believes reasonably possible total amount unrecognized tax benefits december could decrease approximately million next months result various audit closures settlements expiration statute limitations ultimate finalization companys examinations relevant taxing authorities include formal administrative legal proceedings could significant impact timing reversal unrecognized tax benefits company believes reserves uncertain tax positions adequate cover existing risks exposures expenses interest penalties associated uncertain tax positions amounted million million million amounts reflect beneficial impacts various tax table contents settlements including discussed liabilities accrued interest penalties million million december respectively internal revenue service irs concluded examinations mercks us federal income tax returns result company required make payment approximately billion companys reserves unrecognized tax benefits years examination exceeded adjustments relating examination period therefore company recorded net million tax benefit net benefit reflects reductions reserves unrecognized tax benefits tax positions relating years examination partially offset additional reserves tax positions previously reserved well adjustments reserves unrecognized tax benefits relating years remain open examination affected settlement although irss examination companys federal tax returns concluded prior one issue relating refund claim remained open issue resolved company received refund approximately million exceeded receivable previously recorded company resulting tax benefit million irs currently conducting examinations companys tax returns years addition various state foreign tax examinations progress significant tax jurisdictions us state foreign companys income tax returns open examination period earnings per share calculations earnings per share shares millions follows years ended december net income attributable merck co inc average common shares outstanding common shares issuable average common shares outstanding assuming dilution basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders issuable primarily sharebased compensation plans million million million respectively common shares issuable sharebased compensation plans excluded computation earnings per common share assuming dilution effect would antidilutive table contents comprehensive income loss changes aoci component follows employee cumulative accumulated benefit translation comprehensive derivatives investments plans adjustment income loss balance january net taxes comprehensive income loss reclassification adjustments pretax tax comprehensive income loss reclassification adjustments net taxes reclassification adjustments pretax tax reclassification adjustments net taxes comprehensive income loss net taxes balance december net taxes comprehensive income loss reclassification adjustments pretax tax comprehensive income loss reclassification adjustments net taxes reclassification adjustments pretax tax reclassification adjustments net taxes comprehensive income loss net taxes balance december net taxes comprehensive income loss reclassification adjustments pretax tax comprehensive income loss reclassification adjustments net taxes reclassification adjustments pretax tax reclassification adjustments net taxes comprehensive income loss net taxes balance december net taxes relates foreign currency cash flow hedges reclassified aoci sales represents net realized gains losses sales availableforsale investments reclassified aoci income expense net includes net amortization prior service cost actuarial gains losses included net periodic benefit cost see note includes pension plan net loss billion billion december respectively postretirement benefit plan net gain loss million million december respectively well pension plan prior service credit million million december respectively postretirement benefit plan prior service credit million million december respectively table contents segment reporting companys operations principally managed products basis include four operating segments pharmaceutical animal health healthcare services alliances segments pharmaceutical segment reportable segment pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities large component pediatric adolescent vaccine sales made us centers disease control prevention vaccines children program funded us government additionally company sells vaccines federal government placement vaccine stockpiles sales vaccines major european markets marketed companys spmsd joint venture termination december see note company also animal health segment discovers develops manufactures markets animal health products including vaccines company sells veterinarians distributors animal producers companys healthcare services segment provides services solutions focus engagement health analytics clinical services improve value care delivered patients table contents sales companys products follows years ended december us intl total us intl total us intl total primary care womens health cardiovascular zetia vytorin atozet adempas diabetes januvia janumet general medicine womens health nuvaring implanonnexplanon follistim aq hospital specialty hepatitis zepatier hiv isentressisentress hd hospital acute care bridion noxafil invanz cancidas cubicin primaxin immunology remicade simponi oncology keytruda emend temodar diversified brands respiratory singulair nasonex dulera cozaarhyzaar arcoxia fosamax vaccines gardasilgardasil proquadmmr iivarivax pneumovax rotateq zostavax pharmaceutical total pharmaceutical segment sales segment sales total segment sales us plus international may equal total due rounding sales cubicin represent sales subsequent cubist acquisition date december merck sanofi terminated equallyowned joint venture spmsd marketed vaccines major european markets see note accordingly vaccine sales include sales european markets previously part spmsd amounts include sales vaccines sold spmsd results reflected equity income affiliates included income expense net amounts however include supply sales spmsd pharmaceutical primarily reflects sales human health pharmaceutical products including products within franchises listed separately represents nonreportable segments animal health healthcare services alliances primarily comprised miscellaneous corporate revenues including revenue hedging activities well thirdparty manufacturing sales also includes million million respectively related sale marketing rights certain productstable contents consolidated revenues geographic area derived follows years ended december united states europe middle east africa asia pacific japan latin america reconciliation total segment profits consolidated income taxes follows years ended december segment profits pharmaceutical segment segments total segment profits profits unallocated interest income interest expense equity income affiliates depreciation amortization research development amortization purchase accounting adjustments restructuring costs loss extinguishment debt gain sale certain migraine clinical development programs charge related settlement worldwide keytruda patent litigation gain divestiture certain ophthalmic products foreign currency devaluation related venezuela net charge related settlement vioxx shareholder class action litigation unallocated net segment profits comprised segment sales less standard costs certain operating expenses directly incurred segments internal management reporting presented chief operating decision maker merck allocate materials production costs standard costs majority research development expenses general administrative expenses cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits addition costs related restructuring activities well amortization purchase accounting adjustments allocated segments profits primarily comprised miscellaneous corporate profits well operating profits related thirdparty manufacturing sales unallocated net includes expenses corporate manufacturing cost centers goodwill intangible asset impairment charges gains losses sales businesses expense income related changes estimated fair value contingent consideration miscellaneous income expense items table contents equity income affiliates depreciation amortization included segment profits follows pharmaceutical total year ended december included segment profits equity income affiliates depreciation amortization year ended december included segment profits equity income affiliates depreciation amortization year ended december included segment profits equity income affiliates depreciation amortization property plant equipment net geographic area located follows december united states europe middle east africa asia pacific latin america japan company disaggregate assets products services basis internal management reporting therefore information presented table contents report independent registered public accounting firm board directors shareholders merck co inc opinions financial statements internal control financial reporting audited accompanying consolidated balance sheets merck co inc subsidiaries december related consolidated statements income comprehensive income equity cash flows three years period ended december including related notes collectively referred consolidated financial statements also audited companys internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso opinion consolidated financial statements referred present fairly material respects financial position company december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued coso basis opinions companys management responsible consolidated financial statements maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included managements report internal control financial reporting appearing item responsibility express opinions companys consolidated financial statements companys internal control financial reporting based audits public accounting firm registered public company accounting oversight board united states pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audits accordance standards pcaob standards require plan perform audits obtain reasonable assurance whether consolidated financial statements free material misstatement whether due error fraud whether effective internal control financial reporting maintained material respects audits consolidated financial statements included performing procedures assess risks material misstatement consolidated financial statements whether due error fraud performing procedures respond risks procedures included examining test basis evidence regarding amounts disclosures consolidated financial statements audits also included evaluating accounting principles used significant estimates made management well evaluating overall presentation consolidated financial statements audit internal control financial reporting included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk audits also included performing procedures considered necessary circumstances believe audits provide reasonable basis opinions definition limitations internal control financial reporting companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail table contents accurately fairly reflect transactions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate pricewaterhousecoopers llp florham park new jersey february served companys auditor since table contents b supplementary data selected quarterly financial data contained condensed interim financial data table condensed interim financial data unaudited millions except per share amounts th q rd q nd q st q sales materials production marketing administrative research development restructuring costs income expense net income taxes net loss income attributable merck co inc basic loss earnings per common share attributable merck co inc common shareholders loss earnings per common share assuming dilution attributable merck co inc common shareholders sales materials production marketing administrative research development restructuring costs income expense net loss income taxes net loss income attributable merck co inc basic loss earnings per common share attributable merck co inc common shareholders loss earnings per common share assuming dilution attributable merck co inc common shareholders amounts include provisional net tax charge related enactment us tax legislation see note amounts include charge settle worldwide patent litigation related keytruda see note amounts include aggregate charge related formation collaboration astrazeneca see note amounts reflect acquisition divestiturerelated costs see note impact restructuring actions see note table contents item changes disagreements accountants accounting financial disclosure applicable item controls procedures management company participation chief executive officer chief financial officer evaluated effectiveness companys disclosure controls procedures based evaluation end period covered companys chief executive officer chief financial officer concluded companys disclosure controls procedures defined rules ae de securities exchange act amended act effective period covered report changes internal control financial reporting materially affected reasonably likely materially affect companys internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af act management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued committee sponsoring organizations treadway commission based evaluation management concluded internal control financial reporting effective december pricewaterhousecoopers llp independent registered public accounting firm performed assessment effectiveness companys internal control financial reporting attestation report included filing managements report managements responsibility financial statements responsibility integrity objectivity companys financial statements rests management financial statements report managements stewardship company assets statements prepared conformity generally accepted accounting principles accordingly include amounts based managements best estimates judgments nonfinancial information included annual report also prepared management consistent financial statements assure financial information reliable assets safeguarded management maintains effective system internal controls procedures important elements include careful selection training development operating financial managers organization provides appropriate division responsibility communications aimed assuring company policies procedures understood throughout organization staff internal auditors regularly monitors adequacy application internal controls worldwide basis ensure personnel continue understand system internal controls procedures policies concerning good prudent business practices annually employees company required complete code conduct training includes financial stewardship training reinforces importance understanding internal controls reviewing key corporate policies procedures systems addition company compliance programs including ethical business practices program reinforce companys longstanding commitment high ethical standards conduct business financial statements financial information included annual report fairly present material respects companys financial condition results operations cash flows formal certification securities exchange commission included filing managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af securities exchange act companys internal control financial reporting designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles united states america management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued table contents committee sponsoring organizations treadway commission based evaluation management concluded internal control financial reporting effective december inherent limitations internal control financial reporting may prevent detect misstatements projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate effectiveness companys internal control financial reporting december audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears herein kenneth c frazier robert davis chairman president executive vice president chief financial chief executive officer officer global services item b information none table contents part iii item directors executive officers corporate governance required information directors nominees incorporated reference discussion proposal election directors companys proxy statement annual meeting shareholders held may information executive officers set forth part document required information compliance section securities exchange act incorporated reference discussion heading section beneficial ownership reporting compliance companys proxy statement annual meeting shareholders held may company code conduct values standards applicable employees including principal executive officer principal financial officer principal accounting officer controller code conduct available companys website wwwmerckcomaboutcodeofconductpdf company intends disclose future amendments certain provisions code conduct waivers code conduct granted executive officers directors website within four business days following date amendment waiver every merck employee responsible adhering business practices accordance law ethical principles reflect highest standards corporate individual behavior printed copy sent without charge shareholder requests writing chief ethics compliance officer merck co inc galloping hill road kenilworth nj required information identification audit committee audit committee financial expert incorporated reference discussion heading board meetings committees companys proxy statement annual meeting shareholders held may item executive compensation information required executive compensation incorporated reference discussion headings compensation discussion analysis summary compensation table compensation table grants planbased awards table outstanding equity awards table option exercises stock vested table pension benefits table nonqualified deferred compensation table potential payments upon termination change control including discussion subheadings separation change control well footnote information various tables companys proxy statement annual meeting shareholders held may required information director compensation incorporated reference discussion heading director compensation related director compensation table schedule director fees table companys proxy statement annual meeting shareholders held may required information headings compensation benefits committee interlocks insider participation compensation benefits committee report incorporated reference companys proxy statement annual meeting shareholders held may table contents item security ownership certain beneficial owners management related stockholder matters information respect security ownership certain beneficial owners management incorporated reference discussion heading stock ownership information companys proxy statement annual meeting shareholders held may equity compensation plan information following table summarizes information options warrants rights equity compensation companys equity compensation plans close business december table include information tax qualified plans merck us savings plan number number securities remaining securities available future issued upon weightedaverage issuance equity exercise exercise price compensation plans outstanding outstanding excluding options warrants options warrants securities rights rights reflected column plan category b c equity compensation plans approved security holders equity compensation plans approved security holders total includes options purchase shares company common stock rights following shareholderapproved plans merck sharp dohme incentive stock plans merck co inc nonemployee directors stock option plans merck co inc scheringplough stock incentive plans excludes approximately shares restricted stock units performance share units assuming maximum payouts merck sharp dohme incentive stock plans also excludes shares phantom stock deferred msd employee deferral program shares phantom stock deferred merck co inc plan deferred payment directors compensation item certain relationships related transactions director independence required information transactions related persons incorporated reference discussion heading related person transactions companys proxy statement annual meeting shareholders held may required information director independence incorporated reference discussion heading independence directors companys proxy statement annual meeting shareholders held may item principal accountant fees services information required item incorporated reference discussion proposal ratification appointment independent registered public accounting firm beginning caption preapproval policy services independent registered public accounting firm fees services provided independent registered public accounting firm companys proxy statement annual meeting shareholders held may table contents part iv item